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ABSTRACT

Neuromechanical Alterations Due to Induced Knee Pain and Effusion
During Functional Movements

Jihong Park
Department of Exercise Sciences, BYU
Doctor of Philosophy

Purpose: Examine neuromechanical alterations due to isolated and/or combined knee pain and
effusion in functional movements. Methods: A 4X3 randomised controlled laboratory study
with repeated measures was used. Nineteen, healthy volunteers (age: 22.4 ± 2.4 years)
underwent four different treatments (control, effusion, pain, and pain/effusion) with a week wash
out period. Ten near-infrared cameras with 43 reflective markers, 12 surface EMG electrodes,
and two ground-embedded force platforms were used to record neuromechanical changes during
functional movements (walking and drop landing). To induce pain, 5% sodium chloride (1 ml)
was injected into the infrapatellar fat pad. To induce effusion, 0.9% sodium chloride (50 ml)
was injected into the knee joint capsule. To induce pain/effusion, both injections were
employed. No injection was used for the control. Subjects performed walking and a single leg
drop landing in three time intervals: precondition (prior to injection), condition (immediate post
injection), and postcondition (30 min post injection). To quantify pain perception, the visual
analogue scale was measured every two minutes. Results: Under pain/effusion treatment,
subjects walked slowly with a shorter stride length. Joint moments of plantarflexion, knee
extension, knee abduction, and hip abduction were reduced. Subjects also showed a decrease at
20% and 80% of stance phase, and an increase in 50% in vertical ground reaction force (VGRF).
Under the same treatment, subjects landed with a less peak VGRF with increased time to peak
VGRF, alterations of joint angles (ankle dorsiflexion, knee extension, and hip adduction), and
moments (knee extension, knee abduction, and hip abduction). Conclusions: Joint pain and
effusion cause neuromechanical alterations in the lower extremity during functional movements.
These compensatory strategies may alter joint loading, potentially resulting in acceleration of the
joint degenerative process. We also recommend use of crutches following injury to avoid
modifications of movement strategies.
Key words: arthrogenous muscle response, gait alteration, joint degeneration
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Introduction
Knee joint injuries are common. For example, approximately 80,000 anterior cruciate
ligament (ACL) ruptures are seen in the United States annually (39). The estimated prevalence
of knee osteoarthritis (OA) is 6.1% in adults aged more than 30 (32) and 12.5% in those aged 45
and above (13). Knee OA often requires total knee arthroplasty (TKA) (89) resulting in 443,008
TKAs from 1990 to 2000 in the United States alone (58). Of all knee joint pathologies, anterior
knee pain (AKP) is the most common (59) with a prevalence rate as high as 25% (27). Although
diagnoses and etiologies vary, a reduction in quadriceps activation is a common consequence in
individuals with knee joint pathologies (29, 52, 76, 107, 112).
Quadriceps dysfunction resulting from a knee joint injury has been termed arthrogenous
muscle inhibition (AMI) (82, 105). AMI is a pre- and postsynaptic inhibition of periarticular
musculature resulting from surgery, distension, pain, or structural damage of a joint (46, 85, 86).
AMI is the body’s natural response following a traumatic injury (46). AMI discourages the
patient’s ability to move the injured joint thus it helps prevent further structural damage (82) and
provide time for tissue healing. The presence of AMI, however, may mediate compensatory
strategies in the functional kinetic chain of the lower extremity (49, 82, 111). Long term
consequences of these abnormalities could modify normal joint loading, eventually resulting in
degenerative joint disease (12, 87, 106).
Structural damage and the ensuing inflammatory response are believed to be initiating
factors that alter normal afferent input, resulting in AMI (52, 53, 115). Among these factors,
pain and joint effusion have been examined as independent contributing factors to AMI. In
clinical and laboratory trials, quadriceps AMI has been associated with knee pain (107-109) and
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alterations in quadriceps muscle activity during stair ascending (45). Joint effusion has also been
shown as an independent cause of quadriceps inhibition (47, 49, 57, 82, 103, 111). Studies
observing the effects of experimentally induced knee effusion on lower extremity muscles
reported quadriceps inhibition with soleus (49) or hamstring (82, 111) facilitation. These studies
reported an increase in knee flexion during walking (111) and an increase in ground reaction
forces during a drop landing task (82).
Despite evidence of the consequences of each factor to AMI, the relative or additive
contribution of pain and effusion to elicit AMI is still unclear. Since pain and effusion are from
different sensory receptors (e.g. nociceptors (14) and Ruffini endings (49)), each stimulus may
follow a different pathway. Although each injury model is effective in evaluating pain and
effusion stimuli separately, we rarely see pain or effusion alone in knee joint injuries.
Introduction of pain and effusion simultaneously in a controlled environment would simulate a
condition in which both stimuli are present. The observation of neuromechanical alterations
using this combined model may clarify if there is an additive effect with the two stimuli.
Additionally, the combined model could potentially help us understand how this additive effect
influences AMI and associated lower extremity compensatory strategies.
The purpose of this study is to determine the contributions of AKP, knee joint effusion,
and a combination of both stimuli on change in lower extremity neuromuscular activities,
kinetics, and kinematics during walking and drop landings. These functional movements
demand dynamic joint stability. Dynamic joint stability requires active muscle contraction along
with proper sensory feedback and feed-forward controls. When AMI is present in the quadriceps,
we expect to observe neuromechanical alterations in the lower extremity.
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Methods
Experimental design
This study was a crossover design. The independent variables were treatment (pain,
effusion, pain/effusion, and control-no injection) and time (precondition, condition, and
postcondition). The dependent variables were subjective pain perception, neuromuscular
activities, kinetic, and kinematic data on the lower extremity. The specific dependent variables
are as followed:
Neuromuscular activities
Walking: Peak and mean electromyography (EMG) values of each muscle in four equal time
intervals (0-25%, 26-50%, 51-75%, 76-100%) during the stance phase in both sides
Drop landing: Peak and mean EMG values of each muscle during the time window from 200 ms
before to initial contact; from initial contact to peak knee flexion of the first landing in the
ipsilateral side
Muscles: medial gastrocnemius, vastus medialis, vastus lateralis, medial hamstring, gluteus
medius, and gluteus maximus
Ground reaction force (GRF)
Walking: Vertical ground reaction force (VGRF) during the stance phase in both sides
Drop landing: Peak VGRF (PVGRF) and time to PVGRF during the stance phase of the first
landing in both sides
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Joint kinematics
Walking:
(1) Walking speed
(2) Stride length in both sides
(3) Peak joint angles in the sagittal plane (dorsi-flexion, plantar-flexion, knee flexion, hip
flexion, and hip extension) and frontal planes (knee abduction, knee adduction, hip
abduction, and hip adduction) during the stance phase in both sides
Drop landing:
(1) Peak joint angles in the sagittal plane (dorsi-flexion, plantar-flexion, knee flexion, hip
flexion, and hip extension) and frontal plane (knee abduction, knee adduction, and hip
adduction) during the stance phase in the ipsilateral side
(2) Hip joint angle in the frontal plane at initial contact in the ipsilateral side
(3) Amount of time between the toe off of the first landing and the initial contact of the second
landing
Joint Kinetics
Walking: Peak joint moments in the sagittal (plantar-flexion, knee extension, hip flexion, and hip
extension) and frontal plane (knee abduction, knee adduction, and hip abduction) during the
stance phase in both sides
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Drop landing:
(1) Peak joint moments in the sagittal (plantar-flexion, knee flexion, knee extension, and hip
extension) and frontal plane (knee abduction, knee adduction, hip abduction, and hip
adduction) during the stance phase in the ipsilateral side
(2)Vertical body stiffness during the stance phase

Participants
Sample size was calculated using an expected change in PVGRF during a single leg drop
landing (GRF: N/kg) of 10 and a standard deviation of 7.29 (82). Based on these estimations, 13
subjects in each group were necessary in order to have an 80% chance of detecting a significant
difference with p=0.001.
Nineteen, (10 males and 9 females, age: 22± 2 years, height: 1.73 ± 0.1 m, mass: 73 ± 16
kg) healthy subjects volunteered to participate. Exclusion criteria included current pregnancy,
history of neuromuscular disorders, lumbar spine or lower extremity surgery, or lower extremity
injury within the past six months. All subjects read and signed the informed consent form
approved by University’s Institutional Review Board.

Data collection and reduction
Neuromuscular activity
Twelve wireless surface EMG electrodes (Trigno Wireless, Delsys Inc., Boston, MA)
were used to record neuromuscular activity of the lower extremity (2000 Hz). Electrode
locations were shaved, debrided with sandpaper, and cleaned with isopropyl alcohol. The
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electrodes were placed on the medial gastrocnemius (MG), vastus medialis (VM), vastus lateralis
(VL), medial hamstring (MH), gluteus medius (GM), and gluteus maximus (GX) in both sides.
EMG placements were guided by the Surface ElectroMyoGraphy for the Non-invasive
Assessment of Muscles (97). EMG during an isometric reference position was recorded to
normalize the EMG amplitude. Subjects were asked to squat down until their butt barely touches
a barrier (an office desk with height of 0.74 m) and maintain the position for four seconds
(Figure 1-a). All EMG signals were band-pass filtered (20-450 Hz), involved a common mode
rejection ratio that was greater than 80 dB, and were amplified using a gain of 1000.
Raw EMG data further were smoothed using a root mean square (RMS) algorithm with a
50 ms moving window for walking trials and a 15 ms moving window for drop landing trials.
The data for the isometric reference position were treated the same way. For the walking trials,
the EMG signals in each muscle were first time-normalized to the stance time: a stance phase on
each leg corresponded to 100% (1,000 data points), then normalized again by the isometric
reference position. A48 ms fixed delay, from sensor input to analog output, was accounted for
all EMG data to harmonise with kinetic and kinematic data.
GRF
GRF data were measured using two-floor-mounted force platforms (AMTI, Watertown,
MA) at a sampling rate of 2,000 Hz. Prior to data collection, both force platforms were
calibrated to zero. Initial contact on the force platforms was defined as the instant at which the
VGRF exceeded 10 N. GRF data were not filtered or normalized in walking and drop landing
trials.
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Joint kinematics and kinetics
Kinematic data were recorded with Vicon Nexus 1.7 (VICON, Centennial, CO). The
movements of the lower extremities were measured using ten high-speed digital video cameras
(Vicon MX, Oxford Metrics Ltd, Oxford, UK) at a sampling rate of 200 Hz. Twenty seven
single reflective markers were attached on the lower extremity and trunk. Four rigid clusters of
four markers each were applied to the mid-lateral thigh and shank on each leg. Single markers
were bilaterally placed over the acromion, inferior angle of the scapula, anterior superior iliac
spine, greater trochanter, lateral and medial femoral condyle, medial and lateral malleoli, dorsal
surface of the mid-foot, toe (between the second and third metatarsal), lateral foot (fifth
metatarsal), and heel. Foot markers were attached onto standardized athletic shoes. Single
markers were also placed over the C7, T7, and sacrum.
A static standing trial (subjects stood with equal distribution of body weight on each foot)
was measured and considered as each subject’s neutral body alignment; subsequent kinematic
measurements were referenced in relation to this position (Figure 1-b). Subjects performed
standing leg motions for each leg in order to estimate the functional hip joint center (44). These
motions consisted of three hip flexions and extensions in the sagittal plane and three hip
abductions and adductions in the frontal plane.
The spatial coordinates for each reflective marker were determined and tracked using
Vicon Nexus and then exported to Visual3D. The coordinates for the walking and drop landing
tasks were smoothed using a 4th-order low-pass Butterworth filter with a cut off frequency of 6
(51) and 12 Hz (66), respectively. A static model was first built using the static standing trial.
This model was applied to each walking and drop landing trial, in order to calculate joint angle.
Joint angles were calculated using a Cardan rotation sequence of flexion-extension and
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abduction-adduction. Three-dimensional internal joint moments were then calculated using
inverse dynamics which combined the kinematic, GRF, and anthropometric data (62).
Vertical stiffness was calculated by dividing PVGRF by vertical displacement of the
center of mass (56) during the first stance during drop landing trials. Vertical displacement of
the center of mass was calculated as the distance between the highest and lowest vertical discrete
value of center of mass. Center of mass was estimated using the reflective markers on the lower
extremity and trunk.
All data were synchronised using Vicon Nexus (VICON, Centennial, CO) and exported
into Visual3D (C Motion, Germantown, MD) for analysis. Afterwards, Matlab 7.12 (Mathworks,
Natick, MA) software was utilized to reduce and extract the necessary values in the outcomes
from Visual3D.
Perceived pain
Subjective pain perception was quantified using a 10 cm VAS (18). Terms “No pain”
and “pain as bad as it could possibly be” were placed on each end of scale. Every two minutes
throughout each time interval, subjects were asked to mark where their pain level is at the time of
measurement.

Treatments
Following the precondition trials (see the testing procedures below), subjects sat on a
table and received one of the four treatments. Saline injections were used in each treatment
except for the control. A licensed, board certified physician performed all injections on the
subject’s dominant side. Dominant side was defined as the preferred leg used to kick a ball.
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Prior to injection, the needle insertion area was cleaned with povidone-iodine. After removal of
the needle, the puncture site was cleaned with an alcohol swab and covered with sterilised gauze.
Control
The control consisted of no injection. Subjects simply sat on a table for five minutes and
performed the condition trials at the same time intervals.
Effusion
For anesthetic purpose, sterile lidocaine (1%, 2.0-ml, Hospira, Inc., Lake Forest, IL) was
subcutaneously injected using the 25-gauge needle and 3-ml syringe. An 18-gauge needle was
inserted into the superolateral knee joint. Sterile saline (0.9% sodium chloride, 50.0-ml, Hospira,
Inc., Lake Forest, IL) was injected using a 50-ml syringe (Becton Dickinson Medical Systems
Inc, Sandy, UT). An effusion wave and ballotable patella test were performed to ensure that the
effusion was within the knee joint capsule (60).
Pain
A 25-gauge needle (Becton Dickinson Medical Systems Inc, Sandy, UT) was inserted
into the lateral infrapatellar fad pad. The needle was inserted at an angle of 45 degrees, in an
inferior-medial direction, to a depth of 1 cm (15). Sterile hypertonic saline (5% sodium chloride,
1.0-ml, B. Braun medical, Inc., Irvine, CA) was injected using 1-ml syringe (Becton Dickinson
Medical Systems Inc, Sandy, UT).
Pain/effusion
To induce a combination of pain and effusion, three injections were performed in the
order of 1% lidocaine, 0.9% isotonic saline, and 5% hypertonic saline. The same volume of each
saline solution was injected as the volume used for pain and effusion treatments. Effusion was
induced first followed by pain due to the limited amount of time for effective pain sensation.
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Testing Procedures
Subjects also completed the demographic information. Subjects’ height and mass were
measured. Subjects performed several trials of drop landings for familiarization. This helped
ensure a consistent drop height between sessions. Qualified subjects came back a week later for
data collection.
Each subject experienced all four treatments (control, effusion, pain, and pain/effusion) in
each session with a week wash-out period in between sessions. Each session consisted of three
time intervals (precondition, condition, and postcondition). During each time interval, three
trials of functional movements (walking trials first followed by drop landing trials) were
recorded. Order of the treatments was randomized using Latin Square designs (24).
Upon arrival in the laboratory, subjects were asked to wear standardized spandex shorts
and shirts, socks, and athletic shoes during data collection. EMG electrodes and reflective
markers were attached. Subject’s isometric reference position, static standing video, and
standing leg motions were recorded. Subjects performed the precondition trials (three successful
trials of walking and drop landings). Afterwards, subjects sat on the table and received one of
the treatments (pain, effusion, pain/effusion, control). Two minutes after the injection, subjects
were asked to stand up. Subjects spent a minute in a standing position. Subjects then performed
the condition trials. Data collection was terminated if the subject complained of intolerable pain
and/or fainting, or did not begin condition trial within eight minutes following injection. Subjects
sat on the table (same position as injection) and rested for 20-25 minutes before the
postcondition trials. Resting time prior to the postcondition measurement was dependent up on
the length of time taken to complete the condition measurements.
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Walking
Subjects completed three successful walking trials at a self selected walking speed. A
successful walking trial constituted each foot fully landing on each force platform. For each
successful trial, one gait cycle for each side was collected.
Drop landing
Subjects performed a drop landing task from a 30 cm height wooden box. The box was
placed 20 cm away from the near edge of the force platform. Three successful trials were
collected in each time interval. A successful trial was defined as the subjects dropping down
(not step or jump down) on their dominant leg onto the force platform followed by an immediate
vertical jump as determined visually by the assessor (34, 35, 95). Subjects were instructed not to
touch the ground with the contralateral side and to maintain balance after the second landing for
two seconds (93). The first landing was used for analysis.

Statistical analyses
For perceived pain a 4×24 mixed model analysis of variance (ANOVA) was performed to
test for differences in treatment over time.
For neuromechanical measurements during walking and drop landing, means for each
subject were computed from three trials at each time interval for each treatment.
For neuromuscular activities during walking, twelve separate 4×3×2×4 mixed model
analysis of covariances (ANCOVAs; covariate: walking speed) were performed to test
differences in treatment over time on each leg during different time windows in the stance phase.
For walking speed a 4×3 mixed model ANOVAs was performed to test for differences in
treatment over time. For stride length a 4×3×2 mixed model ANOVA was performed to test for
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differences in treatment over time on each leg. For joint angles and moments during walking,
sixteen separate 4X3X2 mixed model ANCOVAs (covariate: walking speed) were performed to
test for differences in treatment over time on each leg. For VGRF in the stance phase, functional
data analyses were performed to compare the VGRF data as functions rather than discrete values.
This required registering, or time normalizing, where we warped the peaks and unloading in the
VGRF.
Similar statistical analyzes were performed for the measurements recorded during drop
landing trials. For neuromuscular activities, twelve separate 4×3×2×2 mixed model ANOVAs
were performed to test differences in treatment over time on each leg during different time
windows in the stance phase. For the PVGRF, time to PVGRF, vertical stiffness, joint angles,
and joint moment, twenty four separate 4×3 mixed model ANOVAs were performed to test
differences in treatment over time.
Subjects were blocked on all statistical analyzes. In order to avoid the type I error,
Bonferroni type adjustment for multiple comparisons with the significant level as ≤ 0.001 were
used for all tests. All data except VGRF during walking were analyzed using SAS 9.2 (SAS
Institute Inc., Cary, NC). R 2.14.0 was used to analyze VGRF data during walking.

Results
Pain perception
We found a treatment by time interaction (F69,1242=12.36, p<0.0001) for perceived pain
(Figure 2). Compared to control treatment, subjects immediately felt knee pain after saline
injections for effusion (p<0.0001), pain (p<0.0001), and pain/effusion (p<0.0001). Compared to
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the control treatment, saline injection for effusion, pain, and pain/effusion resulted in knee pain
for six minutes (p<0.0001), ten minutes (p<0.0001), and 16 minutes (p=0.0001), respectively.
During the painful time period for the effusion treatment, knee pain intensity was noted to be
lower when compared to those subjects who received the pain and pain/effusion treatment
(p<0.0001).

Walking
Neuromuscular activities
Peak and mean EMG values of during walking trials are presented in Table 1-a through
h). We did not find any treatment, time, side, or time window effect in the peak and mean EMG
values during the stance phase during walking. The peak EMG data, F statistics 6,108 ranged from
0.3 to 0.95 with p values between 0.52 and 0.99. For the mean EMG data, F statistics 6,108 were
ranged from 0.47 to 1.13 with p values between 0.31 and 0.97.
Walking speed
Summary data of walking speed and stride length during walking trials are presented in
Figure 4-a. We found a treatment by time interaction in walking speed (F6,108=7.46, p<0.0001).
Compared to precondition (p<0.0001) and postcondition (p<0.0005) measurements, subjects for
pain/effusion walked slower during condition measurements. Compared to the control
(p<0.0003) and pain (p<0.0005) treatment, subjects for pain/effusion walked slower during
condition measurement. There was a trend towards slower walking speed between the
precondition and condition measurement under the effusion treatment (p=0.002).
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Stride length
We did not find a treatment by time by side interaction in stride length (F6,108=1.96,
p=0.08). However, there was a treatment by time interaction (F6,108=5.58, p<0.0001: Figure 4-b).
Subjects for the pain/effusion treatment walked in a shorter stride length during condition
measurements than they did during precondition (ipsilateral side: p<0.0001; contralateral side:
p<0.0001) and postcondition measurements (ipsilateral side: p<0.0001; contralateral side:
p<0.0009).
Joint angles
Summary data of joint angles during walking trials are presented in Table 1-i.
For ankle angles, we did not find a treatment by time by side interaction in ankle dorsiflexion (F6,108=0.84, p=0.54) and ankle plantar-flexion (F6,108=1.43, p=0.21).
For knee angles, we did not find a treatment by time by side interaction in, knee flexion
(F6,108=1.19, p=0.32), knee abduction (F6,108=1.08, p=0.38), and knee adduction (F6,108=1.00,
p=0.43).
For hip angles, we did not find a treatment by time by side interaction in hip extension
(F6,108=0.80, p=0.57), hip flexion (F6,108=0.37, p=0.9), and hip abduction (F6,108=1.01, p=0.42),
but found a trend in hip adduction (F6,108=2.20, p=0.05). Compared to the precondition,
condition measurements under the pain/effusion treatment showed a decrease in hip adduction
angle on the ipsilateral side (p=0.002: Figure 4-c). Compared to the condition, postcondition
measurements under the pain/effusion treatment showed an increase in hip adduction angle on
the contralateral side (p=0.004).
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VGRF
Plots containing 95% confidence interval bands in comparisons between each time
interval under each treatment are presented in Figure 3.
When compared to precondition walking, subjects demonstrated reduced ipsilateral
VGRF during condition measurements at around 20 and 80% under the pain/effusion treatment.
In the same comparison, subjects walked with an increased ipsilateral VGRF ranging between 40
and 55%, and 90% and 100% of stance (Figure 3-j). While subjects walked with a reduced
ipsilateral VGRF ranging between 90% and at the end of stance, it was also noted that they
demonstrated an increased contralateral VGRF in the same portion of stance (Figure 3-v).
Joint moments
For ankle joint moments, we found a treatment by time by side interaction in plantarflexion moment (F6,108=5.54, p<0.0001: Figure 4-d). Compared to the precondition (p<0.0001)
and postcondition measurements (p=0.0007), condition measurements under the pain/effusion
treatment showed a decrease in ankle plantar-flexion moment on the ipsilateral side. In
condition measurements subjects under pain/effusion treatment walked with less of a plantarflexion moment than they did under the control (p<0.0001) and pain treatment (p=0.0008) on the
ipsilateral side.
For knee joint moments, we found a treatment by time by side interaction in knee
extension moments (F6,108=4.49, p=0.0004: Figure 4-e) and knee abduction moments (F6,108=8.62,
p<0.0001: Figure 4-f) but not in knee adduction moments (F6,108=0.96, p=0.45). Compared to
the precondition measurements, condition measurement under the pain/effusion treatment had a
decrease in knee extension moment on the ipsilateral side (p<0.0008) and an increase in knee
extension moment on the contralateral side (p<0.0001). Compared to the precondition
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(p<0.0001) and postcondition (p<0.0001) measurements, condition measurements under the pain
and pain/effusion treatment had a decrease in knee abduction moment on the ipsilateral side.
Compared to the postcondition measurements, condition measurements under the pain treatment
had a decrease in knee abduction moment on the ipsilateral side. (p=0.0002)
For hip moments, we found a treatment by time by side interaction in hip abduction
moments (F6,108=6.32, p<0.0001: Figure 4-g) but not in hip extension moments (F6,108=0.45,
p=0.84: Table 1-j). Compared to the precondition (p<0.0001) and postcondition measurements
(p<0.0001), condition measurements under the pain/effusion treatment had a decrease in hip
abduction moment on the ipsilateral side. Compared to the precondition measurements,
postcondition measurements under the pain/effusion treatment had an increase in hip abduction
moment on the contralateral side (p=0.0007).

Drop landing
Neuromuscular activities
We did not find a treatment, time, side, or time window effect (from 200 ms before to
initial contact; from initial contact to peak knee flexion) in the peak EMG values in the stance
phase during drop landing (Table 2-a through d). For the peak EMG data, F statistics 6,108 ranged
from 0.18 to 0.96 with p values between 0.52 and 0.99. For the mean EMG data, F statistics 6,108
ranged from 0.2 to 0.94 with p values between 0.18 and 0.94.
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Joint angles
Summary data of peak joint angles during drop landing trials are presented in Table 2-f.
Except the frontal plane hip angle at initial contact on the force platform, all angles are the peak
angles during drop landing.
For ankle joint angles, we found a treatment by time interaction in peak ankle dorsiflexion (F6,108=7.02, p<0.0001: Figure 5-a) but not in peak plantar-flexion (F6,108=2.43, p=0.03).
Compared to the precondition measurements of each treatment, condition measurements subjects
under the effusion (p<0.0001), pain (p<0.0001), and pain/effusion treatments (p<0.0001) landed
with a less ankle dorsi-flexion.
For knee joint angles, we found a treatment by time interaction in peak knee flexion
(F6,108=4.51, p=0.0004: Figure 5-b) but not in peak knee abduction (F6,108=0.97, p=0.45) and
adduction (F6,108=1.66, p=0.14). Compared to the precondition and postcondition measurements,
condition measurements under the effusion (p<0.0001), pain (p<0.0001), and pain/effusion
(p<0.0001) demonstrated less peak knee flexion during drop landing.
For hip joint angles, we found a treatment by time interaction in hip angle at initial
contact in the frontal plane (F6,108=6.43, p<0.0001: Figure 5-c), but not in peak hip extension
(F6,108=1.95, p=0.08) and flexion (F6,108=0.63, p=0.7). A trend towards a decrease existed in
peak hip adduction during stance (F6,108=2.94, p=0.01: Figure 5-d). Compared to the
precondition measurements, subjects touched the force platform with an increase in hip
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abduction angle under the effusion (p=0.0005) and pain/effusion (p<0.0001) treatment in the
condition measurements.
PVGRF and time to PVGRF
We found a treatment by time interaction in PVGRF (F6,108=9.10, p<0.0001: Figure 5-e).
During condition measurements subjects under the effusion (p=0.0002) and pain/effusion
treatments (p<0.0001) landed with less of a PVGRF than they did under the control. During
condition measurements subjects under the pain/effusion treatment landed with less of a PVGRF
than they did under the control (p<0.0001) and pain treatment (p<0.0001). During postcondition
measurements, subjects under the pain/effusion treatment landed with less of a PVGRF than they
did under the control (p<0.0001).
Vertical stiffness
We did not find a treatment by time interaction in the vertical stiffness (F6,108=1.81, p<0.1:
Table 2-f) but found a trend in the time to PVGRF (F6,108=2.92, p<0.01: Figure 5-f). Compared
to the control, the amount of time to PVGRF increased under the effusion (p=0.003) and
pain/effusion (p=0.001) treatment.
Joint moments
For peak ankle joint moments, we did not find a treatment by time interaction in plantarflexion (F6,108=1.10, p=0.37: Table 2-g).
For knee joint moments, we found a treatment by time interaction in knee extension
moment (F6,108=14.88, p<0.0001: Figure 5-g) and knee abduction moment (F6,108=5.63, p<0.0001:
Figure 5-h) but not in knee flexion moment (F6,108=1.78, p=0.11: Table 2-g) and adduction
moment (F6,108=1.53, p=0.17: Table 2-g). During condition measurements, subjects under the
pain/effusion treatment landed with less of a knee extension moment than did the control
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(p<0.0001). During postcondition measurements, subjects under the effusion (p=0.0009) and
pain/effusion treatment (p=0.0005) landed with a smaller knee extension moment than the
control. Compared to the precondition (p<0.0001) and postcondition (p=0.0004) measurements,
subjects under the pain/effusion treatment landed with a decreased knee abduction moment in the
condition measurement.
For hip joint moments, we found a treatment by time interaction in hip abduction moment
(F6,108=6.84, p<0.0001: Figure 5-i) but not in hip extension (F6,108=1.96, p=0.08: Table 2-g), and
adduction (F6,108=0.69, p=0.66: Table 2-g). Compared to the precondition measurements,
condition measurements under the effusion (p<0.0001) and pain/effusion (p<0.0001) treatment
landed with less hip abduction moment.
For the time between toe off of the first landing and the initial contact of the second
landing, we did not find a treatment by time interaction (F6,108=1.42, p=0.22: Table 2-h).

Discussion
Pain perception
Knee effusion (50-ml of 0.9% sodium chloride injection) increased perceived pain, and
subjects felt pain for six minutes (average pain intensity: 1.9 cm in the VAS). Our subjects
began walking trials two minutes after the injection of fluid into the joint capsule. Since the
measurements of walking and drop landing took approximately five to eight minutes, an
increased pain perception under the effusion treatment during this time period may confound the
results. The minimal amount of volume injected into the knee joint to induce quadriceps
inhibition has been suggested as 20-30-ml for the VM and 50-60-ml for the VL (57). A high
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volume saline injection (>80-ml) may stimulate nociceptors (111). We thought that 2-ml of
lidocaine injected subcutaneously with 50-ml of sodium chloride injected into the joint capsule
was an appropriate volume not only to alter neuromechanics but also to prevent knee pain from
the activation of the receptor specific to tissue stretch and pressure (e.g. Ruffini endings).
Previously, experimental effusion produced no pain (103, 111, 114). Most subjects in our study
described the sensation by saying “My knee feels tight”. “Tightness” is one of the terms
describing pain in the McGill pain questionnaire (91). Many of them may have interpreted the
tightness as pain. Previously, the McGill pain questionnaire showed a score of less than 1out of
78 possible points (48). Therefore, we speculate that there was little stimulation of the
nociceptors under the effusion treatment.
The pain model (1-ml of 5% sodium chloride injection) induced knee pain for ten
minutes. An average pain perception over this time period was 3.0 cm as measured by a VAS.
This is similar to the previous reports in pain duration (approximately 10 minutes) (14) and
intensity (2.58 – 3.20 cm in VAS) (42, 43). Exact mechanisms and neural pathways of pain
induction due to the use of 5% sodium chloride are unclear. 5% sodium chloride could have
caused chemical irritation within the infrapatellar fat pad, causing nociceptor activation (group
III and/or IV) (4), resulting in an increase of pain perception. Hyperosmolarity of the sodium
chloride may also stimulate release of substance P (37). These support the idea that neural
pathways in 5% sodium chloride injection are consistent with musculoskeletal pain. It should be
noted that cognitive processes such as emotion, depression, past experience, cultural background,
or motivation may also affect pain perception, and while pain intensity was controlled on the
sensory level, these factors may have affected pain perception in our subjects as well.

21

We employed experimental knee pain and effusion models to test the single and
combined effects on two different afferent pathways. For the pain perception, a combination of
pain and effusion treatment did not induce a higher intensity of pain compared to the isolated
pain but produced a longer painful period (16 minutes). This may suggest that the interaction of
afferent fibers specific to sensation of pain (nociceptors) and tissue distention (e.g.: Ruffini
endings) produces an additive effect in terms of pain duration. Ruffini endings (group III) are
low-threshold and slow adapting articular mechanoreceptors located in the skin, joint capsules,
and ligaments (92). It could be speculated that interaction of stimulation in nociceptor and
Ruffini endings may further decrease pain tolerance, resulting in a longer painful period.

Walking
Neuromuscular activities
We observed that the isolated pain, and combined effusion and pain stimulus did not
change neuromuscular activity in the lower extremity. Recent data reported that induced knee
pain immediately reduced quadriceps activation (isometric and isokinetic measurements) (43).
Previously, however, the use of non-steroidal anti inflammatory drugs was noted to reduce knee
pain, but did not change quadriceps activation in patients with clinical knee pain (107). This
suggests that quadriceps inhibition may be associated with pain but that other factors (e.g.: tissue
damage, effusion, and inflammation) independently or combined with pain, may also contribute
to inhibition.
In addition to pain, it has been well established that knee joint effusion causes quadriceps
inhibition (47, 49, 84, 85, 111). Previously, knee joint effusion resulted in quadriceps inhibition
and hamstring facilitation during walking (111). This reverse relationship between quadriceps

22

and hamstrings has also been observed in dynamic (single leg drop landing (82)) and static (the
H-reflex (49)) contractions. Many have suggested that activation of Ruffini endings in the knee
joint capsule stimulate the Ib inhibitory interneurons, resulting in quadriceps inhibition (57, 103).
Based on the previous reports, we expected to see a similar effect with both isolated effusion and
combined effusion and pain stimuli, however but we observed no changes.
Speculating, the lack of differences in neuromuscular activity may be due to the various
compensatory strategies used in different individuals under each treatment. This variation in
neuromuscular adaptations include changes in walking speed, step length, and joint kinematics
and kinetics; different onset and magnitude in voluntary withdrawal and involuntary
physiological motor responses; and muscle fiber recruitment patterns. For example, some
subjects may have decreased plantar-flexion angle during the first 50% of stance while others
increased it during the same time period, showing no changes. Another example, the activation
of the fast twitch fibers may have reduced while the recruitment of the slow twitch fibers
increased to compensate the activation deficits in the same muscle, resulting in no difference in
the net motor unit activity (31). While these ideas are purely speculative, the variability in EMG
data between subjects does support the general idea. More data are needed to determine specific
neuromuscular strategies used during painful and/or effused movements.
The EMG data were normalized by isometric reference position (Figure 1-a). Quadriceps
(VM and VL) and gastrocnemius (GA) are the primary musculature to maintain this position.
Comparatively, the MH and GM are relatively relaxed during the isometric reference position
used in this study. If the reference value is small (MH and GM), then any small change in the
reference data would produce large changes in the reported ratios; ultimately adding variability
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to the EMG data. Lastly, the inherent instability of the EMG signals and cross talk may have
increased variability as well, lending to our failure to demonstrate statistical differences.
Walking speed and stride length
Slower walking speeds have previously been reported in patients with knee OA (1, 68,
116). The average walking speed of our subjects in the control during the condition
measurement was 1.32 (0.08) m/s. Our subjects walked at 1.22 (0.13) m/s in the pain/effusion
treatment during the condition measurement. Previous reports show that chronic knee OA
patients walked at 1.3 (0.3) m/s (16). Our subjects only demonstrated a decreased walking speed
in the pain/effusion treatment as compared to the control. Patients’ overall health, joint pain,
joint effusion, quadriceps activation, and alignment of the lower extremity are all potential
factors in changing walking speed (99). Based on our data, the induction of isolated pain or
isolated knee joint effusion does not appear to have altered walking speed. However, when both
pain and effusion stimuli are present in the knee joint, walking speed decreased. This may
suggest that joint pain and effusion elicit a summative effect in relation to walking speed.
Decreased stride length has also been reported in patients with knee OA (1, 5, 6, 68, 74).
The average stride lengths of our subjects under the control and pain/effusion treatment were
1.49 (0.09) m and 1.40 (0.11) m, respectively. Prior research has shown that healthy subjects
had an average stride length of 1.45 (0.12) m compared to knee OA patients with an average of
1.42 (0.13) m. Like walking speed, stride length in patients with knee OA was closer to what
was observed under the control in the current study as compared to the values noted under the
pain/effusion treatment.
Since knee joint pain and effusion are common in the acute stage of knee joint injury, it is
likely that knee joint injury would immediately modify gait mechanics due to changes in walking
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speed, resulting in alterations in VGRF and joint loading (88). In addition, stride length has a
direct proportional relationship with joint moment (2). Clinicians should be aware that a slower
walking speed and/or shorter stride length following a knee joint injury could be an indication of
neuromechanical alterations in the lower extremity. Thus, joint pain and effusion should be
treated in both the acute stage of knee joint injury and found in chronic condition.
Joint angles
In the current study, there was a trend towards a decreased ipsilateral hip adduction angle
under the pain/effusion treatment (p=0.004). Similar results were observed in patients with AKP
(28). During the stance phase, a decrease in hip adduction angle can occur due to either femoral
abduction on a stationary pelvis, or from the elevation of the contralateral pelvis. Additionally,
elevation of the contralateral pelvis can be caused by a lateral trunk shift towards ipsilateral side.
Visual inspection of the data revealed that, subjects tended to shift their trunks to the ipsilateral
side. Unfortunately, trunk motion in the frontal plane was not analyzed and thus cannot be
included in the results. Therefore, we are uncertain if an ipsilateral trunk shift caused a decrease
in hip adduction. In speculation, subjects may have moved the trunk to the ipsilateral side in an
attempt to alter knee joint loading characteristics and relieve pain and/or pressure. This would
have resulted in the elevation of the contralateral pelvis, resulting in the observed decreased in
hip adduction. We also speculate that this compensatory mechanism affected the hip abductor
muscles that stabilize or control the pelvis in the frontal plane, resulting in a decrease of hip
abduction moment.
Alterations in joint angles have been previously reported in patients with AKP (80, 88),
knee OA (9, 74, 77), and experimentally induced knee effusion (111). Although we expected to
observe alterations in joint angles, no such alterations existed. These findings are surprising
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because there was a 10.1% reduction in walking speed and a 4.7% decrease in stride length. As
walking speed was used as a covariate in all statistical tests, it is logical to think that altered
stride length would also demonstrate kinematic changes. With reduction of walking speed and
stride length, one would expect to see changes in the hip joint angle in the frontal (61) and/or
sagittal plane (65) as these are thought to be influential kinematic variables. In the current study,
there was no difference noted in sagittal plane hip angle, however there was a trend towards
decreased ipsilateral hip adduction angle under the pain/effusion treatment (p=0.004). As
previously discussed, these kinematic alterations might elevate the contralateral hip. This may
have altered the hip range of motion in the sagittal plane, resulting in no observed difference in
the hip extension and flexion angles.
Variability in the characteristics of measurements may be an additional explanation. The
data reduction process has more calculations in joint angles, which has greater chance to create
measurement error and/or variability. While stride length with small variability showed
differences, greater variability in the joint angles may hamper to detect statistical differences.
We believe that our study design (within subject comparisons) minimized this issue, but
measurement error and variability could have possibly contributed.
VGRF
VGRF data are commonly reported to describe gait adaptations in patients with AKP (88),
ACL deficiency (70), meniscectomy (110), and knee OA (116). Discreet values of the peak
impact, unloading, and peak push-off values are typically reported during walking (22, 110).
However, a functional analysis was used to detect changes in VGRF throughout the stance phase
in the current study. This allowed us to determine where differences existed as well as the
magnitude. We observed a decrease in VGRF at around 20 and 80% of stance, and an increase in
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VGRF ranging between 40 and 55% of stance under the pain/effusion treatment. The VGRF at
the first 20%, ranging between 40 and 55 %, and 80% during stance phase could be considered
as the peak impact, unloading, and peak push-off VGRF, respectively (22, 33).
Our data are consistent with many previous studies that have reported a reduced impact
PVGRF (first 50% of stance phase) in patients with AKP (88) and knee OA (110, 116). These
studies are in general agreement that reduced GRF was likely from the joint unloading
mechanism to reduce joint pain (110, 116). In addition, altered VGRFs are likely associated with
a decreased knee extension moment although we did not observe any change in the
neuromuscular activity in quadriceps. Therefore, alterations in VGRF may provide additional
support for studies reporting quadriceps inhibition. It should be noted that self-selected walking
speed was not used as a covariate in the statistical analyzes of VGRF data. Since there is a
positive relationship between VGRF and walking speed (64, 116), alterations in VGRF in the
current study may be related to reduced walking speed (88).
An increase in ipsilateral VGRF ranging between 40 and 55% of stance was observed
under the pain/effusion treatment. During the mid stance phase of normal gait, full knee
extension typically occurs and the direction of the VGRF passes over the knee joint center
resulting in unloading VGRF (104). In the current study, the peak impact, unloading, and peak
push-off VGRF were not identifiable in three subjects under the pain/effusion treatment. A
retrospective review of these subjects’ kinematics and GRF data revealed that these subjects did
not fully extend their knees during the mid stance phase. The direction of the GRF did not move
over the knee joint center but stayed posterior to the knee joint. While the joint unloading
mechanism caused reduced VGRF at 20 and 80% of stance, increased VGRF during the midstance may have been a compensatory strategy to maintain upright posture during walking.
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Under the pain/effusion treatment, ipsilateral VGRF was also reduced at the end of
stance phase. This could be associated with decreased ipsilateral plantar-flexion moments,
which we observed in this study and are reported elsewhere (3). Contralateral VGRF at the end
of stance was noted to increase under the pain/effusion treatment. This alteration could be a
compensatory strategy to decrease the amount of time for the contralateral swing and increase
amount of time for the contralateral stance to help unload the ipsilateral side, thus maintaining
functional gait patterns.
Joint moments
The peak ankle plantar-flexion moment decreased due to pain/effusion. Little data are
available regarding alterations of ankle joint moment in patients with knee joint injury. Using a
knee effusion model, previous research has shown that the quadriceps was inhibited while the
soleus was facilitated with measurements of the H-reflex (49). The soleus facilitation was
interpreted as a compensatory response to quadriceps inhibition, possibly to maintain the
functional kinetic chain of the lower extremity (49). Since the H-reflex assesses motoneuron
pool excitability with the subjects’ position completely controlled (83), it allows for the
elimination of the voluntary or intentional withdrawal response. Since the soleus is one the
plantar-flexors, we hypothesized that the plantar-flexor moment would increase, but our results
contradict the previous findings that the soleus was facilitated by knee joint effusion (49). This
could suggest that the subjects’ intentional withdrawal response (deactivation of the ankle
plantar-flexors) dominated the alteration of the motoneuronpool excitability (facilitation of the
solues). We believe that the subjects’ voluntary withdrawal of the ankle plantar-flexors resulted
from the intention of unloading the joint in the ipsilateral side.
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The peak knee extension moment was reduced under both the effusion and pain/effusion
treatment but not under pain treatment. A trend toward decreased knee extension moment
existed under the effusion treatment (p=0.002). Unfortunately, we did not observe any
neuromuscular activity changes in the quadriceps (VM and VL). However, a reduction in the
knee extension moment during walking can be interpreted as a modification that was adjusted to
decrease or avoid quadriceps contraction thus minimizing knee joint loading (63). This
phenomenon has been termed “quadriceps avoidance” (17) and is reported in individuals with
ACL deficiency (17, 63, 67, 113). This response is thought to decrease anterior translation of the
tibia, thus preventing the knee joint from “giving way” (17, 82). A decreased knee extension
moment has also been observed in knee OA patients as compared to normal subjects (6, 54, 63).
However, this protective mechanism causes quadriceps weakness which has been blamed as a
risk factor for re-injury (46). We speculate that quadriceps inhibition may be a key to
modifying/adapting gait patterns, and finally a factor in accelerating degenerative joint disease
(100). Clinicians should attempt to reverse quadriceps inhibition to avoid potential alterations of
normative movement patterns at the knee joint as well as other joints, instead of considering it a
protective response.
The knee extension moment was increased in the contralateral side under the
pain/effusion treatment. Diminishing ipsilateral knee extension can modulate the excitability of
reflex pathways to the contralateral knee extensors (30). When a knee joint is flexed by an
unexpected noxious stimulus, an appropriate response would be to extend the contralateral side
(10). This is called the crossed extensor reflex (11). Excitation of the Ib interneuron is thought to
be the major contributor to quadriceps inhibition on the ipsilateral side (40). Activation of the Ib
afferents may interact with interneurons, resulting in facilitation of excitatory post-synaptic
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potentials of the contralateral quadriceps (69). An increase in the contralateral knee extension
moment is a compensatory mechanism to maintain balance and assist the ipsilateral knee joint
during flexion while walking.
Peak internal knee abduction moment was reduced for the ipsilateral side. Medial
compartment knee compression force during walking is nearly 2.5 times greater than the lateral
compartment (94), which may partially explain why medial tibiofemoral OA is more common
than lateral tibiofemoral OA (54). Internal knee abduction moment reflects joint load
distribution between the medial and lateral compartment of the tibiofemoral joint (55).
Numerous researchers (6, 9, 50, 75, 98) have reported a decreased knee abduction moment for
medial knee OA patients, which results in an increased varus angle (75, 78), and an increased
medial compartment joint load (94). Contrarily, reduced a knee abduction moment may decrease
medial compartment load, due to related lateral trunk movement to the ipsilateral side (77),
which decreases the horizontal distance between the center of mass and knee joint center.
Because abnormal joint loading patterns are a key factor in joint degeneration, either of
aforementioned situations could promote medial compartment articular cartilage degeneration.
The pain/effusion treatment was noted to reduce ipsilateral hip abduction moment, which
has also been reported in individuals with knee OA (19, 77). The hip abduction moment is
associated with the GM activation, possibly suggesting that the knee joint pain and effusion
immediately produced GM inhibition. However, this should be carefully interpreted because we
did not detect any neuromuscular activity change in the GM. Reduced hip abduction may be due
to changes in postural alignment. For example, a position with an increase in the ipsilateral hip
adduction angle, coupled with a trunk shifting towards the ipsilateral side during the stance phase,
may require less activation in GM to maintain functional gait. Subjects could have also shifted
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their body weight to the contralateral side to unload or minimise joint pressure, we speculate that
a decrease in the hip abduction moment may be an intentional gait adaptation due to the
alterations of the knee extension and abduction moments. However, combining a reduction in
the hip abduction moment with a decreased knee abduction moment may place patients in the
position where a higher impact force may be transferred through the medial compartment at the
knee joint. Hip abductor weakness would lead to pelvic drop in the contralateral side during
swing phase (21). The body center of mass then moves towards the contralateral side, resulting
in an increase in joint loading across the medial compartment (21). Iliotibial tightness over time
may cause hip abductor weakness (36), which may increase compressive force in the medial
compartment. These mechanical alterations are consistent with the idea that factors associated
with acute joint injury (e.g.: pain and effusion) could lead to altered knee joint loading, which
could ultimately contribute to chronic joint disease.
We also observed an increase in contralateral hip abduction moment in the postcondition
measurements. This is consistent with the previous report (6) and can be interpreted as
compensation for the decreased ipsilateral hip abduction moment as it assists ipsilateral swing
and unloading during walking. Interestingly, we did not observe the alteration of the
contralateral hip abduction moment in the condition measurements but did in the postcondition
measurements. Compared to the hip in the frontal plane, the contralateral knee extension
moment immediately increased as opposed to a reduction in the ipsilateral knee extension
moment. The contralateral hip seems to adapt slower to an alteration of the hip abduction
moment. It is plausible that the joint movements in the sagittal plane are the primary
contributors to human bipedal forward locomotion, thus the body may attempt to maintain
functional gait without an alteration in contralateral hip motion. It is speculated that the
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increased contralateral hip abduction moment may lead to more adaptations in other joints along
the kinetic chain over time.
Gait adaptations
Level walking is the most common activity of daily living. Following knee joint injury,
patients modify their normal gait pattern. Using experimentally induced knee joint effusion and
pain, our subjects showed immediate gait deviations. Reduced ipsilateral knee extension
moment and knee abduction moment are the first responses noted due to the induced
pain/effusion stimulus. A decreased ipsilateral knee extension moment is likely related to the
observed increase in contralateral knee extension moment. Decreased ipsilateral knee abduction
likely alters knee joint loading characteristics, including the medial compartment. Ipsilateral
peak ankle plantar-flexion and hip abduction moments were also altered due to pain/effusion.
We theorize that these modifications indicate a voluntary withdrawal, in an attempt to unload the
ipsilateral knee. Reduced hip abduction moment moves the center of mass towards the
contralateral side, placing additional force to the medial compartment at the knee joint. However,
this may relieve medial compartment joint pressure depending on the trunk motion. Either case
an abnormal joint loading pattern, potentially accelerating joint degeneration (9, 77, 98). As a
result of reduced ipsilateral hip abduction moment, contralateral hip abduction moment increases
to maintain body posture and assist with the ipsilateral swing phase of gait. Since we added
walking speed as covariate for all statistical analyzes in joint moments, we are confident that
potential effects of walking speed in joint moments were controlled.
Gait adaptations observed in this study are consistent with the idea that pain and/or
effusion, as an independent factor in joint injury, could lead degenerative changes in the joint
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and potentially chronic joint disease. More data are needed to bridge changes observed in this
study to degenerative joint disease.

Drop landing
Neuromuscular activity
With knee joint effusion, reduced quadriceps and increased hamstring neuromuscular
activity have been reported during a single leg drop landing (82). Since we used a knee effusion
model, we expected to observe similar results. Additionally, neuromechanical alterations (knee
extension moments and dorsi-flexion moments) were observed in the current study. We did not,
however, observe any change in the peak and mean values of lower extremity neuromuscular
activity. Similar to the walking trials, the lack of difference observed in the neuromuscular
activity may also be due to similar reasons such as variation in compensatory strategies,
normalization process, and inherent instability of EMG measurements.
PVGRF and time to peak VGRF
The measurement of PVGRF during drop landing can indicate the amount of force
absorbed by the body (96). Interestingly, our subjects landed with a reduced PVGRF under the
effusion and pain/effusion treatment. The previous reports of changes of the PVGRF during a
single leg drop landing have varied. In pre- and post-measurement studies, the PVGRF was
decreased in the fatigued group (71, 101). There was no difference of the PVGRF in between
healthy controls and patients with ACL deficiency (73) and ACL reconstruction (25). Artificial
knee effusion caused an increase in the PVGRF in healthy subjects (82). The inconsistency in
PVGRF change, during drop landing, was one of the reasons that we employed the controlled
injury models. Among those previous data, it would be parallel to compare our results to those
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that used the knee effusion model. Our results are in contradiction to the previous study
reporting an increase in the PVGRF by artificial knee joint effusion (82).
Several factors may explain why our subjects showed a reduction in the PVGRF under
the effusion and pain/effusion treatment. First of all, we observed changes in joint angles: a
decrease in dorsi-flexion angle, knee flexion, and hip adduction. Compared to a normal landing
technique, the stiffer landing of the lower extremity has previously shown to increase the
PVGRF during drop landing (height of 32 cm; current study: 30 cm) (117). Contrarily, our
subjects landed with a more erected posture causing a decrease of the PVGRF. This may suggest
that the energy from the imposed force to the body may have not been dissipated by the lower
extremity or the subjects have tried to avoid absorption of the impact force using their lower
extremity. Additionally, the amount of time between the toe off of the first landing and the
initial contact of the second landing was not different among the treatments at any time interval.
This may suggest that the secondary vertical jump did not affect the alterations in the PVGRF.
Therefore, we believe that trunk shifting towards the ipsilateral side may have been strategy used
by subjects to absorb the energy, resulting in a decrease in the PVGRF. It is unfortunate that the
trunk motions were not analyzed but this is indirectly supported by decreased ipsilateral hip
adduction. We also observed a trend towards an increase in the amount of time to PVGRF under
the effusion (p=0.003) and pain/effusion (p=0.001) treatment. These results also support the idea
that trunk lateral shifting delayed the time to PVGRF, potentially dissipating forces over a longer
period of time.
Length-tension relationships in the activation of the plantar-flexors may be considered a
factor to reduce the PVGRF. The gastrocnemius and the Achilles tendon slack when the peak
knee flexion angle increases during stance. This is not the optimum position for the
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gastrocnemius to generate full force according to the length–tension relationship (90). In a
previous study, landing technique with decreased knee flexion showed slightly lower PVGRF
than the normal knee bent landing technique (96). Unfortunately, this idea is not supported by
the neuromuscular activity data in the current study. For the gastrocnemius, however, stiffer
landing posture may have been a better position to eccentrically absorb the impact force in the
current study.
Finally, subjects may have changed their dropping technique to drop from a different
height due to the saline injections, resulting in decreased PVGRF. Subjects were instructed to
drop from the box without bending the leg used to support their mass while on the box. The
assessors visually verified that subjects did not bend the support leg prior to dropping from the
box. While the landing was controlled as much as possible, we admit that the landing techniques
under the different treatments may have varied slightly. However, we believe that varied landing
techniques caused minimal effects.
Vertical stiffness
Stiffness has been calculated as the ratio between the PVGRF and the maximal vertical
displacement of the center of body mass during drop landing (20). To date, there is little whole
body stiffness data to make a comparison with our calculations. Previous data in whole body
stiffness during a single leg hopping activity ranging between 2000 – 8000 N/m in children
(6.1±1.2 yrs) (38). This range is six times less than the range in the current study (8000 – 48000
N/m). The big differences in stiffness values may be due to the performed activity in our study
and subjects’ age. Our subjects (22.4 ±2.4 yrs) performed a higher velocity activity (landing
from a box at a height of 30 cm) while the children performed several hops on the ground (38).
Our subjects, under the effusion and pain/effusion treatment, landed with decreased knee flexion
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and ankle dosiflexion angle, but stiffness was not different. This may be due to large variations
in stiffness values and/or reduced PVGRF.
Joint angles
Subjects landed with a more extended knee under the effusion and pain/effusion
treatment as compared to the control. Previously, a decreased knee flexion angle was reported in
healthy subjects with artificial knee effusion (82) and in patients with ACL reconstruction (25).
A stiffer landing posture may be associated with a decreased knee extension moment. The
greater the knee flexion angle becomes after landing requires increased eccentric contraction of
the quadriceps. Since the knee extension moment was reduced, subjects may have been
dependent on the straightened lower extremity alignment and bony architecture rather than
eccentric contraction of the quadriceps.
There was a decrease in ankle dorsi-flexion angle under the effusion, pain, and
pain/effusion treatment compared to the control. Combined with decreased knee flexion angle,
decreased dorsi-flexion angle allowed the subjects to balance using the lower extremity
alignment (more straightened leg) rather than contracting the lower extremity musculature,
especially quadriceps. There has been sufficient evidence to support quadriceps weakness with
AKP (81) and knee joint effusion (49, 82). Although there was no change observed in
neuromuscular activity in the quadriceps, we speculate that the quadriceps inhibition by saline
injections resulted in decreased dorsi-flexion and knee flexion.
Subjects were instructed to drop down on the ipsilateral foot followed by an immediate
vertical jump. The peak hip abduction occurred at initial contact and at toe off from a jump.
Since the results from either movement confound each other, the hip angle in the frontal plane at
initial contact would be more appropriate to compare. Subjects touched the force platform with
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an increase in hip abduction angle under the effusion and pain/effusion condition. Subjects may
have intentionally tried to stretch the ipsilateral limb to prepare for landing, resulting in increased
hip abduction. This may have been due to hesitance to land on the ipsilateral side. We also
observed a trend towards a decreased ipsilateral hip adduction angle under the pain/effusion
treatment (p=0.002) as compared to the control. Upon closer review of the kinematic data, an
increase in ipsilateral adduction of the femur was less common in most subjects. As discussed
for walking trials, this alteration more likely occurs due to the lateral trunk shifting towards the
ipsilateral side, resulting in an elevation of the contralateral pelvis.
Joint moment alterations and injury risk
Landing from a jump is a common and essential movement in most physical activities.
Lower extremity neuromechanical changes due to a knee joint injury alters the normal landing
strategies, resulting in an injury. For example, a prospective study (79) tracking two seasons of
professional handball players reported that a non-contact mechanism of injury occurred in 95%
of all ACL ruptures. Non-contact ACL injuries have been reported most commonly in the last
15 minutes of the first half and in the last 30 minutes of the second half of soccer games (41).
Therefore, fatigue has been thought to be a factor in increasing the risk of non-contact ACL
ruptures. Neuromechanical modifications during drop landing due to fatigue include: a decrease
in the PVGRF (71, 101); and landing with a more straightened leg (101). Our data are in
general agreement with those previously reported with fatigue, thereby supporting the idea that
knee joint pain and effusion stimuli may increase the risk of non-contractile injuries.
Even though we did not observe any neuromuscular changes, a reduction in the ipsilateral
knee extension moment could have resulted from quadriceps inhibition under the effusion and
pain/effusion treatment. This is consistent with the previous research using artificial knee
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effusion (82). Knee extensors are believed to serve as the major energy absorbers (25, 26),
suggesting that decreased knee extension moment may reduce knee joint stability during
dynamic landing from a jump. Sufficient evidence provides that quadriceps dysfunction exists in
patients with ACL injuries (23, 102, 112). A decrease in knee extension moment due to
quadriceps inhibition may decrease the capability of the quadriceps to provide as an active
restraint in the knee joint stability (7). A reduced knee extension moment was observed during
walking in the current study, which supports the previous reports in patients with knee OA (6,
54). Immediate joint pain and effusion appear to produce quadriceps inhibition not only during
walking but also during single leg drop landing. As discussed in walking, we believe that
quadriceps inhibition triggered other neuromechanical modifications during drop landing.
Therefore, it is apparent that the key factor in early rehabilitation following a knee joint
injury/surgery will be to reverse quadriceps inhibition and/or restore quadriceps function.
There was a trend towards a decrease in peak internal knee abduction moment in the
condition measurement compared to the precondition (P=0.002) and postcondition (P=0.02).
This finding is consistent with the walking trials in the current study, suggesting that a decrease
in knee abduction moment may affect normal joint loading due to trunk motion. As discussed
earlier, we assume that subjects shifted their trunks towards to the ipsilateral side. Speculatively,
this compensatory motion changes the center of mass shifting to the ipsilateral side, resulting in a
reduction in joint stress on the medial compartment due to a reduction in external knee adduction
moment. Again, since an abnormal joint loading is a major factor, either adaptation will cause
joint degeneration at the knee joint.
Cadeveric (72) and computer model (8) studies suggest that knee joint loading changes in
either direction of the frontal plane (abduction and/or adduction) can increase tension of the ACL.
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This suggests that the combination of a reduced knee extension moment and a reduced knee
abduction moment could potentially increase the risk of ACL injury.

Assumptions and limitations
We assumed that joint sizes and the ability to absorb the sterile saline (infrapatellar fat
pad and knee joint capsule) were similar. In addition, physiological capacity to absorb or reduce
the effects of saline may differ from subject to subject. However, the amount of saline should be
standardized to produce pain and/or effusion stimuli. In our pilot study, the minimum amount of
hypertonic saline was 1-ml to produce AKP for 10 minutes, which allows enough time for the
measurements.
The neuromechanical alterations reported in our study are limited to immediate responses.
Patients with chronic knee OA have likely been reprogramming their movement strategies for a
relatively longer time period. In other words, it could take neuromechanical alterations greater
than those observed immediately or 30 minutes post injury, to accelerate joint degeneration.
Therefore, we assume that patients will maintain the neuromechanical alterations shown
immediately post injection or further develop movement modifications as time progresses.
During walking, we observed both an increase in the hip adduction angle and hip abduction
moment on the contralateral side in the postcondition measurement. These compensatory
adaptations were not observed in the condition measurements. Therefore, it is safe to assume
that further compensatory movements will occur following knee joint injury.
Even though this artificial pain produced similar types of clinical pain such as aching
and throbbing (14), the experimental pain model does not necessarily reproduce the clinical or
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chronic AKP. Therefore, the movement adaptations due to the experimental injury models in the
current study should not directly be considered as those in patients with clinical knee joint
injuries. We only examined the isolated and combined effects of knee joint pain or effusion on
altered neuromechanics in walking and drop landing. It should be noted that there are more
complicated chemical and mechanical interactions following a knee joint injury. For example, a
clinical knee joint injury typically involves the primary and secondary tissue damage with the
resultant inflammatory response in addition to pain and joint effusion.

Conclusion
We were interested in examining how isolated joint effusion or joint pain, as well as
combination of these two stimuli, would alter neuromechanics in functional movements. In
quantifiable comparisons, a total number of 16, 7, and 3 dependent variables were altered during
functional movements under the pain/effusion, effusion, and pain treatments, respectively.
Based on our results, isolated joint effusion appears to play a wider role in neuromechanical
alterations during functional movements. When pain stimulus is combined with effusion
stimulus it appears to produce a summative effect that is greater than either isolated effusion or
pain. Since joint effusion is typically accompanied by pain, both variables should be
aggressively managed in all stages of knee joint injury and rehabilitation.
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Tables and figures
Figure 1-a. EMG during this isometric reference position was recorded to normalize the EMG
amplitude. Subjects were asked to squat down until their butt slightly touches an edge of the
desk.

46

Figure 1-b. A static standing trial was first measured and considered as each subjects’ neutral
body alignment. Twelve surface EMG electrodes and four clusters of four reflective markers
were attached to the lower extremity. In addition to, twenty seven single reflective markers were
attached to the lower extremity and trunk.

47

Figure 2. Mean and standard deviations for pain perception (VAS) for each treatment over time.
† indicates a difference between the effusion and control treatment. § indicates a difference
between the pain and control treatment. * indicates a difference between the pain/effusion and
the control treatment. All differences indicate p<0.0001.

48

Figure 3. Plots are showing the results of the functional data analyses for VGRF during walking.
The solid line within the shaded area indicates the mean difference in VGRF values between
comparisons. The shaded area represents the 95% confidence interval bands.
Figure 3-a. 95% confidence interval for ipsilateral VGRF between the precondition and
condition measurements under the control treatment.
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Figure 3-b. 95% confidence interval for ipsilateral VGRF between the condition and
postcondition measurements under the control treatment.
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Figure 3-c. 95% confidence interval for ipsilateral VGRF between the precondition and
postcondition measurements under the control treatment.
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Figure 3-d. 95% confidence interval for ipsilateral VGRF between the precondition and
condition measurements under the effusion treatment. Compared to precondition measurements,
the mean VGRF recorded during condition measurements was approximately 25 N higher at 95%
of stance.

52

Figure 3-e. 95% confidence interval for ipsilateral VGRF between the condition and
postcondition measurements under the effusion treatment. Compared to condition measurements,
the mean VGRF recorded during postcondition measurements was approximately 20 N less at 95%
of stance.
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Figure 3-f. 95% confidence interval for ipsilateral VGRF between the precondition and
postcondition measurements under the effusion treatment.

54

Figure 3-g. 95% confidence interval for ipsilateral VGRF between the precondition and
condition measurements under the pain treatment.
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Figure 3-h. 95% confidence interval for ipsilateral VGRF between the condition and
postcondition measurements under the pain treatment.
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Figure 3-i. 95% confidence interval for ipsilateral VGRF between the precondition and
postcondition measurements under the pain treatment.
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Figure 3-j. 95% confidence interval for ipsilateral VGRF between the precondition and condition
measurements under the pain/effusion treatment. Compared to precondition measurements, the
mean VGRF recorded during condition measurements was approximately 75 N less at
approximately 20% and 80% of stance, but 75 N higher ranging between 40 and 55%, and 30 N
higher at 95% of stance.
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Figure 3-k. 95% confidence interval for ipsilateral VGRF between the condition and
postcondition measurements under the pain/effusion treatment. Compared to condition
measurements, the mean VGRF recorded during postcondition measurements was approximately
25 N higher ranging from approximately 90% until the end of stance.

59

Figure 3-l. 95% confidence interval for ipsilateral VGRF between the precondition and
postcondition measurements under the pain/effusion treatment.
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Figure 3-m. 95% confidence interval for contralateral VGRF between the precondition and
condition measurements under the control treatment.
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Figure 3-n. 95% confidence interval for contralateral VGRF between the condition and
postcondition measurements under the control treatment.
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Figure 3-o. 95% confidence interval for contralateral VGRF between the precondition and
postcondition measurements under the control treatment.
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Figure 3-p. 95% confidence interval for contralateral VGRF between the precondition and
condition measurements under the effusion treatment.
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Figure 3-q. 95% confidence interval for contralateral VGRF between the condition and
postcondition measurements under the effusion treatment.
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Figure 3-r. 95% confidence interval for contralateral VGRF between the precondition and
postcondition measurements under the effusion treatment.
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Figure 3-s. 95% confidence interval for contralateral VGRF between the precondition and
condition measurements under the pain treatment.
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Figure 3-t. 95% confidence interval for contralateral VGRF between the condition and
postcondition measurements under the pain treatment.
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Figure 3-u. 95% confidence interval for contralateral VGRF between the precondition and
postcondition measurements under the pain treatment.

69

Figure 3-v. 95% confidence interval for contralateral VGRF between the precondition and
condition measurements under the pain/effusion treatment. Compared to precondition
measurements, mean VGRF during condition measurements was approximately 50 N higher
ranging from approximately 90% until the end of stance.

70

Figure 3-w. 95% confidence interval for contralateral VGRF between the condition and
postcondition measurements under the pain/effusion treatment. Compared to condition
measurements, the mean VGRF recorded during postcondition measurements was approximately
50 N less ranging from approximately 90% until the end of stance.
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Figure 3-x. 95% confidence interval for contralateral VGRF between the precondition and
postcondition measurements under the pain/effusion treatment.
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Figure 4-a. Means and standard deviations for walking speed during walking. * compared to the
precondition (p=0.0001) and the postcondition measurement (p=0.0005) under the pain/effusion
treatment. * the pain/effusion treatment compared to the control (p=0.0003) and the pain
treatment (p=0.0005) during the condition measurement. † compared to the precondition
measurement (p=0.002) under the effusion treatment.
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Figure 4-b. Means and standard deviations for stride length during walking. * compared to the
precondition (p=0.0001) and the postcondition measurement (p=0.0005) under the pain/effusion
treatment.
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Figure 4-c. Means and standard deviations for the peak hip adduction angles during walking. *
compared to the precondition measurement (p=0.002) under the pain/effusion treatment in the
ipsilateral side. † compared to the condition measurement (p=0.004) under the pain/effusion
treatment in the contralateral side.
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Figure 4-d. Means and standard deviations for the peak ankle dorsi-flexion moments during
walking. * compared to the precondition (p=0.002) under the pain/effusion treatment in the
ipsilateral side. † compared to the condition (p=0.004) measurement under the pain/effusion
treatment in the contralateral side.
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Figure 4-e. Means and standard deviations for the peak knee extension moments during walking.
* compared to the condition (p=0.0008) and the postcondition measurement (p=0.004) under the
pain/effusion treatment in the ipsilateral side. § compared to the precondition measurement
(p=0.002) under the pain/effusion treatment in the contralateral side. ‡ compared to the
precondition (p<0.0001) and the postcondition (p=0.002) measurement under the pain/effusion
treatment in the contralateral side.
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Figure 4-f. Means and standard deviations for the peak knee abduction moments during walking.
* compared to the precondition (p<0.0001) and the postcondition measurement (p<0.0001) under
the pain/effusion treatment in the ipsilateral side. † compared to the condition measurement
(p=0.0002) under the pain treatment in the ipsilateral side.
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Figure 4-g. Means and standard deviations for the peak hip abduction moments during walking.
* compared to the precondition and the postcondition measurement (p<0.0001) under the
pain/effusion treatment in the ipsilateral side. † compared to the precondition measurement
(p=0.0007) under the pain treatment in the contralateral side.
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Figure 5-a. Means and standard deviations for the peak ankle dorsi-flexion angles during drop
landing. * compared to the precondition (p<0.0001) and the postcondition measurement
(p=0.001) under the pain/effusion treatment in the ipsilateral side. † compared to the
precondition (p<0.0001) and the postcondition measurement (p=0.003) under the pain treatment
in the ipsilateral side. ‡ compared to the condition and the postcondition measurement
(p<0.0001) under the effusion treatment in the ipsilateral side.
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Figure 5-b. Means and standard deviations for the peak knee flexion angles during drop landing.
* compared to the precondition and the postcondition measurement (p<0.0001) under the
pain/effusion treatment in the ipsilateral side. † compared to the precondition and the
postcondition measurement (p<0.0001) under the pain treatment in the ipsilateral side. ‡
compared to the condition and the postcondition measurement (p<0.0001) under the effusion
treatment in the ipsilateral side.
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Figure 5-c. Means and standard deviations for the peak hip angles at initial contact during drop
landing. * compared to the precondition (p<0.0001) and the postcondition measurement (p=0.05)
under the pain/effusion treatment in the ipsilateral side. † compared to the precondition
(p=0.0005) and the postcondition measurement (p=0.02) under the effusion treatment in the
ipsilateral side. ‡ compared to the condition measurement (p=0.002) under the pain treatment in
the ipsilateral side.
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Figure 5-d. Means and standard deviations for the peak hip adduction angles during drop landing.
* compared to the precondition measurement (p=0.002) under the pain/effusion treatment in the
ipsilateral side.
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Figure 5-e. Means and standard deviations for PVGRF during drop landing. * compared to the
precondition measurement and the postcondition (p<0.0001) under the pain/effusion treatment in
the ipsilateral side. † compared to the precondition measurement (p<0.0002) under the effusion
treatment in the ipsilateral side.
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Figure 5-f. Means and standard deviations for time to PVGRF during drop landing. * compared
to the control treatment (p=0.001) under the pain/effusion treatment in the ipsilateral side. †
compared to the condition measurement (p=0.001) under the effusion treatment in the ipsilateral
side.
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Figure 5-g. Means and standard deviations for the peak knee extension moments during drop
landing. * compared to the precondition measurement (p=0.0001) under the pain/effusion
treatment in the ipsilateral side. † compared to the precondition measurement (p<0.02) under the
effusion treatment in the ipsilateral side. ‡ compared to the effusion (p=0.009) and the
pain/effusion (p=0.005) treatment during the postcondition measurements.
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Figure 5-h. Means and standard deviations for the peak knee abduction moments during drop
landing. * compared to the condition (p<0.0001) and the postcondition measurement (p=0.0004)
under the pain/effusion treatment in the ipsilateral side. † compared to the condition (p=0.001)
and the postcondition measurement (p=0.02) under the effusion treatment in the ipsilateral side.
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Figure 5-i. Means and standard deviations for the peak hip abduction moments during drop
landing. * compared to the effusion (p=0.002) and the pain/effusion treatment (p=0.001) during
the condition measurement. † compared to the effusion (p=0.04) and the pain/effusion treatment
(p=0.007) during the postcondition measurement.
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Table 1-a. Means and standard deviations for peak EMG for each muscle, side, and treatment
during the first quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
7.33 (7.91)
10.05 (12.79)
9.82 (14.15)
7.32 (3.60)
8.41 (5.73)
9.85 (8.63)
1.38 (0.73)
3.18 (4.66)
2.12 (2.22)
2.17 (3.63)
3.05 (6.40)
2.66 (4.52)
1.76 (1.73)
3.03 (4.98)
4.55 (9.98)
1.45 (0.78)
1.94 (2.08)
2.03 (1.76)
8.06 (4.97)
12.95 (12.33)
12.35 (10.00)
5.73 (2.66)
6.98 (4.53)
7.20 (4.16)
6.02 (4.09)
6.04 (3.71)
5.99 (4.03)
5.70 (3.46)
6.15 (4.31)
5.88 (4.16)
3.29 (1.25)
3.25 (1.23)
3.18 (1.12)
4.10 (2.61)
4.16 (2.92)
4.20 (2.36)

effusion
5.88 (3.74)
7.47 (5.87)
6.39 (5.50)
9.31 (11.69)
8.33 (7.23)
8.23 (7.34)
1.09 (0.50)
1.27 (0.44)
1.08 (0.42)
1.35 (0.8)
1.26 (1.18)
1.04 (0.97)
1.92 (2.26)
1.93 (1.55)
1.39 (1.07)
1.42 (0.59)
1.34 (1.53)
1.12 (0.97)
8.76 (7.54)
6.24 (3.51)
10.06 (24.11)
6.10 (4.75)
8.86 (15.09)
7.97 (13.78)
8.21 (4.13)
9.21 (3.99)
8.58 (3.98)
7.47 (5.15)
8.16 (5.86)
7.98 (4.78)
3.57 (1.56)
3.48 (1.30)
3.60 (1.74)
3.91 (3.02)
4.27 (2.95)
5.14 (4.83)

pain
8.7357 (6.12)
8.6813 (6.39)
8.2172 (6.86)
18.71 (44.91)
17.77 (44.15)
17.22 (45.11)
1.20 (0.78)
1.43 (1.09)
1.39 (1.36)
1.71 (2.06)
1.29 (0.98)
1.28 (0.93)
2.05 (2.60)
1.81 (2.16)
1.56 (1.30)
2.85 (4.34)
1.72 (1.26)
1.96 (2.13)
10.69 (19.38)
11.27 (20.06)
9.72 (18.82)
10.00 (21.49)
9.18 (19.75)
9.65 (20.89)
7.81 (4.94)
8.13 (4.69)
8.19 (5.44)
8.79 (5.77)
8.09 (5.49)
8.67 (6.13)
7.19 (14.66)
7.19 (14.63)
7.30 (14.95)
4.88 (5.27)
5.03 (5.62)
4.61 (5.32)

pain/effusion
6.69 (4.49)
7.36 (3.12)
8.39 (8.65)
7.56 (4.70)
6.84 (4.06)
6.69 (4.72)
1.24 (0.64)
1.36 (0.64)
1.23 (0.63)
1.52 (1.24)
1.16 (1.01)
0.89 (0.56)
1.42 (0.84)
1.51 (0.88)
1.16 (0.52)
1.47 (0.59)
1.08 (0.55)
0.92 (0.59)
6.29 (4.47)
6.88 (6.95)
5.30 (3.18)
5.94 (4.51)
5.86 (4.49)
5.10 (4.89)
6.50 (4.58)
6.77 (4.01)
6.78 (4.60)
6.19 (3.29)
6.08 (5.17)
5.98 (3.79)
2.87 (1.52)
2.87 (1.36)
2.55 (1.15)
3.11 (1.96)
5.13 (8.14)
3.27 (2.29)
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Table 1-b. Means and standard deviations for peak EMG for each muscle, side, and treatment
during the second quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
13.31 (10.26)
13.70 (10.56)
13.77 (11.38)
13.21 (7.83)
12.52 (8.67)
13.51 (8.74)
0.50 (0.47)
1.03 (1.62)
0.78 (1.19)
1.07 (2.57)
1.06 (1.79)
0.90 (1.42)
0.63 (0.36)
1.02 (1.40)
3.34 (11.01)
0.50 (0.35)
0.69 (0.68)
0.87 (0.95)
2.37 (1.29)
3.36 (2.46)
3.26 (1.93)
2.50 (1.98)
3.34 (2.92)
3.08 (2.26)
2.48 (1.30)
2.62 (1.88)
2.63 (2.02)
2.39 (1.28)
2.19 (1.10)
2.44 (1.13)
1.09 (0.37)
1.09 (0.40)
1.06 (0.32)
1.14 (0.29)
1.14 (0.33)
1.31 (0.46)

effusion
13.82 (9.19)
14.65 (11.24)
13.97 (9.50)
14.20 (10.3)
12.27 (7.95)
13.24 (8.86)
0.49 (0.40)
0.50 (0.38)
0.34 (0.28)
0.55 (0.57)
0.68 (0.9)
0.46 (0.84)
0.47 (0.21)
0.64 (0.28)
0.39 (0.20)
0.52 (0.33)
0.46 (0.32)
0.34 (0.18)
3.42 (3.43)
2.27 (1.35)
3.99 (9.23)
2.99 (3.06)
8.73 (26.87)
7.91 (24.78)
3.25 (2.12)
3.49 (2.36)
3.08 (2.05)
3.03 (3.12)
3.73 (3.74)
3.88 (3.99)
1.12 (0.49)
1.19 (0.52)
1.01 (0.49)
1.12 (0.36)
2.90 (7.06)
1.52 (2.36)

pain
12.64 (7.08)
12.93 (6.12)
14.67 (9.40)
22.32 (44.34)
21.96 (43.49)
22.51 (44.17)
0.55 (0.71)
0.54 (0.66)
0.50 (0.71)
0.92 (1.43)
0.67 (0.89)
0.59 (0.84)
0.81 (0.97)
0.71 (0.57)
0.55 (0.52)
1.02 (1.62)
0.91 (0.98)
0.70 (0.65)
10.07 (34.57)
10.59 (35.72)
9.68 (34.24)
13.67 (50.17)
13.62 (48.93)
13.36 (49.69)
3.63 (3.5)
3.88 (3.49)
3.56 (3.12)
4.12 (3.96)
4.12 (3.78)
3.81 (3.86)
2.79 (7.10)
2.77 (6.36)
2.98 (8.10)
4.52 (14.16)
4.56 (13.43)
4.79 (15.46)

pain/effusion
12.50 (7.07)
14.83 (9.01)
13.99 (10.55)
11.68 (8.03)
10.70 (7.24)
11.34 (8.61)
0.39 (0.23)
0.40 (0.22)
0.41 (0.34)
0.55 (0.53)
0.56 (0.92)
0.30 (0.24)
0.67 (0.54)
0.63 (0.43)
0.47 (0.20)
0.53 (0.45)
0.55 (0.34)
0.31 (0.17)
1.76 (1.08)
2.43 (1.72)
2.08 (1.68)
2.29 (1.55)
4.49 (7.05)
2.48 (2.07)
2.49 (1.57)
3.00 (1.94)
2.43 (1.59)
2.79 (2.66)
3.80 (4.65)
3.09 (2.46)
1.07 (0.35)
1.25 (0.63)
0.95 (0.41)
1.12 (0.42)
2.42 (4.58)
1.09 (0.49)
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Table 1-c. Means and standard deviations for peak EMG for each muscle, side, and treatment
during the third quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
22.38 (14.63)
21.92 (14.65)
21.82 (13.45)
18.78 (13.18)
18.12 (11.87)
18.37 (11.78)
0.32 (0.29)
0.50 (0.70)
0.38 (0.46)
0.48 (0.91)
0.59 (1.28)
0.59 (1.25)
0.26 (0.13)
0.29 (0.20)
1.11 (3.59)
0.23 (0.15)
0.26 (0.24)
0.25 (0.17)
1.66 (1.01)
1.66 (0.95)
1.65 (0.91)
2.08 (1.92)
2.12 (1.86)
1.82 (1.26)
1.99 (0.92)
2.30 (1.48)
2.52 (2.22)
2.09 (1.42)
1.84 (0.99)
1.94 (1.17)
1.09 (0.70)
1.04 (0.56)
0.97 (0.40)
0.98 (0.34)
1.03 (0.35)
1.02 (0.33)

effusion
23.20 (16.80)
25.22 (19.55)
24.03 (17.79)
17.59 (9.27)
16.54 (9.14)
16.82 (10.43)
0.21 (0.13)
0.29 (0.23)
0.20 (0.19)
0.42 (0.71)
0.56 (1.04)
0.50 (1.07)
0.23 (0.20)
0.26 (0.16)
0.21 (0.14)
0.25 (0.22)
0.27 (0.31)
0.24 (0.20)
1.40 (0.79)
1.80 (1.18)
2.62 (6.39)
1.72 (1.39)
1.42 (1.11)
1.27 (1.02)
2.42 (1.40)
2.25 (1.22)
2.23 (1.16)
2.45 (2.78)
2.59 (2.59)
2.26 (2.58)
0.97 (0.37)
0.93 (0.38)
0.83 (0.37)
1.08 (0.46)
1.34 (2.29)
0.76 (0.35)

pain
20.27 (11.66)
22.51 (14.10)
21.30 (12.88)
26.76 (44.19)
25.61 (43.38)
25.99 (44.09)
0.33 (0.71)
0.41 (0.70)
0.35 (0.69)
0.63 (1.14)
0.60 (0.99)
0.59 (1.05)
0.47 (0.91)
0.43 (0.84)
0.50 (0.88)
0.36 (0.46)
0.36 (0.48)
0.27 (0.28)
9.58 (36.38)
1.40 (0.63)
6.79 (25.08)
14.62 (58.85)
14.50 (57.99)
14.32 (58.64)
2.57 (2.84)
2.20 (1.26)
2.46 (1.84)
3.47 (4.89)
3.29 (4.05)
3.31 (4.45)
1.62 (2.63)
0.95 (0.34)
1.33 (1.82)
4.46 (14.31)
4.19 (13.85)
4.52 (15.55)

pain/effusion
23.14 (15.79)
23.84 (14.64)
22.84 (14.13)
17.59 (11.06)
14.06 (10.67)
16.43 (13.62)
0.33 (0.38)
0.34 (0.30)
0.28 (0.32)
0.34 (0.34)
0.48 (0.99)
0.21 (0.17)
0.27 (0.16)
0.34 (0.21)
0.24 (0.18)
0.22 (0.13)
0.32 (0.29)
0.13 (0.09)
1.46 (1.19)
1.49 (1.21)
1.16 (0.80)
1.30 (0.95)
3.43 (8.19)
1.09 (0.60)
1.84 (1.26)
2.03 (1.42)
1.65 (1.24)
2.30 (1.95)
2.84 (3.46)
2.28 (1.98)
0.99 (0.30)
1.00 (0.40)
0.80 (0.33)
1.01 (0.38)
1.37 (1.56)
0.81 (0.32)
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Table 1-d. Means and standard deviations for peak EMG for each muscle, side, and treatment
during the fourth quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
10.24 (7.4)
8.64 (4.75)
9.46 (6.16)
8.38 (6.47)
7.79 (4.74)
9.76 (6.26)
0.50 (0.61)
0.74 (0.88)
0.81 (1.45)
0.65 (1.20)
0.88 (1.44)
1.05 (1.63)
0.33 (0.26)
0.55 (0.80)
0.98 (2.00)
0.26 (0.14)
0.41 (0.63)
0.46 (0.61)
2.54 (2.35)
4.06 (7.18)
3.77 (5.75)
1.96 (1.28)
2.03 (1.42)
2.22 (1.89)
1.69 (2.70)
2.11 (2.89)
1.90 (2.31)
2.17 (4.67)
1.89 (2.96)
1.23 (0.77)
1.09 (0.70)
1.08 (0.56)
1.03 (0.43)
1.04 (0.32)
1.11 (0.44)
1.08 (0.40)

effusion
10.26 (9.88)
11.22 (11.8)
9.45 (8.82)
9.04 (5.79)
9.34 (7.99)
10.72 (12.27)
0.38 (0.42)
0.50 (0.71)
0.54 (1.36)
0.63 (0.87)
0.83 (1.29)
0.61 (1.14)
0.31 (0.35)
0.27 (0.25)
0.27 (0.38)
0.29 (0.23)
0.35 (0.64)
0.32 (0.64)
2.37 (2.57)
2.26 (2.07)
3.54 (9.47)
1.88 (1.93)
1.28 (0.71)
1.14 (0.59)
1.57 (1.36)
1.08 (0.53)
0.94 (0.39)
1.25 (1.33)
1.38 (1.80)
0.95 (1.07)
0.98 (0.38)
0.89 (0.34)
0.75 (0.26)
1.08 (0.41)
1.13 (1.17)
0.75 (0.28)

pain
12.34 (13.70)
12.92 (13.72)
12.41 (13.37)
19.99 (49.41)
18.43 (47.60)
18.51 (48.36)
0.73 (1.25)
0.49 (0.82)
0.51 (0.90)
0.82 (1.25)
0.70 (0.99)
0.79 (1.05)
1.09 (2.89)
0.89 (2.79)
0.95 (2.78)
0.48 (0.78)
0.32 (0.36)
0.31 (0.27)
2.18 (2.03)
1.64 (0.87)
1.31 (0.65)
1.22 (0.62)
1.21 (0.55)
1.36 (1.57)
0.94 (0.46)
0.88 (0.40)
0.93 (0.49)
1.07 (0.83)
0.91 (0.62)
0.89 (0.54)
1.05 (0.54)
0.95 (0.43)
1.01 (0.78)
1.13 (0.59)
1.01 (0.65)
0.86 (0.44)

pain/effusion
8.97 (6.56)
12.34 (8.85)
9.52 (6.22)
7.86 (5.16)
8.25 (7.39)
7.14 (4.84)
0.57 (0.79)
0.56 (0.91)
0.47 (0.81)
0.56 (0.48)
0.88 (1.30)
0.39 (0.44)
0.28 (0.16)
0.23 (0.15)
0.22 (0.17)
0.27 (0.19)
0.38 (0.79)
0.13 (0.08)
2.06 (1.72)
2.24 (2.13)
1.63 (1.51)
1.55 (0.99)
1.18 (0.58)
1.30 (1.34)
0.89 (0.40)
0.94 (0.78)
0.81 (0.88)
1.00 (0.42)
1.12 (0.57)
0.92 (0.45)
1.00 (0.42)
0.94 (0.48)
0.75 (0.27)
1.05 (0.39)
1.00 (0.51)
0.83 (0.35)
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Table 1-e. Means and standard deviations for mean EMG for each muscle, side, and treatment
during the first quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
3.81 (4.48)
5.53 (8.14)
5.75 (10.16)
3.62 (2.030)
4.10 (2.92)
5.21 (4.78)
0.87 (0.45)
1.62 (2.01)
1.20 (0.96)
1.15 (1.41)
1.38 (1.95)
1.41 (1.93)
1.07 (0.91)
1.71 (2.43)
2.54 (5.65)
0.92 (0.47)
1.11 (0.73)
1.24 (0.95)
4.32 (2.19)
7.10 (6.79)
6.88 (5.66)
3.18 (1.25)
4.10 (2.85)
4.08 (2.21)
3.64 (2.37)
3.70 (2.29)
3.69 (2.28)
3.45 (2.14)
3.64 (2.64)
3.56 (2.44)
1.79 (0.54)
1.74 (0.50)
1.68 (0.48)
2.01 (0.72)
2.05 (0.82)
2.20 (0.91)

effusion
3.11 (2.11)
3.97 (3.65)
2.68 (2.00)
4.86 (7.16)
4.17 (3.81)
3.90 (3.28)
0.71 (0.39)
0.83 (0.28)
0.66 (0.27)
0.83 (0.53)
0.71 (0.68)
0.72 (0.88)
0.92 (0.6)
1.07 (0.58)
0.78 (0.35)
0.91 (0.39)
0.76 (0.64)
0.66 (0.44)
4.71 (4.12)
3.45 (2.04)
5.55 (14.24)
3.35 (2.68)
3.09 (1.88)
4.81 (9.04)
5.06 (2.55)
5.41 (2.65)
5.10 (2.49)
4.43 (3.12)
4.55 (3.35)
4.87 (3.27)
1.87 (0.70)
1.76 (0.57)
1.80 (0.83)
1.98 (0.92)
2.18 (0.97)
2.97 (3.97)

pain
5.42 (4.88)
5.06 (4.55)
5.02 (5.01)
14.44 (45.2)
13.84 (44.51)
13.71 (45.26)
0.82 (0.70)
0.91 (0.65)
0.80 (0.68)
1.13 (1.26)
0.92 (0.86)
0.88 (0.84)
1.19 (1.06)
1.03 (0.61)
0.90 (0.55)
1.54 (1.91)
1.05 (0.63)
1.18 (1.04)
6.59 (13.32)
6.86 (13.46)
6.04 (12.74)
3.94 (3.89)
3.53 (3.41)
3.40 (3.26)
4.93 (3.28)
5.09 (2.91)
5.17 (3.54)
5.30 (3.58)
4.87 (3.54)
5.05 (3.55)
4.86 (12.43)
4.78 (12.07)
4.96 (13.15)
3.05 (4.73)
3.23 (4.98)
2.96 (4.62)

pain/effusion
3.13 (2.33)
3.71 (1.70)
3.88 (5.14)
3.58 (1.71)
3.61 (1.92)
2.84 (1.59)
0.75 (0.34)
0.87 (0.39)
0.75 (0.41)
0.99 (0.70)
0.81 (0.93)
0.54 (0.34)
0.94 (0.56)
1.00 (0.57)
0.75 (0.35)
0.97 (0.40)
0.72 (0.42)
0.57 (0.37)
0.93 (0.76)
3.69 (3.18)
2.82 (1.60)
3.24 (2.58)
3.45 (2.64)
3.09 (3.02)
3.84 (2.47)
3.99 (2.21)
3.95 (2.57)
3.76 (2.23)
4.21 (4.43)
3.82 (2.45)
1.60 (0.71)
1.59 (0.76)
1.37 (0.55)
1.77 (0.93)
3.53 (6.99)
1.78 (0.90)
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Table 1-f. Means and standard deviations for mean EMG for each muscle, side, and treatment
during the second quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
7.81 (5.96)
8.15 (6.05)
8.34 (6.44)
8.71 (4.92)
8.63 (5.53)
8.82 (5.38)
0.28 (0.29)
0.47 (0.70)
0.42 (0.64)
0.35 (0.53)
0.48 (0.77)
0.42 (0.61)
0.30 (0.22)
0.41 (0.39)
1.28 (4.01)
0.22 (0.08)
0.30 (0.34)
0.35 (0.32)
1.29 (0.53)
1.78 (1.30)
1.73 (1.06)
1.55 (1.10)
1.88 (1.26)
1.74 (1.12)
1.59 (0.76)
1.70 (1.07)
1.73 (1.18)
1.61 (0.77)
1.51 (0.73)
1.60 (0.75)
0.82 (0.31)
0.81 (0.30)
0.80 (0.27)
0.85 (0.24)
0.85 (0.23)
0.90 (0.24)

effusion
8.19 (5.31)
7.44 (4.73)
8.29 (5.46)
8.82 (5.99)
8.03 (5.27)
8.47 (5.94)
0.19 (0.11)
0.24 (0.19)
0.17 (0.11)
0.29 (0.29)
0.27 (0.24)
0.35 (0.84)
0.23 (0.10)
0.29 (0.13)
0.20 (0.09)
0.23 (0.14)
0.25 (0.18)
0.20 (0.14)
1.74 (1.54)
1.18 (0.61)
2.52 (6.59)
1.74 (1.73)
1.44 (1.07)
5.14 (17.18)
2.09 (1.45)
2.31 (1.48)
1.99 (1.39)
2.12 (2.43)
2.69 (3.07)
2.54 (3.17)
0.84 (0.32)
0.82 (0.32)
0.73 (0.32)
0.84 (0.24)
1.69 (3.66)
0.93 (1.08)

pain
8.59 (5.45)
8.35 (4.68)
9.10 (5.61)
18.47 (44.98)
18.38 (44.09)
18.49 (44.82)
0.33 (0.70)
0.36 (0.66)
0.34 (0.69)
0.56 (1.11)
0.43 (0.88)
0.37 (0.83)
0.45 (0.64)
0.41 (0.52)
0.33 (0.51)
0.50 (0.83)
0.44 (0.52)
0.32 (0.35)
7.62 (27.94)
7.06 (25.70)
7.19 (27.08)
10.12 (38.81)
9.77 (37.05)
9.90 (38.25)
2.49 (2.81)
2.66 (2.60)
2.48 (2.47)
2.69 (2.56)
2.81 (2.59)
2.53 (2.52)
1.75 (3.70)
1.65 (3.23)
1.74 (4.05)
3.04 (9.37)
2.92 (8.51)
3.17 (10.19)

pain/effusion
7.72 (4.58)
9.07 (5.23)
8.77 (6.33)
7.84 (5.31)
7.31 (5.08)
7.85 (6.26)
0.22 (0.12)
0.22 (0.13)
0.21 (0.15)
0.27 (0.23)
0.41 (0.92)
0.16 (0.12)
0.31 (0.19)
0.32 (0.22)
0.21 (0.11)
0.25 (0.20)
0.30 (0.20)
0.14 (0.07)
0.96 (0.48)
1.20 (0.70)
0.96 (0.61)
1.39 (0.87)
3.04 (5.77)
1.40 (1.02)
1.58 (0.92)
1.91 (1.20)
1.55 (1.00)
1.81 (1.67)
2.78 (3.87)
2.02 (1.74)
0.80 (0.22)
0.85 (0.37)
0.70 (0.27)
0.82 (0.28)
1.49 (2.38)
0.79 (0.34)
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Table 1-g. Means and standard deviations for mean EMG for each muscle, side, and treatment
during the third quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
15.08 (9.62)
14.55 (8.67)
14.88 (8.83)
12.95 (8.89)
12.37 (8.05)
12.59 (7.89)
0.21 (0.16)
0.32 (0.41)
0.26 (0.30)
0.26 (0.39)
0.31 (0.49)
0.30 (0.49)
0.17 (0.08)
0.19 (0.13)
0.57 (1.69)
0.15 (0.07)
0.17 (0.14)
0.16 (0.11)
1.01 (0.42)
1.05 (0.49)
1.05 (0.50)
1.13 (0.98)
1.23 (1.00)
1.10 (0.68)
1.13 (0.50)
1.23 (0.70)
1.45 (1.21)
1.10 (0.59)
1.06 (0.51)
1.09 (0.61)
0.83 (0.46)
0.78 (0.34)
0.75 (0.30)
0.76 (0.24)
0.80 (0.25)
0.78 (0.22)

effusion
15.61 (11.27)
16.57 (12.75)
16.13 (11.73)
12.15 (6.26)
11.65 (6.82)
12.05 (7.77)
0.15 (0.08)
0.16 (0.10)
0.13 (0.08)
0.24 (0.34)
0.21 (0.31)
0.35 (0.86)
0.16 (0.08)
0.17 (0.10)
0.14 (0.08)
0.17 (0.11)
0.18 (0.22)
0.16 (0.15)
0.96 (0.48)
1.07 (0.61)
1.62 (3.71)
1.05 (0.76)
0.83 (0.50)
0.71 (0.33)
1.38 (0.66)
1.24 (0.60)
1.15 (0.51)
1.41 (1.33)
1.61 (1.41)
1.20 (1.26)
0.77 (0.30)
0.72 (0.28)
0.65 (0.27)
0.83 (0.32)
0.96 (0.98)
0.61 (0.27)

pain
14.10 (7.94)
15.52 (9.06)
14.70 (8.40)
22.07 (44.65)
21.09 (43.78)
21.21 (44.51)
0.32 (0.70)
0.31 (0.65)
0.29 (0.69)
0.45 (1.04)
0.42 (0.91)
0.38 (0.85)
0.33 (0.65)
0.31 (0.62)
0.33 (0.63)
0.25 (0.36)
0.23 (0.30)
0.19 (0.25)
1.44 (2.67)
0.85 (0.39)
1.15 (1.94)
5.39 (20.24)
5.89 (22.46)
5.85 (22.85)
1.13 (0.53)
1.18 (0.64)
1.12 (0.53)
1.64 (1.64)
1.61 (1.59)
1.62 (1.73)
0.81 (0.26)
0.76 (0.30)
0.74 (0.25)
2.06 (5.22)
2.10 (5.67)
2.18 (6.22)

pain/effusion
15.21 (9.78)
16.07 (10.12)
15.16 (9.73)
12.17 (7.75)
9.79 (7.56)
11.10 (8.62)
0.20 (0.16)
0.21 (0.19)
0.16 (0.13)
0.21 (0.19)
0.37 (0.91)
0.13 (0.08)
0.18 (0.09)
0.20 (0.12)
0.15 (0.10)
0.14 (0.08)
0.20 (0.19)
0.09 (0.05)
0.92 (0.61)
0.93 (0.66)
0.70 (0.40)
0.88 (0.68)
1.04 (0.89)
0.68 (0.31)
1.05 (0.62)
1.05 (0.58)
0.93 (0.63)
1.25 (0.92)
1.37 (0.98)
1.25 (0.98)
0.77 (0.23)
0.75 (0.28)
0.65 (0.25)
0.80 (0.29)
0.77 (0.41)
0.64 (0.24)
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Table 1-h. Means and standard deviations for mean EMG for each muscle, side, and treatment
during the fourth quartile of stance during walking.
Variable
Medial

Side
Left

Gastrocnemius

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
2.94 (2.08)
2.70 (1.42)
2.95 (1.67)
2.60 (1.52)
2.53 (1.08)
3.05 (2.21)
0.29 (0.28)
0.44 (0.53)
0.40 (0.53)
0.34 (0.53)
0.45 (0.66)
0.53 (0.77)
0.19 (0.11)
0.30 (0.43)
0.51 (1.03)
0.17 (0.09)
0.24 (0.33)
0.25 (0.30)
1.29 (0.72)
1.65 (1.43)
1.61 (1.18)
1.22 (0.75)
1.26 (0.87)
1.24 (0.82)
1.02 (1.41)
1.22 (1.42)
1.18 (1.26)
1.13 (1.61)
1.13 (1.48)
0.83 (0.43)
0.81 (0.44)
0.79 (0.36)
0.77 (0.28)
0.78 (0.23)
0.81 (0.27)
0.81 (0.26)

effusion
3.09 (2.62)
2.71 (1.84)
2.63 (2.49)
2.83 (1.78)
2.46 (1.50)
3.60 (5.41)
0.22 (0.17)
0.24 (0.24)
0.22 (0.26)
0.32 (0.35)
0.54 (0.98)
0.40 (0.92)
0.19 (0.14)
0.16 (0.10)
0.16 (0.14)
0.18 (0.14)
0.22 (0.40)
0.19 (0.37)
1.30 (1.19)
1.06 (0.50)
1.58 (3.28)
1.11 (0.82)
0.79 (0.37)
0.74 (0.34)
0.97 (0.49)
0.75 (0.29)
0.63 (0.20)
0.81 (0.62)
0.79 (0.79)
0.61 (0.44)
0.76 (0.26)
0.69 (0.25)
0.61 (0.22)
0.81 (0.28)
0.70 (0.33)
0.59 (0.21)

pain
4.74 (7.96)
4.78 (7.45)
4.85 (6.97)
13.48 (47.24)
12.89 (46.20)
13.08 (46.87)
0.43 (0.83)
0.34 (0.71)
0.33 (0.72)
0.55 (1.02)
0.48 (0.85)
0.48 (0.82)
0.65 (1.79)
0.56 (1.73)
0.55 (1.69)
0.29 (0.42)
0.22 (0.25)
0.21 (0.23)
0.98 (0.49)
0.94 (0.40)
0.82 (0.34)
0.81 (0.35)
0.75 (0.27)
0.81 (0.67)
0.67 (0.29)
0.65 (0.31)
0.63 (0.31)
0.69 (0.35)
0.66 (0.35)
0.60 (0.28)
0.80 (0.39)
0.74 (0.29)
0.75 (0.40)
0.79 (0.30)
0.79 (0.49)
0.69 (0.35)

pain/effusion
2.60 (1.37)
3.62 (2.87)
2.93 (2.41)
2.34 (1.00)
2.68 (2.56)
2.08 (1.23)
0.28 (0.27)
0.25 (0.26)
0.24 (0.38)
0.30 (0.21)
0.49 (0.95)
0.20 (0.16)
0.19 (0.11)
0.16 (0.09)
0.14 (0.10)
0.17 (0.11)
0.23 (0.49)
0.10 (0.04)
1.05 (0.68)
1.12 (0.78)
0.85 (0.54)
0.98 (0.49)
0.82 (0.37)
0.80 (0.69)
0.62 (0.28)
0.62 (0.42)
0.56 (0.48)
0.70 (0.26)
0.72 (0.30)
0.63 (0.28)
0.72 (0.20)
0.71 (0.29)
0.69 (0.20)
0.77 (0.26)
0.74 (0.35)
0.65 (0.25)
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Table 1-i. Summary data in peak joint angles during walking. For ankle angles, the neutral
position (90 °) was referenced as zero °. Values are mean (SD).
Unit: °
Variable
Ankle dorsiflexion

Side
Left

Right

Ankle
plantarflexion

Left

Right

Knee flexion

Left

Right

Knee
abduction

Left

Right

Knee
adduction

Left

Right

Hip flexion

Left

Right

Hip extension

Left

Right

Hip
abduction

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
15.19 (4.30)
14.11 (4.60)
14.46 (4.54)
12.51 (4.28)
12.59 (4.51)
13.11 (4.61)
16.07 (4.20)
15.60 (4.10)
15.43 (4.26)
16.95 (5.80)
17.24 (5.70)
17.98 (5.40)
54.48 (3.22)
55.13 (3.05)
54.91 (3.11)
53.48 (2.55)
54.16 (3.01)
54.37 (3.06)
7.43 (4.42)
7.79 (5.16)
7.60 (5.10)
5.77 (3.67)
5.96 (3.77)
6.23 (3.87)
2.69 (2.05)
2.89 (2.05)
2.68 (2.26)
3.23 (3.16)
3.25 (3.21)
3.54 (3.18)
12.20 (6.64)
12.07 (6.88)
12.57 (6.76)
10.00 (5.41)
10.73 (6.13)
10.72 (7.01)
25.01 (7.19)
25.26 (7.16)
25.03 (7.15)
23.97 (6.84)
23.97 (7.32)
23.87 (7.23)
6.95 (2.52)
7.11 (2.90)
6.87 (2.79)
6.25 (7.12)
5.70 (3.30)
5.71 (3.47)

effusion
14.70 (4.00)
14.61 (3.65)
15.08 (3.8)
13.14 (3.71)
12.97 (4.48)
13.21 (4.38)
14.87 (4.44)
14.46 (4.01)
14.34 (4.01)
16.59 (5.00)
15.65 (5.31)
16.39 (4.75)
54.80 (4.26)
53.68 (4.27)
54.45 (3.77)
53.25 (3.45)
53.17 (4.0)
53.55 (4.0)
6.56 (3.04)
6.17 (3.07)
6.58 (4.32)
6.03 (3.58)
6.02 (3.64)
6.12 (3.66)
3.66 (2.30)
4.36 (2.54)
3.91 (2.75)
3.24 (2.46)
3.43 (2.14)
3.44 (2.28)
12.06 (6.43)
10.95 (6.29)
11.16 (7.10)
10.44 (6.92)
10.78 (7.63)
11.19 (7.39)
25.03 (8.04)
26.02 (7.59)
25.36 (8.44)
24.46 (6.94)
24.24 (7.49)
24.67 (7.56)
6.24 (3.63)
5.76 (3.88)
5.64 (3.61)
5.16 (3.15)
4.74 (2.90)
4.21 (2.44)

pain
14.27 (4.20)
14.38 (3.74)
14.30 (4.12)
12.80 (4.11)
12.78 (4.07)
13.09 (4.06)
14.65 (4.20)
15.29 (4.37)
15.06 (4.37)
16.53 (5.24)
16.31 (5.20)
16.97 (4.69)
54.06 (3.00)
53.90 (3.11)
54.26 (2.82)
53.53 (3.50)
54.49 (3.73)
54.47 (3.84)
7.17 (3.85)
7.33 (3.97)
7.83 (3.79)
6.78 (4.58)
7.36 (4.90)
7.69 (5.29)
3.03 (2.09)
2.94 (2.24)
3.07 (2.17)
2.97 (2.78)
3.05 (2.75)
3.30 (2.51)
11.42 (5.25)
10.78 (5.40)
11.19 (5.57)
11.18 (5.84)
11.79 (6.63)
12.21 (6.19)
25.41 (5.78)
26.32 (6.64)
25.99 (6.74)
24.93 (6.18)
24.38 (6.28)
24.54 (6.49)
5.98 (3.15)
5.78 (5.52)
5.95 (3.06)
5.81 (2.62)
5.94 (3.19)
5.43 (3.55)

pain/effusion
14.18 (3.33)
13.85 (3.04)
14.30 (2.87)
12.51 (4.20)
12.59 (4.56)
13.11 (4.87)
15.13 (3.75)
14.26 (3.71)
15.00 (3.32)
16.94 (5.80)
14.25 (5.63)
15.63 (5.30)
54.39 (3.06)
52.31 (4.47)
54.14 (4.19)
52.40 (4.44)
52.47 (4.80)
54.17 (4.41)
7.53 (4.32)
6.51 (4.34)
7.44 (4.52)
5.15 (4.32)
5.29 (4.25)
5.41 (4.44)
3.69 (3.07)
3.61 (2.40)
4.10 (3.13)
3.15 (2.14)
3.25 (2.22)
3.27 (2.13)
2.38 (5.92)
11.62 (5.07)
12.33 (5.41)
11.09 (5.04)
10.03 (5.50)
10.07 (5.14)
25.21 (5.62)
24.91 (5.23)
24.81 (5.08)
24.61 (5.95)
22.11 (6.85)
22.78 (6.84)
6.94 (3.30)
5.28 (3.44)
6.14 (4.12)
5.58 (3.00)
5.45 (3.05)
6.50 (8.05)
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Table 1-j. Means and standard deviations for the peak hip extension moments during walking.
Unit: N·m
Variable
Hip extension

Side
Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
Control
67.18 (21.99)
69.76 (25.47)
68.73 (26.39)
47.21 (15.72)
48.74 (19.89)
49.21 (18.32)

Effusion
66.32 (25.35)
62.90 (27.12)
66.31 (26.88)
46.61 (16.34)
44.05 (17.60)
46.76 (15.78)

Pain
66.91 (22.19)
63.32 (19.28)
63.73 (21.05)
48.62 (15.76)
43.10 (12.54)
45.94 (14.97)

pain/effusion
63.36 (19.50)
58.40 (23.80)
62.94 (22.16)
46.56 (15.76)
38.18 (14.56)
44.10 (13.44)
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Table 2-a. Means and standard deviations for peak EMG data of each muscle 200 ms prior to
initial contact during drop landing.
Variable
Medial
Gastrocne
mius

Side
Left

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
Control
13.85 (18.28)
16.39 (28.25)
11.52 (10.67)
41.96 (30.69)
38.14 (24.48)
38.91 (22.53)
7.18 (17.01)
2.79 (2.97)
4.31 (7.13)
6.41 (4.96)
5.27 (3.41)
5.25 (3.95)
1.43 (1.21)
1.28 (0.77)
1.37 (0.90)
3.38 (1.42)
3.49 (1.30)
3.47 (1.50)
35.09 (23.80)
32.66 (28.03)
27.38 (18.55)
12.16 (6.62)
12.72 (7.58)
10.31 (5.25)
9.22 (7.03)
8.68 (5.43)
9.78 (6.72)
13.17 (16.36)
19.71 (29.51)
13.02 (16.50)
2.37 (1.48)
2.45 (1.40)
2.66 (1.79)
10.51 (7.46)
8.65 (5.60)
9.85 (5.91)

Effusion
12.80 (17.00)
10.89 (7.45)
13.48 (13.37)
37.45 (21.52)
28.06 (26.03)
36.45 (24.48)
1.35 (0.85)
4.01 (8.12)
2.02 (2.26)
5.32 (3.93)
5.38 (3.54)
4.94 (3.72)
1.12 (0.73)
1.65 (1.25)
1.49 (1.44)
3.54 (1.72)
3.48 (1.51)
3.17 (1.54)
31.05 (15.57)
30.84 (15.09)
31.82 (15.34)
14.85 (13.59)
11.33 (7.78)
10.35 (7.90)
12.20 (9.68)
12.16 (10.10)
12.22 (9.82)
13.69 (7.45)
10.94 (6.78)
11.48 (6.69)
2.68 (1.79)
2.68 (1.54)
2.45 (2.19)
9.36 (4.95)
8.56 (5.34)
8.39 (4.78)

pain
15.67 (15.27)
13.70 (9.05)
13.23 (9.73)
39.05 (26.33)
32.79 (20.81)
34.89 (21.67)
2.14 (2.36)
2.29 (1.68)
1.99 (2.27)
4.25 (2.21)
3.57 (2.23)
3.88 (1.95)
1.34 (0.89)
1.76 (1.38)
1.29 (1.07)
3.56 (1.65)
3.12 (1.63)
3.26 (1.29)
25.11 (13.93)
28.77 (17.47)
23.85 (16.43)
10.87 (7.23)
9.90 (6.50)
9.72 (7.03)
9.31 (7.71)
9.93 (5.87)
10.16 (8.01)
15.09 (10.98)
13.72 (12.06)
16.08 (12.22)
3.43 (3.36)
2.93 (2.07)
2.99 (2.75)
8.88 (5.99)
9.28 (7.07)
7.88 (5.63)

pain/effusion
17.14 (27.86)
18.29 (15.62)
12.70 (11.47)
34.96 (19.03)
31.98 (20.67)
35.04 (23.78)
3.22 (3.82)
3.59 (3.64)
2.76 (2.63)
4.58 (2.62)
4.16 (2.87)
4.47 (2.76)
2.04 (2.16)
3.26 (3.91)
2.18 (2.14)
3.39 (1.47)
3.27 (1.88)
3.30 (1.88)
27.75 (18.96)
33.49 (23.93)
30.15 (30.22)
13.62 (11.49)
9.86 (7.54)
9.83 (8.49)
8.67 (8.20)
9.29 (8.35)
6.99 (6.25)
13.74 (16.96)
12.37 (16.03)
13.00 (15.33)
2.33 (1.15)
2.39 (0.96)
2.00 (0.90)
7.14 (6.40)
7.57 (5.96)
7.94 (7.94)
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Table 2-b. Means and standard deviations for peak EMG data of each muscle from initial contact
to peak knee flexion during drop landing.
Variable
Medial
Gastrocne
mius

Side
Left

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
Control
64.96 (105.23)
63.34 (105.33)
67.43 (83.92)
11098 (133.87)
105.22 (12.077)
88.72 (119.34)
9.18 (17.45)
5.15 (7.43)
6.368 (7.09)
23.77 (13.18)
24.41 (14.18)
24.28 (13.39)
3.87 (8.68)
1.87 (1.43)
2.18 (1.84)
19.30 (13.23)
20.79 (12.72)
20.03 (12.85)
37.88 (41.18)
34.08 (33.31)
28.93 (20.31)
25.76 (13.15)
37.01 (27.06)
41.02 (25.10)
15.11 (12.86)
15.76 (10.11)
16.27 (10.58)
36.39 (28.10)
42.40 (29.08)
35.17 (26.31)
23.32 (30.40)
25.88 (34.05)
22.49 (26.75)
46.16 (30.05)
53.33 (51.35)
54.26 (63.64)

effusion
35.83 (35.95)
38.15 (36.12)
30.29 (28.34)
84.72 (119.34)
62.87 (66.07)
53.34 (38.32)
3.95 (6.21)
3.85 (5.95)
2.30 (1.81)
20.72 (9.01)
18.64 (10.11)
19.12 (9.61)
3.36 (7.12)
1.40 (1.34)
3.26 (9.76)
19.18 (10.80)
14.39 (8.65)
15.03 (9.77)
25.94 (16.78)
22.79 (15.33)
21.52 (20.87)
29.32 (13.15)
22.00 (27.06)
18.83 (25.10)
23.50 (21.08)
22.93 (21.80)
18.53 (20.07)
36.32 (24.44)
31.87 (18.52)
33.32 (23.68)
19.56 (20.68)
16.54 (19.17)
20.91 (33.91)
50.53 (36.51)
42.51 (28.58)
40.57 (23.95)

pain
77.14 (106.21)
38.50 (43.65)
51.30 (62.26)
85.72 (84.90)
77.89 (88.99)
53.34 (107.34)
4.00 (4.79)
2.61 (3.07)
2.76 (2.77)
28.72 (23.54)
23.61 (16.83)
26.06 (16.06)
3.56 (9.35)
2.95 (7.18)
2.76 (5.31)
24.41 (22.31)
21.93 (16.31)
20.97 (12.66)
25.88 (29.59)
23.42 (26.31)
16.16 (8.13)
26.61 (18.25)
22.30 (14.67)
20.93 (13.04)
15.71 (14.73)
16.87 (15.35)
20.10 (21.52)
36.85 (21.77)
36.34 (20.58)
35.77 (18.89)
30.57 (56.99)
23.72 (44.21)
23.80 (57.64)
45.54 (34.90)
45.22 (34.17)
46.03 (39.06)

pain/effusion
38.35 (36.68)
51.44 (44.20)
36.12 (32.11)
69.09 (59.48)
60.35 (57.07)
54.59 (42.66)
3.74 (4.82)
2.82 (2.76)
2.59 (1.75)
20.30 (14.39)
17.40 (15.53)
17.56 (14.99)
2.23 (5.24)
1.38 (1.18)
1.15 (0.92)
18.24 (10.37)
11.94 (5.40)
12.98 (5.39)
27.55 (22.70)
23.37 (20.29)
19.49 (19.33)
25.01 (18.10)
20.39 (12.29)
18.74 (11.36)
13.29 (8.40)
13.75 (11.87)
12.75 (11.06)
31.79 (21.96)
28.50 (18.33)
35.35 (26.91)
23.80 (33.32)
10.24 (9.47)
9.89 (9.41)
40.36 (41.75)
28.65 (18.43)
32.24 (21.67)
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Table 2-c. Means and standard deviations for mean EMG data of each muscle 200 ms prior to
initial contact during drop landing.
Variable
Medial
Gastrocne
mius

Side
Left

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
Control
4.74 (6.12)
4.34 (5.30)
3.82 (3.43)
15.59 (10.09)
15.09 (9.54)
15.10 (9.50)
4.05 (11.62)
0.89 (0.92)
1.19 (1.73)
2.43 (3.96)
1.47 (0.96)
1.43 (1.10)
0.48 (0.42)
0.43 (0.29)
0.46 (0.30)
1.03 (0.51)
1.02 (0.52)
0.98 (0.48)
11.85 (7.98)
10.71 (8.59)
9.55 (6.89)
3.32 (1.48)
3.68 (2.05)
3.15 (1.36)
2.82 (2.09)
2.79 (1.59)
3.13 (1.91)
4.65 (5.41)
6.66 (9.07)
4.70 (5.77)
1.11 (0.52)
1.17 (0.59)
1.32 (0.83)
3.39 (2.18)
3.10 (1.70)
3.18 (1.84)

effusion
Pain
3.75 (3.88)
11.49 (31.80)
3.22 (1.76)
4.39 (2.50)
3.09 (2.23)
4.06 (3.11)
14.70 (7.97)
14.51 (7.92)
14.40 (8.95)
12.90 (7.68)
13.99 (8.11)
13.70 (7.49)
0.51 (0.32)
0.68 (0.80)
1.10 (2.20)
0.65 (0.50)
0.61 (0.58)
0.60 (0.68)
1.51 (1.13)
1.26 (0.72)
1.51 (1.11)
1.17 (0.78)
1.55 (1.26)
1.24 (0.75)
0.39 (0.25)
0.43 (0.32)
0.49 (0.33)
0.55 (0.45)
0.44 (0.40)
0.44 (0.38)
1.11 (0.55)
1.08 (0.47)
1.11 (0.57)
1.03 (0.55)
1.10 (0.590)
1.05 (0.56)
10.77 (4.98)
9.68 (5.53)
11.21 (4.79)
10.62 (5.59)
11.27 (5.20)
8.67 (5.05)
3.79 (2.53)
2.99 (1.64)
3.29 (1.94)
2.71 (1.45)
3.05 (1.87)
2.85 (1.81)
3.75 (3.53)
3.00 (2.91)
3.55 (3.28)
2.82 (1.96)
3.38 (3.14)
3.07 (2.83)
5.10 (2.81)
5.26 (3.49)
4.40 (2.60)
5.15 (3.68)
4.36 (2.33)
5.65 (4.38)
1.24 (0.58)
1.40 (0.94)
1.19 (0.54)
1.26 (0.57)
1.09 (0.61)
1.26 (0.74)
3.16 (1.53)
2.82 (1.51)
3.11 (1.96)
3.04 (1.65)
2.95 (1.74)
2.70 (1.62)

pain/effuseon
4.51 (5.37)
4.74 (3.11)
3.76 (2.49)
13.29 (7.10)
12.06 (7.09)
13.17 (8.09)
0.96 (1.26)
1.08 (1.11)
0.78 (0.75)
1.36 (0.82)
1.30 (0.84)
1.36 (0.82)
0.55 (0.51)
0.81 (0.69)
0.58 (0.57)
1.00 (0.43)
1.02 (0.58)
1.02 (0.49)
10.55 (7.46)
11.62 (7.93)
10.19 (6.80)
3.70 (2.52)
2.98 (1.94)
2.69 (1.85)
2.64 (2.21)
2.61 (2.09)
2.11 (1.65)
5.00 (6.39)
4.62 (4.96)
4.69 (4.79)
1.11 (0.42)
1.14 (0.38)
0.97 (0.34)
2.22 (1.03)
2.62 (1.72)
2.71 (2.28)
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Table 2-d. Means and standard deviations for mean EMG data of each muscle from initial
contact to peak knee flexion during drop landing.
Variable
Medial
Gastrocne
mius

Side
Left

Right

Vastus
Medialis

Left

Right

Vastus
Lateralis

Left

Right

Medial
Hamstring

Left

Right

Gluteus
Medius

Left

Right

Gluteus
Maximus

Left

Right

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
Control
28.56 (45.49)
22.19 (29.80)
25.67 (33.17)
43.76 (54.58)
38.65 (39.58)
30.70 (29.86)
4.75 (10.86)
2.06 (3.12)
2.33 (2.43)
10.59 (6.88)
9.85 (5.15)
10.24 (5.17)
1.71 (4.20)
0.77 (0.51)
0.83 (0.63)
7.94 (4.55)
8.68 (4.89)
8.29 (4.65)
15.99 (14.20)
15.49 (11.82)
13.58 (7.85)
10.06 (4.70)
14.21 (9.34)
15.43 (9.44)
6.82 (5.27)
7.44 (5.50)
7.20 (4.46)
14.10 (8.20)
15.60 (8.36)
14.06 (7.48)
6.66 (6.68)
7.35 (7.77)
6.86 (6.67)
18.68 (12.71)
19.57 (14.97)
19.60 (17.78)

effusion
15.07 (14.86)
15.01 (14.13)
11.83 (10.84)
33.40 (45.42)
21.74 (15.67)
20.43 (14.65)
1.57 (2.58)
1.51 (2.22)
0.88 (0.56)
9.39 (4.58)
8.00 (4.16)
8.13 (4.36)
1.17 (1.90)
0.62 (0.59)
0.89 (1.88)
8.04 (4.19)
5.91 (3.28)
5.79 (2.98)
12.22 (7.51)
10.54 (5.74)
10.00 (7.12)
11.94 (11.61)
8.26 (5.00)
7.19 (3.71)
10.08 (8.91)
9.23 (8.06)
7.99 (8.47)
15.14 (8.65)
13.99 (8.13)
14.16 (9.16)
7.02 (7.41)
6.17 (6.83)
7.17 (10.67)
19.28 (12.17)
16.36 (9.72)
16.31 (9.05)

pain
26.87 (33.09)
15.78 (16.32)
19.68 (24.37)
32.65 (29.61)
27.62 (26.42)
27.63 (28.97)
1.53 (1.70)
1.04 (1.07)
0.98 (0.76)
12.26 (10.41)
9.26 (6.42)
9.93 (5.99)
1.23 (2.75)
1.01 (2.06)
0.93 (1.60)
9.48 (7.49)
8.38 (6.16)
8.02 (4.73)
11.61 (10.33)
10.71 (8.93)
7.65 (3.43)
10.16 (5.89)
8.57 (4.71)
7.94 (4.21)
6.88 (5.67)
7.15 (5.82)
8.24 (7.00)
15.88 (8.19)
15.70 (8.37)
15.24 (8.12)
9.42 (15.66)
7.88 (13.37)
8.94 (17.13)
16.08 (8.89)
17.20 (10.55)
16.71 (12.03)

pain/effusion
14.56 (13.37)
18.94 (16.29)
13.37 (11.38)
26.63 (18.62)
23.02 (17.11)
20.77 (12.40)
1.59 (2.05)
1.23 (1.21)
1.01 (0.67)
8.65 (5.50)
7.40 (6.58)
7.09 (4.90)
0.84 (1.52)
0.60 (0.49)
0.47 (0.31)
7.64 (4.13)
5.03 (2.03)
5.60 (2.07)
12.23 (8.49)
10.36 (6.71)
9.24 (7.13)
9.76 (5.82)
7.44 (3.31)
7.51 (3.73)
6.22 (4.03)
6.34 (5.99)
5.78 (4.75)
13.84 (8.13)
12.24 (8.10)
15.24 (10.77)
7.66 (8.93)
3.49 (2.15)
3.57 (2.82)
14.74 (11.69)
12.09 (7.42)
12.68 (8.88)
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Table 2-e. Means and standard deviations for vertical stiffness during drop landing. .
Variables
Stiffness
(N/m)

Time
precondition
condition
postcondition

Treatment
control
26420.9 (11601.4)
27180.7 (12982.2)
24907.6 (11825.9)

effusion
26771.4 (10439.7)
25907.0 (14854.6)
27205.5 (13588.6)

pain
27651.6 (15998.2)
27081.6 (11140.6)
25560.5 (10215.2)

pain/effusion
27792.4 (15998.2)
27938.9 (19246.2)
26470.4 (14581.1)
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Table 2-f. Summary data in peak joint angles during drop landing. For ankle angles, the neutral
position (90 °) was referenced as zero °. Values are mean (SD).
Unit: °
Variables
Knee abduction

Knee adduction

Hip flexion

Hip extension

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
4.92 (3.79)
5.02 (3.80)
5.14 (3.78)
5.62 (4.51)
5.56 (4.55)
5.62 (4.63)
20.39 (9.44)
18.97 (9.70)
19.51 (10.11)
6.87 (6.40)
8.29 (6.10)
8.01 (6.28)

effusion
5.29 (3.67)
5.32 (3.86)
5.81 (4.03)
4.72 (3.49)
4.23 (3.25)
4.13 (3.32)
20.41 (9.62)
19.37 (9.27)
18.90 (9.08)
8.16 (7.06)
7.97 (6.06)
8.82 (6.52)

pain
6.85 (4.08)
7.84 (4.70)
7.77 (4.98)
4.42 (3.32)
4.77 (4.05)
4.63 (3.78)
20.08 (8.91)
21.16 (15.76)
19.37 (8.09)
8.52 (4.58)
11.64 (12.57)
7.43 (4.28)

pain/effusion
4.71 (3.23)
5.19 (3.78)
5.40 (3.56)
4.37 (3.54)
3.67 (2.96)
3.82 (3.37)
20.12 (8.78)
21.19 (8.98)
20.56 (9.27)
8.50 (7.46)
8.24 (6.03)
7.36 (5.88)
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Table 2-g. Summary data in peak joint moments during drop landing. Values are mean (SD).
Unit: N·m
Variables
Ankle
Plantar-flexion
Knee flexion

Knee adduction

Hip extension

Time
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition
precondition
condition
postcondition

Treatment
control
160.62 (49.43)
156.03 (44.62)
158.76 (45.19)
41.81 (17.41)
41.55 (15.69)
41.51 (17.76)
24.90 (12.23)
23.80 (10.61)
26.04 (11.37)
217.54 (73.61)
229.95 (79.89)
228.51 (86.47)

effusion
162.37 (48.34)
157.81 (48.09)
157.04 (51.57)
43.34 (16.41)
41.18 (17.51)
39.62 (19.65)
31.78 (21.62)
27.60 (15.24)
27.86 (15.78)
230.34 (70.23)
215.31 (71.84)
214.13 (60.07)

pain
164.82 (45.65)
163.01 (48.42)
157.33 (48.65)
44.23 (20.09)
42.82 (18.68)
41.94 (16.67)
32.48 (19.61)
34.39 (21.98)
32.43 (19.14)
205.76 (61.10)
202.91 (54.74)
207.04 (60.94)

pain/effusion
161.31 (38.55)
153.73 (39.00)
158.94 (46.34)
43.12 (13.25)
39.09 (14.85)
40.40 (16.53)
26.06 (12.76)
25.51 (12.39)
26.15 (13.13)
210.00 (67.66)
195.97 (57.20)
198.23 (65.15)
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Table 2-h. Means and standard deviations for the time between the toe off of the first landing and
the initial contact of the second landing.
Unit: s
Time
precondition
condition
postcondition

Treatment
control

effusion
0.19 (0.08)
0.19 (0.06)
0.19 (0.06)

pain
0.19 (0.06)
0.17 (0.06)
0.18 (0.06)

0.20 (0.06)
0.18 (0.06)
0.18 (0.06)

pain/effusion
0.19 (0.07)
0.17 (0.07)
0.17 (0.07)
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Appendices
To provide a better understanding of when the peak joint angles and moments occur,
pictures and graphs during walking and drop landing are presented in the appendices. All
variables are in the ipsilateral side (the limb on the second force platform). Initial contact is
highlighted in yellow and toe off is highlighted in red.
Walking
1. Ankle angles and moments in the sagittal plane.

PADFA: peak ankle dorsi-flexion angle
PAPFA: peak ankle plantar-flexion angle
PAPFM: peak ankle dorsi-flexion moment
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2. Knee angles and moments in the sagittal plane

PKFLA: peak knee flexion angle
PKETM: peak knee extension moment
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3. Knee angles and moments in the frontal plane

PKADA: peak knee adduction angle
PKABM: peak knee abduction moment
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4. Hip angles and moments in the sagittal plane

PHETA: peak hip extension angle
PHFLM: peak hip flexion moment
PHETM: peak hip extension moment

110

5. Hip angles and moments in the frontal plane

PHADA: peak hip adduction angle
PHABA: peak hip abduction angle
PHABM: peak hip abduction moment
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Drop landing
6. Ankle angles and moments in the sagittal plane

PADFA: peak ankle dorsi-flexion angle
PAPFM: peak ankle plantar-flexion moment
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7. Knee angles and moments in the sagittal plane

PKFLA: peak knee flexion angle
PKETM: peak knee extension moment
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8. Knee angles and moments in the frontal plane

PKADA: peak knee adduction angle
PKABM: peak knee abduction moment
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9. Hip angles and moments in the sagittal plane

PHFLA: peak hip flexion angle
PHETM: peak hip extension moment
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10. Hip angles and moments in the frontal plane

PHADA: peak hip adduction angle
PHABM: peak hip abduction moment
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Prospectus
Introduction
Knee joint injuries are common. For example, approximately 80,000 anterior cruciate
ligament (ACL) ruptures are seen in the United States annually.1 The estimated prevalence of
knee osteoarthritis (OA) is 6.1 % in adults aged more than 302 and 12.5 % in those aged 45 and
above.3 Knee OA often requires total knee arthroplasty (TKA)4 resulting in 443,008 TKAs from
1990 to 2000 in the United States alone.5 Of all knee joint pathologies, anterior knee pain (AKP)
is the most common6 with prevalence rate as high as 25%.7 Although diagnosis and etiologies
vary, a reduction in quadriceps activation is a common consequence in individuals with knee
joint pathologies.8-12
Quadriceps dysfunction resulting from a knee joint injury has been termed arthrogenous
muscle inhibition (AMI).13,14 AMI is a pre- and postsynaptic inhibition of periarticular
musculature resulting from surgery, distension, pain, or structural damage of a joint.15-17 AMI is
the body’s natural response following a traumatic injury.15 AMI discourages the patient’s ability
to move the injured joint thus it helps prevent further structural damage13 and provide time for
tissue healing. The presence of AMI, however, may limit full recruitment of active motor units
and reduce voluntary contraction.18 Furthermore, AMI may mediate compensatory strategies in
the functional kinetic chain of the lower extremity.13,19,20 Long term consequences of these
abnormalities could modify normal joint loading, eventually resulting in degenerative joint
disease.21-23
Structural damage and the ensuing inflammatory response are believed to be initiating
factors that alter normal afferent input, resulting in AMI.11,24,25 Among these factors, pain and
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joint effusion have been examined as independent contributing factors to AMI. In clinical and
laboratory trials, quadriceps AMI has been associated with knee pain8,26,27 and alterations in
quadriceps muscle activity during stair ascending.28 Joint effusion has also been shown as an
independent cause of quadriceps inhibition.13,19,20,29-31 Studies observing the effects of
experimentally induced knee effusion on lower extremity muscles reported quadriceps inhibition
with soleus20 or hamstring13,19 facilitation. These studies reported an increase in knee flexion
during walking19 and an increase in ground reaction forces during a drop landing task.13
Despite evidence of the consequences of each factor to AMI, the relative or additive
contribution of pain and effusion to elicit AMI is still unclear. Since pain and effusion are from
different sensory receptors (e.g. nociceptors32 and Ruffini endings20), each stimulus may follow a
different pathway. Although each injury model is effective in evaluating pain and effusion
stimuli separately, we rarely see pain or effusion alone in knee joint injuries. Introduction of
pain and effusion simultaneously in a controlled environment would simulate a condition in
which both stimuli are present. The observation of neuromechanical alterations using this
combined model may clarify if there is an additive effect with the two stimuli. Additionally, the
combined model could potentially help us understand how this additive effect influences AMI
and associated lower extremity compensatory strategies.
The purpose of this study is to determine the contributions of AKP, knee joint effusion,
and a combination of both stimuli on change in lower extremity neuromuscular activities,
kinetics, and kinematics during walking and drop landings. These functional movements
demand dynamic joint stability. Dynamic joint stability requires active muscle contraction along
with proper sensory feedback and feed-forward controls. When AMI is present in the quadriceps,
a decrease in knee extension moment and a reduction in knee flexion angle would be expected.
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To compensate for these alterations, subjects may display a higher neuromuscular activation in
the hip extensors and triceps surae.

Research questions
-

Will induced pain, effusion, or a combination of pain and effusion cause neuromuscular,
kinetic, and kinematic alterations in walking and drop landing?

-

Will a combination of pain and effusion cause additive effects to elicit neuromuscular,
kinetic, and kinematic changes?

Research hypotheses
-

Compared to the control condition, all three injury models (pain, effusion, and a
combination of pain and effusion) will cause neuromuscular, kinetic, and kinematic
alterations during walking and drop landing.
o Neuromuscular alterations during both walking and drop landing


Peak EMG activation in the quadriceps will be decreased in the involved
leg

o Kinetic alterations during walking


Internal knee extension moment will change in the involved leg

o Kinematic alterations during walking


Knee flexion angle will change at initial contact and toe off.

o Kinetic alterations during drop landing


Peak vertical GRF will change in the involved leg



Peak internal knee extension moment will change in the involved leg
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o Kinematic alterations during drop landing

-

Peak knee flexion angle will change in the involved leg

A combination of pain and effusion stimulus will show a greater degree in alterations
compared with pain and effusion individually. The pain condition and effusion condition
will show a similar degree in alterations.

Operational definitions
-

Anterior knee pain: this term is interchangeably used with patellofemoral pain syndrome
in this literature review

-

Arthrogenous (arthrogenic) muscle response: an ongoing reflex inhibition or facilitation
of joint musculature after distension or damage to structures of the joint.15

-

Drop landing: landing on the dominant leg from 30 cm height wooden box onto the force
plate while the non-dominant leg is non-weight bearing

-

External knee adduction moment: the torque that tends to adduct the knee during stance
phase. Higher external knee adduction moment indicates a greater load on the medial
compartment.

-

External moment: equal and opposite to the net internal moment. (i.e. internal knee
extension moment = external knee flexion moment)

-

Feedback controls: process of motor responses within the corresponding system after an
input of the sensory information33

-

Feed-forward controls: a pre-programmed anticipated motor response before an input of
the sensory information33
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-

Frontal plane lever arm: the perpendicular distance from the GRF to the knee joint centre
of the rotation (tibial tuberosity)34

-

Ground reaction force (GRF): a single equivalent force equal to the sum of a distribution
of forces applied to a surface35

-

Internal moment (the net joint moment): the net effect of the moments that are created
about a single joint by muscle, bone, and soft tissue forces

-

Kinematics: “the study of bodies in motion without regard to the causes of motion”35

-

Kinesthesia: awareness of body segment or position during movement

-

Kinetics: “study of the causes of motion”35

-

Loading rate: the ratio between the peak vertical GRF and the amount of time from initial
contact to the peak vertical GRF (VGRF/∆ time).

-

Loading response: immediately after initial contact until double limb support ends36

-

Nociception: ability to feel pain

-

Peak joint angles: ankle, knee and hip joint angles relative to the joint position captured
during static standing trial
o Peak ankle angle: Ankle joint angle relative to the static standing trial position


A positive value: dorsiflexion and inversion



A negative value: plantarflexion and eversion

o Peak knee angle: knee joint angle relative to a knee joint during the static standing
trial position


A positive value: extension and adduction



A negative value: flexion and abduction

o Peak hip angle: hip joint angle relative to the static standing trial position
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-



A positive value: flexion and adduction



A negative value: extension and abduction

Proprioception: “a specialized variation of the sensory modality of touch that
encompasses the sensation of joint movement (kinesthesia), joint position sense, and
force sense.”37

-

Quadriceps avoidance gait: a decrease in the internal knee extension moment at midstance

-

Stiffness: the ratio between the peak GRF and the maximal vertical displacement of the
whole body centre of mass during contact with the ground (VGRF/∆ y)38

-

Stride length: the distance between the sequential points of initial contact by the same
foot

-

Total support moment: sum of the extensor moment of the ankle, knee, and hip joint39

-

Weight acceptance phase of gait: initial contact (heel strike) to peak knee flexion39

Assumptions
-

Subject will honestly answer the pre-participation health questionnaire and VAS.

-

The reflective markers and EMG electrodes will be located at the same places over four
condition sessions.

-

A week will be sufficient time to wash-out any injection effects.

-

Each subject’s diet and regular exercising pattern will not be changed over the 4-week
data collection period.

-

Each subjects will not take any medication (over-the-counter and prescription) over the 4week data collection period.
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-

Medial and lateral hamstrings have the same activation pattern.

Delimitations
-

Subjects will be limited in age ranged between 18 and 35.

-

All subjects will be free from neurological, vascular, or endocrine disorders.

-

All subjects will be free from any lower extremity injury for the last six months and never
had lower extremity surgery.

Limitations
-

Induced AKP mimic but does not produce clinical AKP or knee joint pain.
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Review of literature
This literature review discusses arthrogenous muscle inhibition and neuromechanical
alterations in the lower extremity after knee joint injuries. These are organized by the following
topics:
ARTHROGENOUS MUSCLE INHIBITION (AMI)
What is AMI and why is it issue? Evidence of AMI
Sensory receptors associated with AMI
Afferent pathway: primary, secondary, and tertiary afferents
Pain theories
Mechanism of AMI: why is extension muscles inhibited?
Types of inhibition
Interneurons
Does pain directly cause AMI?
Pain model
AMI with joint effusion
Effusion model
Limitations on the pain and effusion model
Acceptable disinhibitory interventions
Cryotherapy
Electrotherapy
Transcranial magnetic stimulation
Manual therapy
Thermotherapy
Voluntary exercise
NEUROMECHANICAL ALTERATIONS RESULTING FROM KNEE JOINT INJURIES
Ground reaction force
Knee joint moments
Joint range of motion and angles
Walking speed and stride length
Joint loading
Gait adaptation and its long-term effects
Drop landing task
Stiffness
MEASUREMENTS
Neuromuscular activity
Kinetic
Kinematic
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Data base and key word searched
I searched Google Scholar, MEDLINE (EBSCO and PUBMED), SPORTDiscuss
(EBSCO), and Web of Science (ISI). I also cross-referenced for identification of studies not
found using original search terms. I used the following keywords:
Arthrogenous muscle inhibition OR arthrogenic muscle inhibition
Quadriceps inhibition OR quadriceps activation
Motoneuron pool excitability OR MNP excitability
Pre- AND post-synaptic inhibition
Knee injury OR knee joint injury
Anterior knee pain OR patellofemoral pain syndrome OR knee pain
ACL OR anterior cruciate ligament
Proprioception OR proprioceptors
Pain OR pain receptors
Pain theory OR pain theories
Gate control theory OR gate control
Beta endorphins
Opioid release
Central biasing
Nociception or nociceptors
Muscle receptors
Muscle spindles
Golgi tendon organs OR GTO
Thermoreceptors
Interneurons
Afferent pathway
Hypertonic saline OR experimental knee pain OR inducing pain OR pain model
Knee joint effusion OR effusion model
Transcutaneous magnatic stimulation OR TMS
Transcutaneous electrical nerve stimulation OR TENS or electrotherapy
Voluntary exercise OR volitional exercise
Cryotherapy OR cold application
Walking OR gait OR locomotion OR ambulation
Drop landing OR single leg landing OR single leg drop landing
Osteoarthritis OR knee osteoarthritis
Ground reaction force OR GRF
Kinetics
Kinematics
Knee adduction moment
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Joint loading
Joint angle
Walking speed OR gait speed
Stride length
Stiffness

Arthrogenous muscle inhibition (AMI)
What is AMI and why is it an issue?

AMI is a pre- and post-synaptic ongoing reflex inhibition of periarticular musculature
resulting from surgery, distension, pain, or structural damage of that joint.15 AMI is the body’s
natural response following traumatic injury.15 AMI discourages patients from moving the
injured joint, therefore, preventing further structural damage13 and providing time for tissue
healing. The persistent presence of AMI, however, may limit full recruitment of active motor
units thus reducing voluntary contraction.18 Other negative effects of AMI include
neuromuscular deficits and muscular atrophy. Therefore, patients may return to normal function
with symptoms of AMI which place patients at a higher risk of recurrent injury.14,40 Additionally,
AMI may alter joint mechanics, resulting in long-term structural change such as degenerative
joint disease.21,22

Evidence of AMI

Since the frequency of joint injury and measurable availability to the surrounding
musculature, researchers have primarily focused on the quadriceps in knee joint injuries (Table
1).
Table 1. Knee joint injury and alterations of motor function in the lower extremity
Injury

Author (year)

Patellar

Manal

Pathology or
intervention
Patellar contusion

Main findings and significances
Less knee extension force (MVIC) on the involved side
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contusion
AKP

Effusion
ACL

Meniscus

OA

TKA

(2000)41
O’Reilly
(1998)42
Suter
(1998)43
Suter
(1998)8

(<4 months)
Knee pain
(aged 40-79)
Knee arthroscopy in
AKP patients.
NSAIDs in AKP
patients.

Suter
(1999)27
Suter
(2000)26
Mellor
(2005)44

SI joint manipulation
in AKP patients.
SI joint manipulation
in AKP patients.
(RCT)
anterior/retro patellar
knee pain

Fahrer
(1988)45
Suter
(2001)46

Chronic effusion
(aspiration)
ACL deficiency &
reconstruction

Urbach
(2001)10

ACL deficiency &
reconstruction

Williams
(2005)47

ACL deficiency

Drechsler
(2006)9
Shakespeare
(1985)48
Becker
(2004)22

ACL reconstruction

Thorlund
(2010)49
Messier
(1992)50
Hurley
(1993)11

Medial
meniscectomy
Partial menisectomy
(48+/-9 months post
surgery)
Meniscectomy
Knee OA
Typical rehabilitation
in early onset knee
OA (radiography)

Hassan
(2001)51
Lewek
(2004)52

Knee OA
(radiography)
Knee OA (medial
compartment)

Petterson
(2008)53

End stage of knee
OA (K/L grade IV)

Mizner
(2003)12
Stevens
(2003)54

TKA
OA & TKA

compared to the uninvolved side.
Knee pain subjects had lower quadriceps strength (MVC) and
activation (ITT) than those without pain.
Surgery reduced pain but did not change quadriceps activation
(ITT) and extension moment (N).
Direct relationship between pain and quadriceps inhibition
(involved leg > contralateral limb > control). NSAIDs reduced
pain but did not change quadriceps activation.
SI joint manipulation reduced quadriceps inhibition and
increased knee extension torque and EMG activity.
SI joint manipulation reduced quadriceps inhibition on the
ipsilateral side but not on the contralateral side. No change in
knee extension moments.
Synchronized firing motor units in the VM are less than are
these in the VL in the patients with knee pain, compared to
normative.
Quad strength (MVIC) in the involved limb was weaker than
the non-involved limb. Aspiration increased strength.
Both ACL deficiency and ACL reconstruction groups had
quadriceps inhibition (ITT) compared to the control.
(quadriceps inhibition: ACL deficiency > ACL reconstruction
> control)
Quadriceps inhibition (ITT) presented before operation. After
reconstruction quadriceps inhibition decreased but remained
less than that of controls.
Quadriceps activation (SIB: involved/non-involved) was
weaker on the ipsilateral side compared to the contralateral
side.
Post ACL reconstruction, quadriceps activation (EMG) was
less compared to healthy control.
Injection of 0.5% bupivacaine decreased pain level but
quadriceps inhibition (RF, IEMG) was still presented.
Patients with partial menisectomy had less quadriceps force
output (MVIC) and activation (ITT) compared to healthy
control.
Meniscectomised leg had reduced quadriceps muscle activity
relative to the non-operated leg.
The OA group had less quadriceps strength (isokinetic).
The OA patients had quadriceps inhibition (ITT) on the
involved leg compared to non-involved leg. Rehabilitation
program decreased quadriceps inhibition but not when
compared to the non-involved leg.
Patients with OA had less quadriceps strength (MVC) and
activation relative to the control subjects.
The subjects with OA had less quadriceps strength (N/BMI)
and activation (CAR) relative to BMI than the group of
healthy control subjects.
The OA side had weaker quadriceps strength (MVIC) and
lower activation (CAR), and smaller lean muscle CSA
compared to contralateral side.
TKA patients had lower knee extension force (N/BMI) and
quadriceps activation (CAR) compared to the control.
OA patients had quadriceps inhibition and TKA decreased
quadriceps inhibition.
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VAS: Visual Analogue Scale
ITT: Interpolated Twitch Technique
RCT: Randomised Clinical Trial
JPS: Joint Position Sense
CSA: Cross Sectional Area
BMI: Body Mass Index

Sensory receptors associated with AMI

Characteristics of four different types of sensory receptors are presented in the Table 2.
Quick adapted receptors respond by initial stimulus but stop responding if similar stimulation is
maintained. Slow adapted receptors initially respond at a high impulse rate and then at a
progressively slower rate until eventually they no longer respond.55
Table 2. Characteristics of sensory receptors37,56-58
Type

Nociceptors

Receptor
Meissner’s corpuscle
Pacinian corpuscle
Merkel disks
Free nerve endings

Proprioceptors

Ruffini endings

Specific nature
Light pressure
Vibration
Touch
Distension
(stretch) & pain
Distension

Muscle spindles
GTOs

Length changes
Tension changes

Joint receptors
Krause’s end bulbs
Corpuscels of
Ruffini

Cold
Heat

Mechanoreceptors

Thermoreceptors

Location
Skin (superficial)
Capsule & ligaments
Skin (superficial)
Around hair roots and
under surface of skin
Joint capsule and
ligaments
Intrafusal muscle fiber
Musculotendinous
junction
Capsules & ligaments
Skin
Skin and capsules in
joints and ligaments

Adaption
Quick
Quick
Slow
Variable

Sensitive to
Joint motion
and pressure

Slow

Joint position

Pain

Slow
Slow

Slow
Slow

Temperature
change

Meissner corpuscles and Pacinian corpuscles (type II) are quick adapting joint
mechanoreceptors. Meissner and Merkel disks (type I) are located in the epidermis, underneath
the skin surface. Pacinian corpuscels are the biggest (1-5 mm) cutaneous mechanoriceptors,
located in the subcutaneous tissue.
Nociceptors (Type IV) are cutaneous receptors attached to a peripheral nerve.59 They are
located all over the body, both in the superficial and deep tissues. Two types are commonly
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classified: mechanical and polymodal nociceptors (Table 4). Mechanical nociceptors (A δ, highthreshold) are activated by strong mechanical pressure or temperature. Polymodal nociceptors
(C fibers) are activated by variety stimuli such as heat, mechanical pressure, and chemicals
released by tissue damage.60 Pain perception is affected by cognitive processes such as emotion,
depression, past experience, cultural background, or motivation.
Ruffini endings (type II) are low-threshold and slow adapting articular mechanoreceptors
located in skin, joint capsule and ligament.33 These are sensitive to joint position and changes in
position. An increased activity of Ruffini endings are believed to be the most responsible for
AMI when artificial effusion is induced.30,31 GTOs (type III) are slow adapting muscular
mechanoreceptors located in musculotendinous junction. These are activated by tendon stretch
(tension) resulting from muscle contraction. Increased stimulation from GTOs inhibits α-motor
neurons, resulting in a relaxation of muscles that is being stretched—this is autogenic inhibition.
Muscle spindles are muscle mechanoreceptors (slow adapting) located in the intrafusal fibers.
Intrafusal muscles fibers are innervated by the gamma-motor neurons, while extrafusal muscle
fibers are served by alpha-motor neurons (Table 3).58 A decrease in muscle spindle activity from
a reduction in γ MN activity following joint injury decreases proprioceptive acuity.25
Table 3. Classification of efferent fibers59
Type
Aα
Aγ
Aβ

Size
(μm)
12-20
2-10
8-12

Conduction
velocity (m/s)
70-120
10-50
30-50

Associated with
Skeletal muscle efferent (extrafusal)
Muscle spindle efferent (intrafusal)
Muscle and muscle spindle efferent

129

Afferent sensory fibers are classified in the Table 4. Numeric system from I (large) to IV
(small) classified by their size.61 Conduction velocity is based on the speed of each fiber
transmit information. Both size and myelination influence conduction velocity.
Table 4. Classification of afferent fibers37,56,57,59
Type

Group

Subgroup

Aα

I
II

Ia
Ib
Muscle

Size
(μm)
12-20
11-19
6-12

Aβ

II

Skin

8-13

Aδ

III
III
IV
IV

Muscle
Skin
Muscle
Skin

1-5

C

0.31.0

Fiber
characteristics
Large,
myelinated
Large,
myelinated
Large,
myelinated
Small, thinly
myelinated
Small,
unmyelinated

Conduction
velocity (m/s)
70-120
66-114
36-70
30-70
12-30
6-36
0.5-2

Associated with
Muscle velocity and length change,
muscle shortening of rapid speed
Muscle length information from touch
and pacinian corpuscles
Mechanical stimuli (touch and vibration)
Temperature, fast pain (sharp & localized,
quick stabbing), mechanical stimuli
Temperature, slow pain (duller & diffuse,
dull throbbing), heat, cold, mechanical
stimuli

Afferent pathway: primary, secondary, and tertiary afferents

Location of sensory neuron synapses are presented in the Table 5. Primary, secondary,
and tertiary afferents are also known as the first, second, and third order neuron, respectively.
Primary afferent fibers from the peripheral sensory receptors go into the spinal cord through the
dorsal side.58 The sensory input at the spinal cord synapse with interneurons that give out as the
secondary sensory neurons (afferents). Synaptic locations between primary and secondary
afferents are dependent on the type of receptors.56 Secondary afferents cross the midline of the
body, so the afferent input is processed on the opposite side of the brain. Afferent input at the
dorsal columns may trigger an automatic descending (ventral column) branch without input from
the brain (e.g. withdrawal reflex or tendon reflex).
The secondary afferent neurons are in the dorsal column of the spinal cord and terminate
in the thalamus.56 The thalamus processes the sensory input and carries it to a higher brain
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center.58 The thalamus is an relay centre that receives sensory input from the spinal cord, eyes,
ears and motor output from the cerebral cortex and cerebellum.56
Tertiary afferents from the synapse onto the thalamus project to the somatosensory region
of the cerebral cortex, the integrating and decision-making center. The cortex interacts with the
cerebellum and brain stem, and initiates motor commands. The cerebellum regulates voluntary
motor action, balance, and coordination of movement. After the sensory information is
integrated in the cortex, it is also passed to the limbic system. The cortex receives feedback from
the limbic system and creates emotional attentiveness.56
Table 5. Location of the sensory neuron synapses56
Type of sensory neuron

Termination of the primary afferents
Termination of the secondary afferents
Termination of the tertiary afferents

Stimulus
Fine touch, 130otoneurons130on,
vibration
Medulla
(path across midline of the body)
Thalamus
Cerebral cortex

irritants, temperature, coarse touch
Dorsal horn of spinal cord
(path crosses midline of body)
Thalamus
Cerebral cortex

Pain theories

The specificity theory (Muller, 1826) is the first pain theory. This theory postulates that
specific pain receptors in the periphery are stimulated and the pain signal goes up to the pain
centre in the brain via the spinothalamic tract, resulting in pain.62 Specific receptors are a
physiological fact, but this theory has an assumption that there is a direct-line for pain signals
between skin and the brain. However, this assumption does not explain how patients missing
their limb feel phantom limb pain or how animals can be trained to respond favorably to noxious
stimuli.60 Additionally, this theory cannot explain why patients differently respond to the same
source of pain.
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Pattern theory (Goldschneider, 1920) was proposed as a reaction aginst the specific
theory; it assumes that there is no specific system for pain perception. Pattern theory suggests
that patients feel pain when the magnitude and pattern of sensory input exceeds a threshold.62
All receptors are alike and shared with other senses such as touch and pressure. When intense
stimulation on certain patterns exceed threshold of the nonspecific receptors, action potential
carrying pain signal goes up to the brain, causing pain sensation.62 However, this theory ignored
that the physiological evidence for the high degree nerve specialisation.62
Gate control theory (Melzack, 196562) was developed by integration of specific and
pattern theory.60 When the pain receptors are activated, either large A δ (sharp and localized
pain) and/or small C fibers (dull and diffused pain) takes the pain signal to the spinal cord (Table
3). At the spinal cord, A δ and/or C fibers synapses with transmission (T) cell which is the gate.
The T cell determines which signal of sensation passes the gate and continues to travel up. The
substantia gelatinosa in an interneuron located in the laminae II and III. Small fiber stimulation
inhibits substantia gelatinosa which keeps the gates open. On the contrast, large fiber (A β)
stimulation (i.e: rubbing the skin) excites the substantia gelatinosa which inhibits the T cell
(closing the gate).
Central biasing theory, also known as Central control trigger theory or Lerant behavior, is
a modification of the gate control theory.62 It addresses how the brain affects afferent and
efferent information.63 Impulses from the thalamus and brain stem are delivered to the dorsal
horn of the spinal cord. This impulse blocks transmission of pain signal at the dorsal horn
synapse.57 Through this blocking system, previous experience, emotional influences, sensory
perception, and other factors could affect pain perception. Central biasing theory may be related
to placebo effects.64 Compared to no treatment condition, therapeutic ultrasound with intensity
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at zero resulted in a reduction in swelling and C-reactive protein in the patients with bilateral
surgical extraction of the third molars.64
Body naturally produces endogenous painkillers such as β-endorphins, enkephalins, and
dynorphins (Castel, 197965). Descending endogenous opioid initiated from in the midbrain
(periaqueductoal grey: PAG) and medulla (raphe nucleus) synapses with enkephalin interneurons.
This results enkephalin into the dorsal horn, inhibiting the synaptic transmission of impulses to
the secondary afferents neurons (Table 4).57 Prolonged aerobic exercise results in β endorphin
and enkephalin release.66-68 β endorphin can produce a strong desire in the runner to keep
running with pain until the “high” is achieved.63

Mechanism of AMI: why are extension muscles inhibited?

Abnormal afferent sensory input from the injured joint is thought to be a major cause of
AMI.11 Suggested sources of this abnormal afferent information include (1) deafferentation from
structural damage caused by the primary and/or secondary injury, (2) an increased amount of
certain sensory input (e.g. nociceptors), or (3) sensitization of the joint receptors.69 When these
abnormal afferent sensory input arrives at the CNS, several different pathways may result in a
reduction of efferent drive to the extensor musculature (Figure 1).24
Figure 1. A network of extensor and flexor muscle response after joint injuries24
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Due to injury, the knee joint is typically immobilized in the extended position. The
atrophy is easily localized in the knee extensors (quadriceps) because knee joint is typically
immobilized with an extended position. This atrophy results in quadriceps weakness, which may
possibly lead to further atrophy. Additionally, it has been shown greater intra-articualr pressure
is in the knee extended position53,70 which is thought to cause more inhibition.71 Convergence of
Ib and joint afferents pathways may converge into the interneuron of spinal cord, resulting in
extensor inhibition.72 Painful stimuli may produce a withdrawal response,73 resulting in flexor
facilitation. Additionally, reciprocal inhibition from knee flexion facilitation may take a role to
inhibit extensors.

134

Central mechanism may take part in AMI. Bilateral quadriceps inhibition has been
reported in subjects with unilateral AKP8 and partial menisectomy.22 Afferent sensory input
from the involved knee joint alters the γ-system in the spinal cord resulting in inhibition on both
sides.25 Reflex neurogenic inflammation—crossover effect of a unilateral inflammation to the
contralateral limb—may also be responsible for AMI. Joint injury may cause mechanical
alterations (e.g. joint moment & angle, and joint stiffness) in the involved limb. This changes a
patient’s neuromuscular control and gait pattern which may also affect muscle activation on the
contralateral side.

Types of inhibition

Arrivals of excitatory stimuli always occur in the CNS. In order to avoid unnecessary
motor effects, these excitatory stimuli need to be offset by inhibited stimuli. Presynaptic and
postsynaptic inhibitions are responsible for controlling an inflow of excitation.58 Both pre- and
postsynaptic inhibition is likely to participate in AMI. Pathological conditions may affect
balance between excitatory and inhibitory stimuli. Inhibitory stimuli become overwhelming,
resulting in a reduction of motor output.
Presynaptic inhibition occurs when activity of inhibitory (or modulatory) neurons in the
presynaptic axonal membrane decreases or blocks neurotransmitter release.56 This inhibitory
mechanism is selective on specific type of neurons while postsynaptic inhibition affects the
whole membrane. GABA (γ-aminobutyric acid inhibitory interneurons) are located in the
brain.56 Glycine is considered a major inhibitory neurotransmitter in the spinal cord.56 They are
responsible for the presynaptic inhibition.74
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Postsynaptic inhibition occurs when the net effect of action potentials are a negative
(hyperpolarisation)15 so action potential is not initiated.56 When the excitatory stimuli reach the
threshold, the postsynaptic membrane generates action potential. When the inhibitory potential
is stimulated, a hyperpolarisation of the synaptic potential occurs. It moves the membrane
potential farther away from the threshold. Thus, the generation of action potential from the
membrane is less likely.58
Reciprocal inhibition is the relationships of the agonist (a muscle being contracted) and
the antagonist (a muscle being stretched) activities. Proprioceptive neuromuscular facilitation
(PNF) stretching technique, especially slow reversal-hold-relax, has been suggested to elicit
reciprocal inhibition of the antagonist by contraction of the agonist.57 Tendon reflex test results
in a quick knee extension movement. A single stimulus of the tap to the patellar tendon activates
muscle spindles (Ia interneurons). In the spinal cord, some afferent input synapses with motor
neurons innervating the quadriceps while the other synapse on inhibitory interneurons
innervating the hamstring.56

Interneurons

Interneurons are located in the brain and spinal cord containing α- and γ-motoneurons.

An interneuron has many dendrites receiving information from afferent input through the dorsal
horn, efferent input from supraspinal center, and other neurons in the CNS; many axon terminals
project to other neurons in the CNS.15,58 Interneurons may take an important role in inhibitory
process.
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Renshaw cells are closely located to α-motoneurons in the ventral horns. An excitation
of α-motoneurons activate Renshaw cells which inhibit α-motoneurons (negative feedback).58
This is called recurrent inhibition. Descending information from supraspinal centre controls
excitation or inhibition of Renshaw cells which affects the activity of α-motoneurons. Renshaw
cells may inhibit γ-motoneurons which affects muscle spindle activity.58
When the agonist muscle is stretched, muscle spindles excite the Ia-interneurons. Then,
the Ia-interneurons inhibit α-motoneurons of the antagonist muscles (reciprocal inhibition).15
Renshaw cells, excited by α-motoneurons from the agonist muscle, may inhibit the Iainterneurons. This results in a reduction of inhibitory effects on antagonist (disinhibition).58 The
Ia-interneurons also receive information from descending inputs such as corticospinal,
rubrospinal, and vestibulospinal tracts.75
Excitation of the Ib-interneurons, activated by Golgi tendon organs of the agonist
muscles, inhibit agonist and excite antagonist.15 Ib-interneurons receive information from
afferents (joint receptors, mechanoreceptors, Golgi tendon organs) and descending signals
originated from supraspinal center (other neurons in the CNS). Change in the net effect of the Ib
interneurons has been thought to cause quadriceps inhibition and soleus facilitation under
condition of artificial knee joint effusion.20,29
γ-motoneurons innervate intrafusal fibers within the muscle spindle.56 They govern the
stretch sensitivity of the muscle spindle so they are active when muscle is relaxed. When muscle
contract, α-γ co-activation maintains spindle function.56 A reduction of γ-motoneuron activity
may affect muscle spindle sensitivity, consequently resulting in a decrease in proprioceptive
function76,77 and motor output.25
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Does pain directly cause AMI?

Pain has been reported as a cause of quadriceps inhibition in the patients with
experimentally induced AKP28,78,79, clinical AKP8,27,43, or post-operative knee pain80 (Table 1).
Experimentally induced knee pain caused a decrease in both voluntary79 (isometric and isokinetic
contractions) and involuntary78 (H:M ratio) quadriceps activation. Pain relief by injecting 0.5%
bupivicaine in the patients with knee OA resulted in an increase of quadriceps activation.81
Additionally, a decrease in post-operative pain level by injection of epidural analgesia with local
anesthetics resulted in an immediate increase in quadriceps activation.80 Contrarily, NSAIDs8 or
knee arthroscopy43 reduced AKP but did not change quadriceps activation. Patients in clinical
pain may be involved in other pathological conditions (e.g. structural damage, effusion, or
inflammation). Thus, factors other than pain may be accounting for quadriceps inhibition. The
results from these studies suggest that AKP may have an association with quadriceps inhibition
but other factors, alone or combined with pain, may be likely to contribute.
Patients with unilateral clinical AKP have shown that the contralateral limb had
quadriceps inhibition.8,43 Neuromechanical alterations from the involved limb may change the
functional kinetic chain, which could affect the muscle activation on the non-involved limb.8 An
alteration in neural activity of the involved limb may cause a transfer of inhibitory mechanism to
the non-involved limb. This neural cross-over effect has been called reflex neurogenic
inflammation.82 Since unilateral AKP affects both ipsilateral and contralateral quadriceps
activation, the values of the quadriceps activation on the non-involved side cannot be a normal
control.8,43
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The neurophysiological mechanisms of how the sensory input (joint pain) affect the
motor response (muscle activation) is not fully understood. The nociceptive-motor interaction
may occur anywhere throughout the CNS and PNS.79 When the abnormal sensory input
resulting from a joint injury reaches the dorsal horn of the spinal cord, the motor unit recruitment
pattern may be altered. The interactions may occur in the supraspinal level. The thalamus is a
relay center receiving and sending the sensory and motor information.56 Since the limbic system
is associated with the thalamus, hypothalamus, and cortex, pain information coming up to this
level affects emotional and affective behavior resulting in motor response alterations. The
cerebral cortex regulates pain perception and voluntary movement56 thus the pain fibers may
change the efferent outcomes.
Do alterations in motor response (AMI) due to stimulation of nociceptors occur under
patients’ voluntary intention? Depending on the severity of nociception, patients may decide to
avoid bearing their weight or contracting the surrounding muscles at the injured joint. This
intentional avoidance in joint movement would remain as long as the nociceptor stimulation is
present. This voluntary inhibition may accelerate AMI progression along with other factors such
as swelling, structural damages, or inflammation. Despites patients’ willingness, however, the
CNS (spinal and/or supraspinal) may automatically reset the motor output in the adjacent
musculature of the injured joint. This includes adjustments on the capacity of recruitment on the
active motor units or excitation of inhibitory interneurons (i.e. increasing recruitment threshold).
It is speculated that both mechanisms may be responsible for AMI. Quadriceps inhibition
estimated by the H:M ratio was observed both during at voluntary and involuntary contraction.30
This suggests that during voluntary and involuntary contraction may take the same inhibitory
pathways.30 Voluntary inhibition may have a larger role to contribute AMI in the acute stage of a
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traumatic joint injury. Involuntary inhibition may be more difficult to reverse if the AMI
remains throughout the rehabilitation process.

Pain models

Since subjectivity, magnitude, onset, and duration of pain confound the results,
researchers experimentally induced pain by injection of hypertonic saline into the muscle83-85 or
infrapatellar fat pad28,32,78,79,86-89 (Table 6). This pain model allows us to examine the
neuromechanical changes under the condition of isolated pain. Subjects described pain induced
by 5% hypertonic saline as aching (50%), annoying (44%), throbbing (38%), and nagging (38%),
and dull (32%).32 The infrapatellar fad pad is a sensitive structure and a potential nociceptor
source for AKP.87,90 Perceived pain level was average of 4.9 on the 11 point numerical rating
scale. Injection of hypertonic saline is thought to cause chemical irritation on nociceptors within
the fat pad. Mechanical pain was less likely because injection of isotonic saline (0.9%) caused
minimal to no pain lasting up to 90s.32 This pain model does not closely mimic clinical pain but
it allows examination of the isolated effects and consequences on motor function parameters.87
Table 6. Summary of studies using pain model
Author
(year)
Bennell
(2004)32
Bennell
(2005)87
Bennell
(2005)86
Farina
(2004)83
Farina
(2005)84
Farina
(2005)85
Hodges
(2009)28

Injection type
(rate)
Single injection
(0.2–0.25 ml)

Injection site
(saline concentration)
Medial infrapatellar
fat pad (5%)

0.2, 0.5, and 0.9
ml separated by
140 s.
Infused (0.5 ml
in 40 s.
Infused (0.2,
0.5, and 0.9 ml)
Single injection
(0.25 ml)

Tibialis anterior
(5.8%)

Medial infrapatellar
fat pad (5%)

Main findings and significances
Subjects felt pain 3 min after injection and pain free by 15
min. Average pain level: 5.8 in 11 point NRS
Pain did not change JPS. Average pain level: 4.9 in 11 point
NRS.
Pain did not change balance. Average pain level: 6.2 in 1
point NRS.
Pain decreased motor unit firing rate (EMG). Motor unit
firing rate was negatively correlated with the pain intensity
(VAS).
Induced pain decreased motor unit discharge rate (EMG)
during contractions.
Induced pain decreased voluntary EMG activity during
contractions.
The onset activation of VM was delayed relative to that of
the VL during ascending. VL EMG amplitude was
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Long
Intermittent
(2009)78
(0.54 ml / min)
Tucker
Single injection
(2009)89
(0.25 ml)
Henriksen Single injection
(2010)88
(0.75 ml)
Henriksen Single injection
(2010)79
(1.0 ml)
NRS: Numeric Rating Scale

Lateral infrapatellar
fat pad (5%)
Medial infrapatellar
fat pad (5%)
Medial infrapatellar
fat pad (5.8%)

decreased from the no pain condition.
Induced pain caused a decrease in the VM H:M ratio and
cryotherapy reverse VM inhibition.
Quadriceps 140otoneurons discharge rate was decreased
while the force was maintained with experimental knee pain.
Experimental knee pain reduced the peak knee moments in
the frontal and sagittal plane.
Pain decreased knee extension/flexion strength (isokinetic)
than control condition.

AMI with joint effusion

Effusion is a common symptom of patients with knee joint injuries. Although the
relationship between AMI and joint effusion, relative to pain, has been well established, there are
not many studies objectively conducted. Clinically, AMI associated with knee joint effusion has
been presented in patients with traumatic injury91, meniscectomy,31 and degenerative joint
damage92 as well as both acute31,48 and chronic45 pain-free joint effusions.
Aspiration of chronic knee joint effusion resulted in an increase in quadriceps strength.45
This may partly explain why voluntary contraction alone may not be beneficial. In the same
study, EMG activity also increased. This supports the idea that AMI is mediated by neurogenic
rather than mechanical effects. Another study examined the effects of aspiration of the chronic
joint effusion did not find changes in quadriceps activation.93 This study also suggested that
amount of the effusion was not related to the inhibition.

Effusion models

Numerous studies used artificial effusion in the knee joint capsule (Table 7). This
inhibition occurred in the absence of pain13,19,94 thus this is an effective model to examine the
isolated effects of joint pressure. Isotonic saline (0.9 %) is injected into the area superomedial20
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or superolateral13,19,29,95 to the patellar (Table 7). Small (<55ml)13,19,20,31,94 or large volume
(>55ml)13,19,29,71,95,96 of saline infusion have been used. Both small and large volumes have been
shown to produce mechanical inhibition of the quadriceps (Table 7). Higher volume (< 80ml)
may stimulate nociceptors.19 The minimal amount of volume injected into the knee joint to
induce quadriceps inhibition has been suggested as 20-30 ml for the VM and 50-60 ml for the
VL.30 Additionally, knee joint effusion produced a greater inhibition in the VM than the VL and
RF. For these reasons, the VM seems to be most sensitive muscle in the quadriceps and a good
candidate for AMI studies.
Intra-articular pressure within the knee joint increased as the knee joint is in extended or
flexed position and decreased in the mid range during passive movement.70 Another study53
showed that intra-articular pressure peaked in the mid-range (90-110° flexion) during active
contraction. The volume of effusion is positively related to the intra-articular pressure30,31,53 and
amount of inhibition.13,31 Increased activity of slow adapting Ruffini endings, resulting in
stimulating of the Ib inhibitory interneurons seems to contribute to muscular inhibition.29-31,94,97
Even a small volume (30 ml) of effusion causes inhibition.24 Small volumes of effusion are not
considered as a big limitation to rehabilitation process, thus it is often untreated. However,
disinhibition should be addressed with effusion even in small amounts.24
As a result of mechanical distension in the knee joint, quadriceps inhibition20,30,31,97 and
soleus facilitation94 has been observed in many studies. Using this knee effusion model,
researchers have further reported quadriceps inhibition with soleus facilitation20 or hamstring
facilitation.20 Quadriceps inhibition with hamstring facilitation has also been observed in the
functional movements such as walking19 and drop landing.13 These alterations may be a
compensatory process to maintain proper lower extremity kinetic chain.20 Similar compensatory
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patterns have also been observed in animal studies.98 The net effect of Ib interneurons may mask
the quadriceps projection to the soleus and hamstring, resulting in soleus and hamstring
facilitation. It would be interesting to see how pain, effusion, or a combination of these two
stimuli would change the measurements of voluntary contractions (MVIC or CAR).
The soleus facilitation with the quadriceps inhibition was observed in the supine
position.20 During walking, however, a reduction in soleus activity in the involved leg has been
reported in the patients with acute ACL rupture.39 Additionally, peak internal plantar flexion
moment was reduced in the early stance phase in subjects with artificial AKP.99 Tricep suare
activation is thought to be associated with the internal plantar flexion moment. Facilitation of
triceps suare against quadriceps inhibition may present only in the static position.
A unilateral knee joint effusion (60ml) caused ipsilateral inhibition but not contralateral
quadriceps (VM) inhibition.95,100 This data suggest that bilateral quadriceps inhibition, resulting
from unilateral joint injury, may not be from pain-free knee joint effusion or isolated stimulation
of slow adapting Ruffini endings.95 Stimulation of nociceptors8,43 or deafferentation from tonic
descending inhibition69 from the inflammation in the injured joint may have be responsible to
initiate the contralateral AMI.

Table 7. Summary of studies using effusion model
Author
(year)
de Andrade
(1965)101
Jones
(1987)93
Kennedy (1982)
Spencer
(1984)31

Injection site
(volume)
Superolateral
(800mm pressure)

Aspiration
Lateral joint
space (60 ml)
Intra-articular
space (60 ml)

Main findings and significances
Gradual distension of the knee joint resulted in quadriceps weakness. Reflex
inhibition may lead to the muscle weakness.
Knee aspiration in the patients with chronic effusion did not change quadriceps
activation (ITT).
Effusion caused quadriceps inhibition (H-reflex). Lidocaine (10 ml) injection
prior to the saline (50 ml) injection did not change quadriceps activation.
Effusion reduced the H-reflex in the VM, VL, and RF. A positive relationship
between the volume of effusion and (1) intra-articular pressure and (2) the H-

143
reflex amplitude.
Intra-articular joint pressure increased as the limb was extension and flexion
position. Minimal pressure occurred in the mid-range. Effusion decreased
voluntary contraction (isometric and isokinetic).
Iles
Lateral knee
Increased pressure gradually decreased the RF (H:M ratio), both at rest and
(1990)30
joint (100 ml)
during contraction.
Jensen
Superolateral
Quad strength (isokinetic) decreased as the amount of effusion increased (20 ml
(1993)53
(60 ml)
increments), and then increased after aspiration.
Hopkins
Superolateral
After joint effusion, the soleus was facilitated (H-reflex) at post injection-3 and
(2000)94
(25 ml)
-4h compared to the baseline.
Torry
Superolateral
Knee effusion resulted in quadriceps inhibition, and hamstring facilitation
(2000)19
(up to 80ml)
(EMG) during gait. It also resulted in an increase in hip and knee flexion, a
decrease in knee extensor torque,
Hopkins
Superolateral
After joint effusion, the soleus was facilitated while the quadriceps was
(2001)20
(30 ml)
inhibited at all measurement intervals (post-30, -90, -150, and -210 min).
Hopkins
Superolateral
Induced knee joint effusion resulted in quadriceps (VM) inhibition (H-reflex).
(2001)29
(60 ml)
Cryotherapy and TENS had disinhibitory effects.
Palmieri
Superolateral
Joint effusion resulted on the ipsilateral quadriceps (VM) inhibition (H:M ratio)
(2003)95
(60 ml)
but not on the contralateral side.
Hopkins
Inferomedial
Effusion resulted in a decrease in peak torque, peak power, and peak VL
(2006)96
(55 ml)
activity (EMG) compared to the control or effusion/cryotherapy group.
Cryotherapy after effusion increased in knee joint reaction force.
Palmieri-Smith
Superolateral
Effusion resulted in the quadriceps inhibition with hamstring facilitation, an
(2007)13
(30 & 60 ml)
increase in GRF, and a decrease in peak knee flexion angle during a single leg
drop landing
*Rice (2009)102
Superomedial
Effusion decreased the quadriceps MVIC, muscle fiber conduction velocity, and
(until 50 mm
EMG signals. Cryotherapy increased the quadriceps MVIC compared with
Hg)
controls.
* Dextrose saline (4% dextrose and 0.19 NaCl) was injected
Wood
(1988)70

Anterolateral
(up to 20 ml)

Limitations on the pain and effusion model

The pain and effusion model nullifies other confounding factors and allows us to examine
how the isolation of specific stimuli affects motor patterns. Although pain and effusion are
known to trigger reflex inhibition leading to AMI, each model still has limitations to make
inferences to a clinical population. Induced pain by 5% hypertonic injection may have different
quality than clinical pain. Additionally, the body’s natural circulatory system absorbs the saline
solution during testing.19 Therefore, intra-articular pressure may diminish at the time of
measurements. Different capsule (body) size may have various pressure effect within the
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capsule96, resulting in various response levels. An injury model that combines pain and effusion
stimuli would more closely reproduce an acute condition of joint injuries.

Acceptable disinhibitory interventions

Cryotherapy: The use of cryotherapy has been shown an effective disinhibitory
intervention in the patients with tibiofemoral knee OA103 and artificial knee joint effusion.29,96,102
Cryotherapy has also been reported to increase quadriceps activation in healthy subjects.104 This
disinhibitory effect has been observed in both voluntary (MVIC102; CAR103,104; EMG96) and
involuntary (H-reflex)29 measurements. The effects of increased muscle activation by
cryotherapy seem to last up to 45 minutes. Most studies29,96,103,104 used two crushed ice bags
(1.5L) placed on the anterior and posterior.29,103,104 A study used three crushed ice bags.102
Joint cooling may reduce nerve conduction velocity and slow the discharge rate from the
joint mechanoreceptors. This would result in less afferent input to the spinal cord causing
disinhibition.29 Joint cooling also stimulates the cutaneous mechanoreceptors which excites Ia
interneurons, resulting in excitatory potential at the motoneuron pool.29 Activation of
thermoreceptors may produce a decrease in the recruitment threshold of the active motorneurons,
thus the inhibited motorneuons may become recruitable. Increased number of active motor units
has been suggested as the primary contributor with an increase in motor unit firing frequency as
secondary to increases in CAR.104
Electrotherapy: The use of electrotherapy (TENS29,103 and NMES105-109) has been
reported to increase quadriceps activation in patients with tibiofemoral knee OA,103,110 ACL
reconstruction,105,106 TKA,107-109 and artificial knee joint effusion.29 This disinhibitory effect has
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been observed in both voluntary (CAR103,105,107 and isometric contraction106) and involuntary (Hreflex)29 measurements. A single session of TENS treatment immediately increased quadriceps
activation.29,103 Multiple sessions of NMES treatments alone have been shown as a superior
intervention over voluntary contraction of the quadriceps alone.105-107 On the contrast, NMES
did not have any treatment effects in female patients with knee OA (mild to moderate).110
However, the female patients in this study had more than 87% activation prior to receiving the
intervention, thus NMES was unable to produce a treatment effect.110

29,103

Compared to

electrotherapy, cryotherapy may have a similar effect103 or be more beneficial.29
Possible explanations for the disinhibitory effects of electrotherapy include: TENS may
inhibit the activity of the Ib inhibitory interneuron or excitate the Ia excitatory interneuron, or
decrease the descending inhibitory fibers connecting to the Ib interneuron. Any of these would
result in an increase of MNP excitability.29 The order of motor unit recruitment and synchrony
for NMES is opposite of voluntary exercise—initially activating type II muscle fiber, then type I.
Patients with ACL reconstruction may have selective atrophy in type II muscle fibers, thus
NMES may be effective in recruiting inhibited type II fibers and reverse AMI.105,106 A positive
relationship between NMES dosage and quadriceps strength has been suggested.107
Transcranial magnetic stimulation (TMS): Direct electrical stimulation of the motor
cortex region results in excitation of descending corticospinal tracts.111 This efferent projects
into the corresponding motoneurons within the target muscles.111 TMS has been manually
delivered (60%112 to 90%74 of maximal stimulator output) to the motor cortex while the subjects
produce voluntary contraction (50%74 or 100%112 of MVIC). TMS increased voluntary
activation in healthy subjects113,114 and patients with TKA.112 TMS did not change quadriceps
activation (CAR) compared to no treatment condition in patients with partial meniscectomy.74 In
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the same study, however, strong effect sizes were found at 10 and 60 minute post-treatment in
the TMS group compared to the control group. Excitation of neural drive by TMS is thought to
increase number of active motoneurons, reducing pre-synaptic inhibition.115
Manual therapy: Sacroiliac (SI) joint manipulation, high-velocity low-amplitude thrust,
has been shown to increase quadriceps strength (MVIC27,116) and activation (CAR116 and ITT26,27)
in AKP patients26,27 and healthy subjects.116 Lumbar manipulation has also shown to reduce
triceps surae (soleus117 and gastrocnemius118,119) activation (H-reflex) in healthy subjects. Soleus
facilitation has been reported in artificial knee joint effusion94 and considered as a compensatory
strategy following quadriceps inhibition.20 Hence, spinal manipulation may be an effective
treatment to reverse the compensatory motor pattern that has been employed following joint
injury. However, this treatment effect does not last longer than a few minutes after spinal
manipulation.116,118
SI joint manipulation increased quadriceps strength (MVIC) while tibiofemoral joint
manipulation did not change in individuals with patellofemoral pain syndrome.120 If this is the
case, knee joint (tibiofemoral) manipulation may not be beneficial. Since cryotherapy causes
changes in peripheral neural drive from the injured joint and have been shown to increase
quadriceps activation,29,103,104 future studies should attempt lumbopelvic cooling to see how
excitation of the thermoreceptors at the spinal level (L2 through S2: femoral and tibial nerves)
assists disinhibition.
Little is known regarding the physiological mechanisms of spinal manipulation on the
motor system. A change in afferent input by high-velocity, low-amplitude thrust may stimulate
efferent pathways to the target muscles.26 Joint manipulation is considered to influence the CNS
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at the segmental level by stimulating receptors (mechanoriceptos, proprioceotors and free nerve
endings) in and around the manipulated joint.117,121 The SI joint (L2-S3), quadriceps (L2-L4),
and knee joint (L2-S2) share similar nerve roots. Changes in afferent input from these spinal
segments may affect efferent signals of the same nerve root.116
Thermotherapy: A 30 minute application of moist heat pack around the ankle joint did
not change the H:M ratio and peak plantar flexion torque of the soleus.122 Superficially, there
are less thermoreceptors responding to heat than cold. Thus, there may be less quantity of
thermal receptors stimulated with heat, resulting in no change in spinal or supraspinal MNP.
Another study123 showed that there was a 19% decrease in MNP excitability with using a heat
blanket. The different result may be from the size of the surface area covered by the heat
modality. Applying heat modality to a bigger area would stimulate more thermoreceptors. This
increase in the quantity of stimulated receptors may disinhibit or excite the motoneuon pool.
Voluntary exercise: Many studies12,18,54,105,106 suggested that performance of voluntary
exercises alone may not be beneficial to improve quadriceps strength in patients with knee joint
injuries. Multiple sessions (3 times/week for 4 weeks) of isometric quadriceps contraction was
not as effective as high intensity NMES in increasing quadriceps activation (CAR) in patients
with ACL reconstructions.105 NMES produced higher thigh strength (knee extension and flexion
torque in MVIC) than did voluntary exercise.106
Any potential source that disrupts normal afferent input (such as joint pain, effusion,
inflammatory response, or structural tissue damage) should be removed prior to performing
voluntary muscle training.45,124 Without addressing neural inhibition, inhibited muscles
associated with AMI (e.g. quadriceps) may employ new motor recruitment patterns based on the
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modified pool of active motoneurons.124 This may cause other musculature (i.e. hamstring or
quadriceps in the contralateral limb) to adjust their activity in order to compensate for quadriceps
inhibition. Therefore, modified muscle activation patterns during traditional voluntary exercises
may lead to future injuries or chronic joint degeneration.
However, voluntary exercises in conjunction with other disinhibitory modalities may be
successful in reversing AMI.107 Cryokinetics125,126 is well known for enhancing the
rehabilitation process by allowing early active movement with less pain and restoration of
normal ROM.60 Initially, the benefits of cryokinetics were discussed based on cold-induced
vasodilation.127,128 However, active movement caused an increase in blood flow to a greater
degree than cold or heat application alone.129 Facilitating pain-free, early active exercises by
numbing the injured area has been considered as the primary benefit.60 However, disinhibitory
effect on the motoneurons pools,29,104,130 that were inhibited by join injury, may play a larger role
than does the analgesic effect.

Neuromechanical alterations resulting from knee joint injuries
Many studies have reported the kinetic and kinematic changes during walking in subjects
with knee OA,131-141 AKP,142-144 meniscectomy, 49 ACL deficiency,145,146 ACL rupture,39
artificial knee pain,88,147 muscle pain,148 and knee effusion13 (Table 8).
Table 8. Summary of studies assessing kinetic and kinematic changes during walking
Author
(year)
Brinkmann
(1985)139
Berchuck
(1990)146
Messier
(1992)50
Nadeau

Injury

Main findings and significances

Arthritic (TKA)

TKA improved knee flexion and extension ROM during walking in the patients
with rheumatoid or osteoarthritis.
ACL deficient patients had less external knee flexion moment in the involved
and non-involved limb, when compared to the control subjects.
Knee OA group had (1) less knee ROM, (2) increased loading rate in the noninvolved leg, and (3) less stride length, and (4) less quad strength than control.
AKP patients had a reduction in knee flexion angle during stance phase. No

ACL deficiency
Knee OA
AKP
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(1997)142
Powers
(1999)143
Hurwitz
(2000)137
Torry
(2000)19
Kaufman
(2001)135
Baliunas
(2002)132
Hurwitz
(2002)136
Lewek
(2004)134
Shrader
(2004)149
Mundermann
(2005)131
Henriksen
(2006)138
Henriksen
(2006)150
Hurd
(2007)39
Henriksen
(2008)148
Zeni Jr.
(2009)141

AKP
Medial knee
OA (K/L grade)
Induced knee
effusion
Knee OA
Medial knee
OA (K/L grade)
Knee OA
Genu varum &
medial knee OA
Medial knee
OA
Medial knee
OA (K/L grade)
Knee OA
(WOMAC)
Medial Knee
OA
Acute ACL
rupture
Induced
quadriceps pain
Medial knee
OA (K/L grade)

difference was found in joint moments relative to control subjects.
AKP patients had a less knee flexion, stride length, and average peak loading
rate than the control subjects.
The change in pain level has been negatively related to the change in the knee
adduction moment (external) during walking.
Knee effusion resulted in increase in hip and knee flexion. Knee extensor and
impulse were decreased with increased knee effusion.
Knee OA patients had a less internal knee extensor moment than normal
subjects.
Subjects with OA had (1) less knee minimal flexion angle and (2) greater knee
adduction moments (external).
Knee OA patients had greater knee adduction moment (external). Mechanical
axis of the leg was the best single predictor of the knee adduction moment.
OA group had a greater knee instability, medial joint laxity, and knee adduction
moments than the control group.
Pain relieving resulted in a increase in gait velocity, cadence, external knee/hip
adduction moment, and ankle abduction moment.
Patients with OA made (1) more extended initial contact, (2) a faster increase of
loading rate, and (3) greater knee adduction moments (external) than matched
control subjects.
OA group had lower joint loads than the control group. Lidocaine injection
decreased pain and increased joint loads in the OA group.
OA patients and control subjects did not differ in impulse forces and joint angles
at heel strike. Pain relief resulted in more extended hip & knee joint.
Compared to the uninjured leg, the involved leg had less peak knee angles,
higher co-contraction in quad/hamstring, and knee flexion moment.
Induced muscle pain did not change impact loading in either gender.

OA patients had less knee and ankle joint moments, GRF, and knee reaction
force relative to the control subjects. These changes possibly from slower
walking speed.
Hunt
Knee OA
Knees with OA had greater knee adduction moments, frontal plane lever arm,
(2006)34
(K/L grade)
and less frontal plane GRF relative to control subjects.
Henriksen
Induced knee
Experimental knee pain reduced the peak knee moments in the frontal and
(2010)88
pain
sagittal plane. Knee angle was decreased in the early and late stance phase.
Hunt
Medial knee
The relationship between quadriceps strength and loading rate become
(2010)140
OA (radiograph) insignificant when controlling for other variables.
Lindstrom
Chronic ACL
Walking speed, stride length, GRFA did not differ between ACL deficient
(2010)145
deficiency
patients and control.
Thorlund
Meniscectomy
Meniscectomised leg had less peak vertical GRF and quadriceps muscle activity
(2010)49
relative to the non-operated leg.
Seeley
Induced knee
Induced pain resulted in a reduction of peak braking and lateral force, peak
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pain
vertical GRF, and peak push off vertical GRF.
(2011)
Seeley
Induced knee
Induced pain reduced (1) the peak support moment, peak PF angle, and moment
(2011)99
pain
during late stance and (2) peak knee extension moment and hip abduction
moment during early stance phase.
* Subjects in all studies had tibiofemoral OA
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Ground reaction force

Induced knee pain in healthy subjects resulted in decreased peak braking GRF, peak
horizontal and vertical GRF, and peak push-off vertical GRF.147 Reduced peak braking GRF
may be associated with a decrease in net internal knee extension moment,88 possibly resulting
from quadriceps inhibition. Vertical unloading GRF has also been shown to increase.147
Subjects in this study147 may have intentionally attempted to avoid bearing weight on the
involved leg, resulting in an increase in vertical unloading GRF.
Many studies49,141,147 have reported a reduction in peak vertical GRF of the involved limb
with knee OA. Patients with AKP had less loading rate in the involved limb relative to the
control subjects.143 Patients with knee OA walked with an increased loading rate in the noninvolved limb than the involved limb.50 This may be from weakened vertical push off with the
involved leg causing the non-involved leg to exert higher vertical GRF.

Knee joint moments

It has been suggested that external knee adduction moment is related to medial
compartment joint loading,151 tibial mineral bone content,152 knee pain,149 and progression of
joint degeneration.153 Patients with medial knee OA have shown a greater knee joint loading
(external knee adduction moment) in the involved leg than control subjects.34,131,132,134,136 This
leads to greater load in the medial compartment which would accelerate degenerative changes on
the medial side of the articular cartilage.153 Contrarily, less knee joint loading (less internal knee
extensor moment in patients with knee OA135,138 and more external knee flexion moment in the
patients with ACL deficient146) than control subjects has been reported. A reduction in knee
adduction joint moment in patients with knee OA may be a compensatory mechanism to avoid
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excessive joint loading of the knee joint141 and/or pain.154 Others reported that there is no
difference in knee joint loading in the frontal135 or sagittal planes142 between patients with knee
OA or AKP and normal subjects.142
Total support moment has been reported in patients with acute ACL rupture (noncopers)39 and artificial knee pain.99 During the weight acceptance phase of walking (initial
contact to peak knee flexion), the contribution of the knee joint to the total support moment was
less while the hip joint increased the moment in the ACL ruptured leg when compared to the
non-injured leg .39 During the mid-stance, the contribution from the ankle joint moment
increased to compensate less joint moment from the hip and knee joint.39 This suggests that
ankle joint may be the primary stabilizer for the total support moment in the patients with knee
joint injuries.
A study using the artificial pain model reported a reduction in the total support moment
in the involved leg.99 The relative contribution of each joint did not change throughout the
stance phase. Experimentally induced AKP Patients’ intentional unloading strategy may explain
this. It would be interesting to observe how the contralateral leg changes its total support
moment when the artificial knee pain and/or knee joint effusion is present.

Joint range of motion and angles

Lower extremity static joint range of motion (ROM), measured using the goniometer, in
patients with knee OA were compared to those in matched control subjects.50 No differences
were found in the ankle and hip joint range of motion. However, patients with knee OA had less
knee flexion and extension range of motion for both involved and non-involved legs than those
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in the control group. Involved limb had less flexion and extension range of motion than noninvolved leg in the OA patients. Interestingly, the non-involved leg of knee OA patients had less
ROM than the control subjects. The non-involved leg may have adapted to the limited activity
level of the involved limb. This adaptation seems to highly affect ROM of the knee joint.
In addition, AKP patients walked with less knee angle relative to control subjects.142,143
Observations of the joint angles in the OA patients have not been consistent.88,132,150 One
study132 reported no difference in the knee flexion angle (mid-stance) or the terminal extension
knee angles between groups. Another study also reported no difference in ankle, knee, and hip
angles at heel strike between groups.150 Others88 found that knee OA patients demonstrated
more knee flexion at heel strike and during late stance phase than the control subjects. This
reduced knee joint angle during the stance phase is thought to produce greater compressive
forces in the knee joint.145 Studies that observed the effects of pain relieving in OA patients
found a reduction in knee flexion,138,150 no difference in any joint angle (hip, knee, and ankle)149,
or a slight increased knee angle.137 Rheumatoid and osteoarthritis patients increased flwx iona
and extension ROM after TKA.139
Artificial knee pain resulted in an increase in knee angle (more flexed knee) in early
stance phase and an increase in knee angle during late stance.88 An artificial knee effusion
study19 also observed more flexed knee at initial contact and an increased hip flexion throughout
the stance phase in the effused group compared to the control group. Additionally, hip flexion
angle was positively related to the amount of effusion.19
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Walking speed and stride length

Faster walking speeds affect joint moment, vertical GRF and loading rate
measurements.140,143,155 Slower walking speed have been observed in patients with AKP143 and
knee OA.141 Decreasing pain by intra-articular injection has shown to increase walking speed in
patients with knee OA.149 Reduced vertical GRF and loading rate are correlated with slower
walking speeds.143 Slower walking speed reduces the demand of knee extension moment during
initial contact.156 Limited knee extension moment is associated with quadriceps inhibition.
Knee OA50,132 and AKP143 patients exhibit less stride length than the control subjects.
However, walking speed, stride length, and stance time did not differ between patients with
chronic ACL deficiency and healthy subjects.145

Joint loading

The literature has not been consistent regarding knee joint loading tendencies in knee OA
patients. Knee joint loading (knee adduction moment) is associated with severity of pain.153
Increased knee joint loading (by pain) causes higher compressive forces within the joint,
resulting in accelerating joint degeneration progression. On the other hand, patients with knee
OA walked with less joint unloading.135 Decreased knee joint loading does not provide normal
joint stress157 to maintain articular cartilage health. Less joint compressive forces may lead (or
accelerate) to degeneration of articular cartilage over the long term effects.158 Additionally, OA
knee pain relief by intra-articualr injection138,149 and NSAIDs137 resulted in a increase in joint
loading (internal extensor moment,138 external adduction,137,149 and external flexion
moment137,149) during walking. Pain may exist as protective mechanism to maintain optimal
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joint loading. This suggests that reducing osteoarthritic knee pain may cause a more rapid
disease progression.88
Knee joint unloading strategies are consistent in artificial knee pain88 and effusion
studies.19 These studies suggest that both nociceptive activity from the infrapatellar fad pad and
mechanical pressure within the joint may influence gait adaptations. Sudden artificial stimulus
(pain or effusion) that the subjects have never experienced may lead to a simple unloading
strategy on the involved side. Thus, intentional avoidance on the ipsilateral weight bearing side
due to acute artificial pain or effusion should be considered as another contributing factor in any
injury model study. Comparisons of abnormal joint loading responses due to pain, effusion, or a
combination of these two stimuli could answer which stimulus places patients at greatest risk for
early joint degeneration.

Gait adaptation and its long-term effects

It is evident that quadriceps activation is diminished following knee joint injuries (Table
1). As a result of quadriceps AMI, internal knee extensor moment decreases99,135 which lead to a
more flexed knee angle at initial contact and throughout the early stance phase of gait.19 By
intentional unloading of the involved limb, or perhaps due to an increase in quadriceps-hamstring
co-contraction,39 knee angle becomes in a more extended position during and after the midstance.19,39,142 Reduction in walking speed143 result in a shortened stride length. Due to longer
duration of activation of the tibialis anterior145 or activity of the ticeps surae,39,99 push off at the
terminal stance on the ipsilateral side decreases.50 These adaptations would result in a decreased
swing phase and an increased vertical GRF and loading rate of the non-involved leg. In order to
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avoid weight bearing in the involved side, trunk would shift towards to the side of non-involved
limb.
Gait is the most common activity of daily living. Following knee joint injury, the lower
extremities alter the normal gait pattern. This temporary adjustment not only helps to protect the
injured joint (i.e. quadriceps avoidance gait and unloading strategy), but may also allows the
lower body to maintain function. These adaptations, however, appear to have long-term negative
effects. Adaptations of the normal gait program may include modifying neuromuscular
activation patterns, changing the degree of contribution of each joint, and creating kinetic and
kinematic asymmetry between limbs. These adaptations create a new motor program. This new
gait program may lead to accelerate and/or early joint degeneration.
Quadriceps weakness has been considered as a strong predictor of joint degeneration.42,159
Persistent quadriceps AMI may directly progress knee joint degeneration. As an active restraint,
the quadriceps provides joint stability and aids in shock absorption within the joint.22 Decrease
knee extensor torque may directly cause alterations in knee joint loading. There have been many
studies that examined alterations in the knee joint moment in the patients with knee OA.
Although some reported34,131 an increase in knee joint loading while others reported135,138
reduced knee joint loading, it seems to be clear that knee joint injury shuts down the knee
extensors and changes knee joint loading and mechanics. Quadriceps AMI from a acute injury
may initiate gait adaptations which cause abnormal joint loading in each joint, eventually
resulting in degenerative joint disease.
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Drop landing task

The drop landing task is experimental movement to examine landing mechanics.160 It has
been used to describe active knee joint strain and mechanism of non-contact ACL injury.13,161-164
ACL injury is two to eight times greater for females than males.165 Studies examining sex
differences during drop landings have reported that females landed with (1) less gluteus
maximus activation166 and greater quadriceps activation161,162 compared to control (2) lower
quadriceps to hamstring ratio,161 (3) greater tibial internal rotation after immediate landing,161 (4)
greater vertical GRF,163 (5) greater knee valgus position before and at landing,164 and (6) less hip
and knee flexion angle (more erect posture).162,163
Patients who have completed their rehabilitation post-injury may still exhibit quadriceps
inhibition along with neuromuscular deficits.167 These potential alterations would hinder active
dynamic joint restraints, resulting in a reduction in knee joint stability. Due to alterations of the
active restraints, passive joint restraints (i.e. ligaments or articular cartilage) compensate the
energy absorption deficit from the quadriceps and exert more force during landing from a jump.
Additionally, quadriceps inhibition may lead to alterations in other musculature (i.e. hamstring
and gluteus medius) which could cause kinetic and kinematic changes.
Unfortunately, there is little data on adaptations in patients with clinical knee joint
injuries during drop landing task. A controlled laboratory study examined how transient
quadriceps inhibition, induced knee joint effusion (60 ml), causes kinetic and kinematic
alterations in drop landing.13 Knee joint effusion caused (1) less peak knee flexion angle
(sagittal plane), (2) less peak knee extension moment, and (3) higher peak GRF compared to no
effusion.13 These findings are consistent with the observation of sex differences during drop
landing. These alterations may be a consequence of clinical knee joint injuries and should be
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addressed the rehabilitation. In the same study,13 low amount of knee effusion (30ml) produced
quadriceps inhibition but did not produce any kinetic or kinematical changes.13 This study13 also
observed hamstring facilitation along with the quadriceps inhibition. The hamstring facilitation
is thought to be a compensatory strategy.
Increasing peak GRF during drop landing is believed to increase joint stress from impact
loading, resulting in lower extremity injury.168 Improper landing technique could contribute to
an even higher incidence of injury. Education in proper landing technique has been shown to
decrease impact loading.169

Stiffness

Stiffness has been defined as a ratio between the force required to deform a material and
the distance the material is deformed.38 This can be simply calculated as the ratio between the
maximal vertical GRF and the maximal vertical displacement of the centre of the body mass
during a landing task. Stiffness is positively related to the demands170 or velocity of the
activity.171
Some level of stiffness is thought to be beneficial for preventing injury and improve
performance. Stiffness is required to utilise the stretch-shortening cycle by storing elastic energy
during eccentric loading phase.172,173 Too much stiffness may increase risk of injury. Increasing
peak vertical GRF, or reducing lower extremity excursion, would increase stiffness, resulting in
an increase in loading rates.174 Increased vertical GRF with an increased loading rate may put a
patient at a greater risk for overuse bony injuries such as osteoarthritis or stress fracture.175 Too
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little stiffness may allow excessive joint motion, resulting in mechanical failure of the soft
tissues.170

MEASUREMENTS
Neuromuscular activity

Walking
Author
(year)
Torry
(2000)19
Burden
(2003)176

EMG locations;
sampling rate
VM, VL, MH, and
LH;1200 Hz
LH, MH, VM, and
VL; 1000 Hz

Hurd
(2007)39

Normalization; data smoothing;
cut off frequency
MVIC (50 ms RMS moving window);
15 ms RMS moving window
Mean dynamic, peak dynamic, MVIC,
and isometric; 50 ms RMS moving
window
MVIC; 8th order Butterworth filter; 10
Hz

Dependent measurements
-Stance phase (four equal time
intervals of the norm base)
-Inter- and intra-individual
variability

VM, VL, TA, MG,
-Muscle co-contraction during
LG, SL, MH, and
mid-stance and weight acceptance
LH; 1080 Hz
(H:Q, Q:G)
Barr
RF (fine wire and
MVIC; High-pass Butterworth filter
-Peak EMG (5 gait cycles were
(2010)177
surface) and VM;
with cutoff at 20 Hz then low-pass filter
averaged) during stance phase
3000 Hz
with cutoff at 9 Hz for linear envelope
Lindstrom
TA, LG, VM, and
Not specified.
-Onset/offset in each muscle, given
(2010)145
LH;
as % of stance time
VM: vastus medialis, VL: vastus lateralis, GM: gluteus medius, BF: rectus femoris, BF: biceps femoris, TA: tibialis
anterior, MH: medial hamstring, LH: lateral hamstring, MG: medial gastrocnemius, LG: lateral gastrocnemius

Drop landing
Author
(year)

Height; distance
for force plate

EMG locations;
sampling rate

Russell
(2006)164

60 cm;
not specified

GM; 1080 Hz

Nagano
(2007)
Palmieri
(2007)13

30 cm; 30 cm

Kellis
(2009)178

30 cm; not
specified

RF, BF, and SM;
1000 Hz
VM, RF, VL, MH,
LH, MG, and
LG;1080 Hz
VM, VL, LH, and
LG; 2000 Hz

30 cm;
not specified

Normalization;
data smoothing;
cut off frequency
IRP (single leg standing);
Band-pass filter with 3 ms
window RMS; 10-500 Hz
% MVC; RMS
% MVIC (50 ms RMS);
4th-order Butterworth highpass; 20 Hz
% MVIC; Zero phase shift
digital high-pass; 10 Hz

Dependent measurements

-100 ms before and after initial
contact (used % IRP of
averaged same interval)
- H:Q ratio at 50 ms before and
after foot contact
- 250 ms after foot contact
(used % MVIC of averaged 15
ms RMS window)
-Preparatory: 100 ms before IC
-Initial loading response: 100

159

§Smith
(2009)179

50 cm; not
specified

VM, VL, MH, LH,
LG; 1000 Hz

Values in non-fatigue
condition; Butterworth
polynomial; 20-400 Hz
EMG data were not reported.

ms interval after IC
-Main loading response:
between 100-200ms after IC
-H:Q ratio
600 ms after IC

*Schmitz Drop-jump
(2010)180 (45 cm;10 cm)
IRP: isometric reference position,
GM: gluteus medius, BF: rectus femoris, BF: biceps femoris, SM: semimembranosis, MH: medial hamstring, LH:
lateral hamstring, MG: medial gastrocnemius, LG: lateral gastrocnemius
IC: initial contact
RMS: root mean square
§ Bilateral drop landing
* Drop-jump task: double leg landing followed by an immediate vertical jump

Kinetics

Walking
Author
(year)
Torry
(2000)19
Mundermann
(2005)131
Hurd
(2007)39

Sampling rate

Normalization; Filter; cut off frequency

Dependent measurements

1200 Hz

Moment: Nm / N (BW) * m (HT)

120 Hz

Henriksen
(2010)88
Hunt
(2010)140
Lindstrom
(2010)145

1500 Hz

-GRF: N / N(BW)
-Moment: Nm / N (BW) * m (HT)
-Moments: Nm / kg (BW) * m (HT)
-2nd order bidirectional low pass
Butterworth; 50 Hz
-Moment: Nm / kg (BW)

-Hip and knee sagittal plane joint
moment and impulse
-External knee and hip moments
-Hip and knee loading rates
-Internal knee moments
-Total support moments

1080 Hz

GRF: N / N (BW)

Not specified.

GRF: N / N (BW)

-Vertical GRF
-Loading rate & time to max loading
-Vertical GRF
-Peak posterior braking force
-peak anterior propulsive force

Sampling rate

Normalization; Filter; cut off frequency

Dependent measurements

1200 Hz

Not specified

1080 Hz

-Low-pass anti-aliasing filter; 1000 Hz

-GRF data were used to determine
initial contact and toe off
-Not reported

1000 Hz

-Not normalized and filtered

-Vertical GRF

1080 Hz

-Internal knee moments

BW: body weight, HT: height

Drop landing
Author
(year)
Ford
(2003)181
†Russell
(2006)
Nagano

160
(2007)161
Palmieri
(2007)13

1080 Hz

Lawrence III
(2008)182

1200 Hz

†Ford
(2010)183
Smith
(2009)179
†Schmitz
(2010)180

1200 Hz
1000 Hz
1000 Hz

-Low- pass, anti-aliasing filter; 1000 Hz
-Internal moment: Nm*kg (BW)
-GRF: Nm/kg (BW)
-Moment: Nm/kg (BW)
-Time series data sets were interpolated
to 100 points during the impact phase
Moment: unnormalized, Nm/Kg (BW),
Nm/m (HT), Nm/kg/m (BW*HT)
-GRF: N/N (body weight)
-4th-order Butterworth low-pass with zero
lag; 60 Hz
-Internal moment: Nm/N/m(body height)
-GRF: N/N (body mass)
-Energy absorption: J/N/m
-Joint stiffness: Nm/N/m/degree (change
in angular position)

-Time to peak GRF
-Peak vertical GRF
-Peak net knee ext. moments
-Hip and knee extensor moment in
the sagittal and frontal planes
-Ankle plantar flexion moment
-External moment
-Peak vertical GRF
-Hip, knee, and ankle extensor
moments
-Energy absorption
-Hip, knee and ankle joint stiffness

BW: body weight, HT: height
§ Bilateral drop landing
† Drop landing task: double leg landing followed by an immediate vertical jump

Kinematics

Walking
Author
(year)
Torry
(2000)19

Sampling
rate
120 Hz

Marker set
13 on the leg

Filter; cut off frequency;
normalization
4th-order Butterworth: 5 Hz

Mundermann
(2005)131
Hurd (2007)39

120 Hz

6 on the leg

Not specified.

120 Hz

Henriksen
(2010)88
Hunt
(2010)140
Lindstrom
(2010)145

100 Hz

Not
specified.
8 on each
leg
8 on each
leg
13 on the leg

Bidirectional 2nd order low
pass Butterworth; 6 Hz
Not specified.

120 Hz
Not
specified.

4th-order Butterworth with
zero lag; 6 Hz
-Not specified.
-Stride length: % body height
-Heel lift ht: % body height

Dependent measurements
-Hip and knee angles at hell contact
-Average hip and knee angle during
stance phase
-Hip and knee angles
-Sagittal plane knee excursion
- Knee angle at heel strike, early
stance, and late stance phase
-Knee flexion angles (stance phase
was normalized to 100 data points)
-Knee and ankle angle in sagittal plane
-Max heel lift-off height during swing
-Stride length

Drop landing
Author
(year)
Russell
(2006)164

Samplin
g rate
120 Hz

Marker set

Filter; cut off frequency

Dependent measurements

16 on the each
leg

Woltering filter (Vicon)

-Frontal plane knee angles
-Sagittal plane knee angles
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†Ford
(2003)181
Nagano
(2007)161

240 Hz
200 Hz

23 on the trunk
and each leg
24 on the right
leg

Low-pass Butterworth; 9 Hz
Not smoothed: due to the use of
PCT (Point Cluster
Technique)184
4th-order Butterworth low-pass
with zero lag; 6 Hz
4th-order Butterworth filter; 10
Hz
Frouth-order no phase shift
Butterworth 2-pass; 6 Hz
Low-pass 4th-order
Butterworth; 12 Hz
4th-order Butterworth low-pass
with zero lag: 12 Hz

-Valgus knee angle (between ICTO)
-Angular displacements
-Anterior tibial translation

Palmieri
120 Hz
18 on the
-Sagittal plane knee angles
(2007)13
dominant leg
Lawrence III 240 Hz
19 on the each
-Knee flexion angle
(2008)182
leg
§Smith
1000 Hz Electrogonio- Knee angles in sagittal and
(2009)179
meter
frontal planes
†Ford
240 Hz
37 on the trunk
- Knee abduction angle
(2010)183
and each leg
†Schmitz
100 Hz
7 on the leg and
-Hip, knee, and ankle flexion
(2010)
trunk
angles
IC: Initial contact, TO: toe off from the jump
§ Landing task: double leg landing
† Landing task: double leg landing followed by an immediate maximal vertical jump

162

Methods
Experimental design
This study will be a crossover design. The independent variables will be condition (pain,
effusion, pain/effusion, and control-no injection) and time (pre-condition, condition, and 30 min
post-condition). The dependent variables will be neuromuscular activities, kinetic, and
kinematic data on the lower extremity; and subjective pain perception. The specific dependent
variables are as followed:
Neuromuscular activity
(1) Peak and mean EMG values of each muscle in four equal time intervals (0-25%, 26-50%, 5175%, 76%-100%) during stance phase
(2) Peak and mean EMG values of each muscle 200 ms before and at peak knee flexion
Kinetic data
(1) Peak impact VGRF, unloading VGRF, peak push-off VGRF, and time to peak VGRF during
stance phase
(2) Ankle, knee, and hip joint moment in the sagittal and frontal planes during stance phase of
walking and at peak knee flexion angle during drop landing
(3) Vertical stiffness during walking drop landing
Kinematic data
(1) Peak joint angles (ankle, knee, and hip joint) in the sagittal and frontal planes during walking
and drop landing
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(2) Stride length and walking speed during walking

Participants
Sample size was calculated using an expected change in peak vertical GRF normalized
by body mass (GRF: N/kg) of 10 and a standard deviation of 7.29 during drop landing.13 Based
on these estimations, 13 subjects in each group will be necessary in order to have an 80% chance
of detecting a significant difference with P=0.01.
Twenty, (10 males and 10 females; aged between 18-35 years old) healthy subjects will
volunteer to participate. Exclusion criteria will include current pregnancy, history of
neuromuscular disorders, lumbar spine or lower extremity surgery, or lower extremity injury
within the past 6 months. All subjects in this study will read and sign the informed consent form
approved by Institutional Review Board.

Instrumentation
Measurements of the neuromuscular activities, kinetic, and kinematic data will be
recorded and synchronized with Vicon Nexus 1.7 (VICON, Centennial, CO). EMG will be
recorded using the Trigno system (Trigno, Delsys Inc., Boston, MA). All data will be exported
into Visual3D (C Motion, Germantown, MD) for analysis.
Neuromuscular activity

Twelve wireless surface electromyography (EMG) electrodes (Trigno Wireless, Delsys
Inc., Bostaon, MA) will be used to record neuromuscular activity of the lower extremity
(sampling rate: 2,000 Hz). Electrode locations will be shaved, debrided with sandpaper, and
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cleaned with isopropyl alcohol. The electrodes will be placed on the medial gastrocnemius
(MG), vastus medialis (VM), vastus lateralis (VL), medial hamstring (MH), gluteus medius
(GM), and gluteus maximus (GX) on both legs (Appendix 1; Figure 1). EMG during an
isometric reference position will be recorded to normalize the EMG amplitude. Subjects will be
asked to squat down until their butt barely touches a barrier (height of 0.74 m) and maintain the
position for four seconds (Figure 2). EMG electrodes consist of band-pass filter of 20-450 Hz
with a common mode rejection ratio greater than 80 dB and a gain of 1000. A 48 ms fixed delay,
from sensor input to analog output, will be accounted for all EMG data to harmonize with kinetic
and kinematic data.
EMG data will be smoothed using a root mean square (RMS) algorithm with a 50 ms
moving window for walking trials and a 15 ms moving window for drop landing trials. The
reference values of the EMG amplitude in each muscle with the same RMS moving window for
each movement will be used to normalize neuromuscular activity changes in the same muscles.
Kinetic data

GRF data will be measured using two-floor-mounted force platforms (AMTI, Watertown,
MA) at a sampling rate of 2,000 Hz. Prior to data collection, both force platforms will be
calibrated to zero. GRF data will not be filtered using a 4th-order low-pass Butterworth filter
with cut off frequency of 20 Hz. Cut off frequency will be confirmed with residual analysis
technique (Winter’s method).185 GRF data will not be normalized.
Kinematic data

The movements of the lower extremity and trunk will be measured using ten nearinfrared cameras (Vicon MX, Oxford Metrics Ltd, Oxford, UK) at a sampling rate of 200 Hz
(Appendix 2).
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Twenty seven single reflective markers will be attached on the lower extremity and trunk.
Four rigid clusters of four markers will be applied to the proximal-lateral thigh and distal-lateral
shank on each leg. Single markers will be bilaterally placed over the acromion, inferior angle of
the scapula, anterior superior iliac spine, greater trochanter, lateral and medial femoral condyle,
medial and lateral maleoli, dorsal surface of the midfoot, toe (between the second and third
metatarsal), lateral foot (fifth metatarsal), and heel. All subjects will wear athletic shoes and
malioli-open socks. Foot markers will be attached onto the athletic shoes. Single markers will
also be placed over the C7, T7, and medial sacral crest (Figure 1).
A static standing trial (subjects will stand with equal distribution of body weight on each
foot) will be measured and considered as each subject’s neutral body alignment (Figure 3);
subsequent kinematic measurements will be referenced in relation of this position. Subjects will
perform standing leg motions for each leg in order to estimate functional hip joint center (Figure
4-a & b).186 These motions will consist of three hip flexions and extensions in the sagittal plane
and three hip abductions and adductions in the frontal plane. Afterwards, ankle and knee joint
markers on each leg will be detached for walking and drop landing trials.
After data collection, spatial coordinates corresponding to the reflective markers will be
tracked using Vicon Nexus and then exported to Visual3D. A static model will be first built
using the static standing trial. This model will be applied to each c3d file of walking and drop
landing trials to calculate joint angles and moments. The model’s coordinate system convention
will be +X forward (posterior to anterior), +Y toward the subject’s left (medial to lateral), and
+Z up (distal to proximal). Kinematic data in walking and drop landing tasks will be smoothed
using a 4th-order low-pass Butterworth filter with cut off frequency of 6 Hz. Cut off frequency
will be confirmed with residual analysis technique (Winter’s method).185
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Perceived pain

Subjective pain perception will be quantified using 10 cm VAS (Appendix 3).187 Every
two minutes throughout each time interval, subjects will be asked to mark where their pain level
is at the time of measurement.

Conditions
Following the pre-condition trials (see the testing procedures below), subjects will sit on
a chair and receive one of the four conditions (Figure 5). Saline injections will be used in each
condition except for the control condition. A licensed, board certified physician will perform all
injections on subject’s dominant limb. Dominant limb will be defined as the leg use when
kicking the ball. Prior to injection, area of the needle insertion will be cleaned with povidoneiodine. After removal of the needle, the puncture site will be cleaned with alcohol swab and
covered with sterilised gauze.
Pain

The 25 gauge needle (Becton Dickinson Medical Systems Inc, Sandy, UT) will be
inserted into the lateral infrapatellar fad pad. The needle will be inserted at an angle of 45
degrees, in an inferior-medial direction, with a depth of 1 cm (Figure 6).87 Sterile hypertonic
saline (5% sodium chloride, 1.0 ml, B. Braun medical, Inc., Irvine, CA) using 1 ml syringe
(Becton Dickinson Medical Systems Inc, Sandy, UT) will be injected. In our pilot study, most
subjects felt minimal pain (less than 2) in approximately eight minutes after a single injection of
1 ml 5% hypertonic saline.
Effusion

Sterile lidocaine (1%, 2.0 ml, Hospira, Inc., Lake Forest, IL) using the 25 gauge needle
and 3 ml syringe will be injected subcutaneously for anesthetic purpose (Figure 7). The 18

167

gauge needle will be inserted into the superolateral knee joint (Figure 8). Sterile saline (0.9%
sodium chloride, 50.0 ml, Hospira, Inc., Lake Forest, IL) using 50 ml syringe (Becton Dickinson
Medical Systems Inc, Sandy, UT) will be used. An effusion wave and ballotable patella test will
be performed to ensure that the effusion is within the knee joint capsule.96
Pain/Effusion

To induce a combination of pain and effusion, three injections will be used in the order of
1% lidocaine, 0.9% isotonic saline, and 5% hypertonic saline. The same volume of each saline
solution will be injected as the volume used for pain and effusion conditions. Effusion will be
induced first followed by pain due to limited amount of time for pain sensation.
Condition

The control condition will consist of no injection. For the control condition, subjects will
simply sit on a chair for five minutes and perform the condition trials at the same time intervals.

Testing Procedures
In the orientation session, subjects will read and sign the informed consent form approved
by the Intuitional Review Board. Subjects will also complete the demographic information.
Subjects’ height and mass will be measured. Subjects will perform several trials of drop
landings for familiarization purpose. This will help ensure a consistent drop height between
sessions. Qualified subjects will come back in a week for data collection.
Each subject will experience all four conditions (pain, effusion, pain/effusion, and control)
in each session with a week wash-out period in between sessions. Each session will consist of
three time intervals (pre-condition, condition, and 30 min post-condition). During each time
interval, three trials of functional movements (walking trials first followed by drop landing trials)
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will be recorded. Order of the conditions will be randomized using Latin Square designs
(Appendix 4).188
Upon arrival in the laboratory, subjects will be asked to wear spandex shorts and shirts,
socks, and athletic shoes during data collection. EMG electrodes and reflective markers will be
attached. Subject’s isometric reference position, static standing video, and standing leg motions
will be recorded. Subjects will perform the pre-condition trials. Afterwards, subjects will sit on
the table and receive one of the conditions (pain, effusion, pain/effusion, control). A minute
after the injection, subjects will perform the condition trials. Data collection will be terminated
if a subject complains of intolerable pain and/or fainting, or a subject does not begin condition
trial in eight minutes following injection. Subjects will sit on the chair (same position as injection)
and rest for 20-25 minutes before the post-condition trials. Resting time will be dependent on
the length of time completing the condition trials.
Walking

Subjects will be walking over the force platforms at a self-selected walking speed. One
gait cycle of each leg will be collected. A successful trial will be defined as subjects’ each foot
completely step on each force platform (Figure 9). Subjects will be asked to keep walking until
three successful trials are recorded in each time interval.
Drop landing

Subjects will perform a drop landing task from a 30 cm height wooden box. The box will
be placed 20 cm away from the rear edge of the force platform for all subjects. Three successful
trials will be collected in each time interval. A successful trial will be defined as which the
subjects will drop down (not step or jump down) on their dominant leg onto the force platform
followed by an immediate vertical jump as determined visually by the assessor (Figure
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10).180,181,183 Subjects will be instructed not to touch the ground with the contralateral limb and
to maintain balance after the second landing for two seconds.164 The first landing will be used
for analysis.

Statistical Analysis
Means will be computed from three trials at each time interval for each condition. To test
condition effect over time, 3 X 4 mixed model analysis of covariances (covariate: pre-condition
measurement) will be used for each dependent variable. To eliminate possible influence to joint
kinetic and kinematics, self selected walking speed will be used as covariate for all walking trial
analyses. In order to avoid the type I error, Bonferroni type adjustment for multiple comparisons
with the significant level of 0.01 will be used for all tests.
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Appendix
Appendix 1. Location of the EMG Electrodes189,190
Muscle
Medial gastrocnemius

Location
50% of distance between medial knee joint space and the insertion of
the gastrocnemius
Vastus medialis
20% of distance between the anterior superior iliac spine and the
medial knee joint space
Vastus lateralis
Distal 33% of distance between the anterior superior iliac spine and
the lateral knee joint space
Medial hamstring
50% of distance between the ischial tuberosity and the medial knee
joint space
Gluteus medius
50% on the line from the iliac crest and the greater trochanter
Gluteus maximus
50% on the line between the sacral vertebrae and the greater trochanter
* No ground electrode will be attached since the Trigno System does not require it.
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Appendix 2. Camera setup and calibration for the motion analysis system
Six cameras will be mounted on the wall (one camera at height of 2.6 m; two cameras at height
of 2.5 m; three cameras at 2.4) and four cameras will be placed on tripods (height of 1.9 m).
Prior to data collection, positions of the each camera will be confirmed to ensure all cameras
capture the entire space required by functional movements. Calibration of the motion analysis
system will be performed using dynamic wand data to calculate camera positions, lens distortion
maps, and focal length.191 Following the dynamic calibration, a 3D coordinate system will be
originated.
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Appendix 3. VAS

No pain

Pain as bad as it
could possibly be
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Appendix 4. Randomization of the condition using Latin Square design
subject
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

control
2
4
1
3
2
4
1
3
2
4
1
3
4
3
1
2
3
4
2
1
4
2
1
3
3
4
2
1
1
3
4
2
2
4
1
3
2
1
4
3

pain
3
2
4
1
4
1
3
2
4
1
3
2
1
4
2
3
4
1
3
2
3
4
2
1
1
2
3
4
3
2
1
4
1
2
3
4
3
2
1
4

effusion
4
1
3
2
3
2
4
1
3
2
4
1
3
2
4
1
2
3
1
4
2
1
3
4
2
1
4
3
4
1
2
3
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1
4
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2

P&E
1
3
2
4
1
3
2
4
1
3
2
4
2
1
3
4
1
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4
3
1
3
4
2
4
3
1
2
2
4
3
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3
2
1
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Figure 1. Placements of the EMG electrodes and the reflective markers
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Figure 2. Isometric reference position for EMG normalisation
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Figure 3. Static standing measurement for neutral body alignment
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Figure 4. Single leg motions for functional hip joint centre
a. Sagittal plane

b. Frontal plane

186

Figure 5. Subject position for injection
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Figure 6. 5% hypertonic saline injection for pain model

188

Figure 7. 1% lidocaine injection prior to effusion model

189

Figure 8. 0.9% isotonic saline injection for effusion model

190

Figure 9. Walking task

191

Figure 10. Drop landing task

